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3-nitrotyrosine (3NT), a stable end product arising from the interaction of 
proteins and reactive nitrogen species such as peroxynitrite, is produced 
during periods of oxidative stress. 3NT is, therefore, of interest as a potential 
biomarker in a variety of disease states where oxidative stress is known to be 
involved in the pathology, for example intermittent claudication. The aim of 
this thesis was to develop sensitive and specific immunoassays to assess the 
levels of 3NT in plasma samples from claudicants and to investigate the 
protein nitration profile. 
Clinical data and plasma samples were collected from claudicant (n=33) and 
control (n=6) subjects.  Analysis of data confirmed the difficulty of using 
parameters such as ankle brachial index (ABI) in diagnosis, supporting the 
need for investigations into potential biomarkers. 
Development of indirect and competitive ELISAs using electrochemically 
nitrated bovine serum albumin as the standard revealed that the detection of 
3NT was dependent on the antibody being able to access the 3NT-residues 
within the protein. Various denaturing conditions and different types of 
microtitre plate were utilised during development. Initially the presence of 3NT 
in claudicant or control whole plasma samples could only be detected using 
dot blot immunodetection. Affinity purification techniques for the fractionation 
of the plasma proteins were therefore applied. Subsequently, 3NT-containing 
plasma proteins were found to be present in all of the claudicant and control 
samples using the developed competitive ELISA. Proteomic analysis of the 
3NT-affinity purified samples, using MALDI-MS and LC-ESI-MS/MS, 
confirmed the presence of human serum albumin, serotransferrin and 
apolipoprotein A1 and A2 precursors within those protein bands staining 
immunopositive for 3NT on SDS-PAGE gels. The identification of 
apolipoprotein A1 within 3NT-immunopositive bands confirms previous reports 
suggesting the oxidative modification of HDL may contribute to the link 
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A     Absorbance 
Ab     Antibody 
ABI     Ankle brachial index 
ACE     Angiotensin converting enzyme 
AHA     American heart association 
ANOVA    Analysis of variance 
Anti-3NT Ab    Anti-3-nitrotyrosine antibody (polyclonal) 
 
BMI     Body mass index 
BSA     Bovine serum albumin 
 
CAD     Coronary arterial disease 
CVA     Cardiovascular accident 
CVD     Coronary vascular disease 
 
DBP     Diastolic blood pressure 
 
EC     Electrochemical detection 
EDTA     Ethylene diamine tetra acetic acid 
ELISA     Enzyme linked immunosorbant assay 
 
HDL     High density lipoprotein 
HPLC     High performance liquid chromatography 
HSA     Human serum albumin 
 
IC     Intermittent claudication 
IgG     Immunoglobulin G 
 
KHz     Kilohertz 





LC-ESI-MS/MS  Liquid chromatography - electrospray 
ionisation - tandem mass spectrometry 
LDL     Low density lipoprotein 
LV-PAD    Large vessel - peripheral arterial disease 
 
MALDI-TOF Matrix assisted laser desorption ionisation-
Time of flight 
MAP     Mean arterial pressure 
MI     Myocardial infarction 
MPO     Myeloperoxidase 




NO     Nitric oxide 
3NT     3-nitrotyrosine 
NT-BSA    Nitrated bovine serum albumin 
NT-HSA    Nitrated human serum albumin 
NT-PL     Nitrated human plasma (electrochemically) 
 
OD     Optical density 
ONOO-    Peroxynitrite 
 
PAD     Peripheral arterial disease 
PBS     Phosphate buffered saline 
pNPP     p-Nitrophenol phosphate 
 
rcf     Relative centrifugal force 
RMM     Relative molecular mass 
RNS     Reactive nitrogen species 
ROS     Reactive oxygen species 
 
SBP     Systolic blood pressure 
SD     Standard deviation 
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SDS     Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis 
SEM     Standard error of the mean 
SMP     Skimmed milk powder 
SV-PAD    Small vessel - peripheral arterial disease 
 
TEMED    N,N,N’,N’-tetramethylethylenediamine 
TIA     Transient ischaemic attack 
Tris     Tris[hydroxymethyl] aminomethane 
Tryp     Trypsin 
Tryp-NT-BSA   Trypsin digested nitrated BSA 
Tyr     Tyrosine 
 
U+M     Urea and mercaptoethanol 
UV     Ultra violet 
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3-nitrotyrosine (3NT) is formed by the addition of a nitro group (NO2) on the 
ortho position of the amino acid tyrosine (Figure 1.1.i.). Nitration can occur 
both in biological systems and can be produced chemically within the 
laboratory. Molecules with aromatic rings such as the amino acid tyrosine are 
more susceptible to nitration than most other molecules in biological systems. 
As a result of the fact that the nitro group is a stable chemical modification that 
dramatically changes the chemical properties of tyrosine it is thought that it 
may have a long lasting effect on protein function. 
3-Nitrotyrosine 
 
Figure 1.1.i. Tyrosine nitration. 
 
Nitric oxide (NO) is an ubiquitous intercellular messenger that is synthesised 
enzymatically from the amino acid L-arginine in a number of tissues by NO 
synthase (NOS) of which there are three isoforms; inducible (iNOS), 
endothelial (eNOS) and neuronal (nNOS). NO has roles in both normal 
physiology and pathological conditions in humans. Under normal conditions 
NO is efficiently removed from the system by reacting with oxyhaemoglobin 
resulting in the formation of nitrite, even with the highest rates of NO 
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synthesis. However data suggests that in specific subcellular compartments 
(when in close proximity to enzymes capable of production of reactive oxygen 
species (ROS) and iNOS) NO-dependent nitration of tyrosine is a 
physiologically relevant process (Heijnen, Van Donselaar, Slot et al. 2006) 
and 3NT was first proposed as an in vivo marker of reactive nitrogen species 
(RNS) by Ohshima et al (1990). Since this time protein nitration has been 
widely investigated as a stable marker of NO derived reactive species 
(extensively reviewed by Beckman and Koppenol 1996, Bruckdorfer 2005, 
Pacher, Beckman and Liaudet 2007).  
Although the exact nitration pathways have yet to be completely elucidated it 
has been established that tyrosine nitration within biological systems is 
associated with NO and reactive oxygen species (ROS). Initial interest in 
biological nitration resulted from observations that chemicals such as 
peroxynitrite (ONOO-) nitrate tyrosine residues. In situations whereby an 
inflammatory response is occurring the simultaneous production of NO and 
superoxide (O2.-) results in the biological actions of NO being completely 
transformed and results in the formation of the potent oxidant ONOO-. At 
present there are many reported models/pathways which have been shown to 
result in nitration of tyrosine residues in vitro (Ischiropoulos, Zhu, Chen et al. 
1992, Eiserich, Cross, Jones et al. 1996), however, very few have been 
replicated in conditions that mimic in vivo. It is likely to be the case that there 
are multiple pathways in vivo which lead to the nitration of tyrosine residues 
(Ischiropoulos 1998). Potential mechanisms of nitration which have been 




ONOO- is formed during periods of oxidative stress and is a powerful oxidant 
and cytotoxic agent, furthermore, its protonated form, peroxynitrous acid, is 
extremely unstable and cleaves rapidly to hydroxyl and NO2 radicals 
potentially initiating further free radical reactions (Beckman, Chen, 
Ischiropoulos et al. 1994). At nanomolar concentrations ONOO- has been 
found to produce significant amounts of 3NT in both physiological and 
pathological events in vivo (Sawa, Akaike and Maeda 2000, Reiter, Teng and 
Beckman 2000). Initially it was thought that 3NT was a specific and stable 
marker of ONOO- activity, but this is now known not to be true (Eiserich, 
Cross, Jones et al. 1996). It has been shown that other species can and do 
nitrate tyrosine at physiological pH. For example the haem enzyme 
myeloperoxidase (MPO, a member of the animal peroxidases) in the presence 
of hydrogen peroxide (H2O2) and nitrite will nitrate tyrosine by radical coupling 
after one electron oxidations of both nitrite and tyrosinate anions. Since 
inflammatory disorders are typically associated with an infiltration of 
phagocytes, which contain high levels of haem peroxidases, this pathway has 
to be considered as a potential alternative pathway to ONOO- in mediating 
protein tyrosine nitration in vivo.  
It has been known for some time that MPO acts to chlorinate tyrosine to 
chlorotyrosine (Hazen and Heinecke 1997) but it is now becoming apparent 
that MPO also acts to nitrate tyrosine in a nitrite-dependent peroxidase 
reaction in cytokine activated macrophages (Podrez, Schmitt, Hoff et al. 1999, 
Hazen, Zhang, Shen et al. 1999, Van Dalen, Winterbourn, Senthilmohan et al. 
2000, Malle, Waeg, Schreiber et al. 2000, Pfeiffer, Lass, Schmidt et al. 2001, 
Gaut, Byun, Tran et al. 2002). It has also been highlighted that the reaction of 
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nitrite, an auto-oxidation product of NO, with HOCl forms reactive intermediate 
species that are also capable of nitrating phenolic substrates such as tyrosine 
(Eiserich, Cross, Jones et al. 1996). As reviewed by Ischiropoulos (1998) 
many other potential protein nitration pathways are present in biological 
systems but the above are classed as the main probable routes, although it is 
likely that multiple nitrating agents function simultaneously. 
Due to the complexity of biological systems it is necessary to evaluate the 
potential nitrating species responsible in every model of disease and it is more 
probable that there are multiple nitration pathways/agents operating at 
different times during the pathology of and progression of a disease state 
(Hazen, Zhang, Shen et al. 1999, Gaut, Byun, Tran et al. 2002). For example, 
in disease states that involve chronic inflammation such as atherosclerosis, 
MPO-dependent pathways must be considered (Podrez, Schmitt, Hoff et al. 
1999). Thus the nitrating agent will be a function of the RNS and ROS present 
along with any secondary reactions with antioxidants and scavengers, and the 
presence of inflammatory cells (Ischiropoulos 1998). Hazen et al (1999) 
generated a model of pathways available to monocytes for promoting LDL 
modification by RNS based on the findings of their research. This model 
highlighted the fact that MPO/H2O2, MPO-generated HOCl and ONOO- 
pathways were all potentially available to monocytes during conditions of 
oxidative stress. 
As most proteins are thought be composed of approximately 4% tyrosine 
residues it was initially thought that all proteins, along with free tyrosine, are 
potential targets for nitration in biological systems. However it has been 
reported that only a subset of proteins are actually nitrated suggesting that 
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there are parameters such as a protein’s innate properties that predispose it 
to nitration (Souza, Daikhin, Yudkoff et al. 1999). Neither the amount of a 
protein nor the number of tyrosine residues within a protein can be used to 
predict the likelihood of a protein being nitrated. For example human serum 
albumin is the most abundant protein in plasma and should, in theory, be a 
target for nitration. However, in actual fact it has been found that on a molar 
basis the extent of nitration for albumin is less than that for other plasma 
proteins (Ischiropoulos 1998). It is apparent that tyrosine nitration is a 
selective process and as such many factors are thought to contribute to the 
likelihood of tyrosine being nitrated, such as protein folding and the nitrating 
species involved (Ischiropoulos 1998). Although free tyrosine is abundant in 
plasma and does serve as a significant biological target for nitrating species, it 
is dynamic and subject to a relatively rapid turnover with a half life of about 
two weeks. Therefore, when quantifying the extent of nitration protein-bound 
3NT should be more stable and consistent over time than free-3NT (Skinner, 
Crow, Skinner et al. 1997). It is probable that the specific disease pathology, 
nitrating agent involved and protein folding all contribute to the likelihood of a 
protein being nitrated and more specifically which tyrosine residues within a 
protein are nitrated. 
NO-dependent nitration has been identified as being a physiologically relevant 
process localised in specific subcellular compartments in close proximity to 
enzymes capable of peroxidase activity, ROS and iNOS (Heijnen, Van 
Donselaar, Slot et al. 2006). Lanone et al. (2002) have shown that iNOS is 
susceptible to nitration both in vitro and in vivo leading to loss of activity and 
that this may serve as an endogenous mechanism of modulation of iNOS 
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enzymic activity. iNOS expression in itself (through the production of large 
amounts of NO) has been implicated in extensive nitration of cellular proteins 
in transplant coronary artery disease, via ONOO- (Ravalli, Albala, Ming et al. 
1998). Nitrated proteins, along with production of the iNOS inhibitor 
asymmetric diemethylarginine (ADMA), have been identified as being a 
feature of diffuse scleroderma, suggesting that this may be a reflection of 
abnormal NO regulation in systemic sclerosis (Dooley, Gao, Bradley et al. 
2006). The susceptibility of a protein to be degraded has also been found to 
be enhanced by protein nitration (Souza, Choi, Chen et al. 2000) thus 
suggesting that nitration may have an important physiological role. Thus the 
identification of protein targets of nitration in human disease and animal 
models of disease is important in the understanding of the role of protein 
nitration in both normal physiology and mechanisms of disease progression. 
However, at present, data on the role of protein nitration in signal transduction 
events and in the pathogenic mechanism of diseases is extremely sparse 
when compared to the number of diseases 3NT has now been associated 
with. 
Several in vitro methods are available to nitrate tyrosine residues; the majority 
of these are chemical methods of modification. Tetranitromethane is widely 
used to nitrate tyrosine residues in proteins, initiating nitration via a charge 
transfer/radical mechanism. Chemically formed ONOO- is also widely used to 
nitrate proteins in biological models. The major problem with chemical 
nitration is that the reactions are not easily controlled therefore making it 
difficult to nitrate a protein to a set degree of nitration. Electrochemical 
nitration will be used within this study and has been shown to specifically 
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nitrate tyrosine residues within proteins (Kendall, Cooper, Heptinstall et al. 
2001). The major advantage of this type of nitration is that using a potential to 
drive oxidation makes the reaction easier to control thus allowing for proteins 
to be nitrated to exact levels of nitration. Kendall et al (2001) suggest that 
electrochemical nitration of tyrosine residues may occur as a result of a 
radical/radical coupling reaction reliant upon the reaction of the protein to be 
nitrated and a nitrogen source (sodium nitrite) at the anode (see Figure 1.1.ii.). 
 
Figure 1.1.ii. Potential mechanism for electrochemical nitration of tyrosine as put 















Atherosclerosis is a disease affecting large and intermediate sized arteries 
and is defined as the build up of fatty deposits beneath the endothelium 
known as ‘atheromatous’ plaques. It is one of the most significant causes of 
health problems in the Western world and it is thought that almost half of all 
people in the USA and Europe die of atherosclerotic related complications 
(Rosamond, Flegal, Friday et al. 2007). When the arteries of the heart are 
affected by atherosclerosis it is known as coronary artery disease, CAD, and 
when affecting other arteries outside the heart and is then classified as 
peripheral arterial disease (PAD). PAD is a generalised term and affects four 
major areas; the arteries of the brain including the carotid arteries, kidneys, 
intestines and the legs. Although the main focus of PAD generally tends to be 
placed on the arteries of the legs. PAD is associated with a poor 
cardiovascular prognosis and is often considered an indicator of generalised 
systemic atherosclerosis. The main emphasis of this current study was to 
investigate the presence of 3NT in the plasma of patients suffering from 
intermittent claudication (IC) which is a clinical manifestation of PAD within the 
lower limbs.  
Peripheral arterial disease and intermittent claudication 
Intermittent claudication (IC), from the Latin claudicare – to limp, is a direct 
result of atheromatous plaque build up within the arteries supplying the legs. 
IC tends to be the first and most common clinically significant manifestation 
reported by those suffering from lower extremity PAD; although it is known 
that many with PAD do not present with classic IC symptoms (Burns, Gough 
and Bradbury 2003). Most individuals tend not to present with IC symptoms 
until the artery has narrowed by at least 60%. The first indication of someone 
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suffering from IC is that they experience a cramp like pain in their leg muscles 
upon mild exertion such as walking. This pain is a result of an inadequate 
supply of oxygenated blood to the muscle to meet its demands due to a 
blockage in the arteries supplying the leg. This cramp like pain is often 
reported within the calves but can also be present within the thighs and or 
buttocks depending on the position of the blockage. The affected artery can 
usually provide an adequate supply of oxygenated blood at rest in order to 
meet the muscles demands thus ceasing exercise results in the claudication 
pain stopping.  
The development of atherosclerotic disease is thought to progress at a very 
slow rate beginning as early as childhood but, depending on the individual, 
after the fourth decade of life this progression can increase dramatically 
(Kiechl and Willeit 1999). Although the exact pathology of atherosclerosis and 
causative agents are not known it is thought to involve the proliferation of 
smooth muscle cells and the accumulation of fats, cholesterol, fibrin, platelets, 
cellular debris and calcium following endothelium damage. This accumulation 
of substances is then thought to act as a further stimulus resulting in the 
production of a variety of biological responses by the endothelium, including 
production of cytokines, leading to both local and systemic responses involved 
in the inflammatory response (Ross 1999). Atheromatous plaques consist of a 
mass of lipid-engorged monocytes covered by a fibrous cap protruding into 
the vessel lumen thus reducing the amount of blood being able to flow past 
this point and causing periods of ischaemia in the area affected. It is within 
these plaques that 3NT has been found to be present (Beckmann, Ye, 
Anderson et al. 1994). 
 11 
 
Atherosclerotic plaques have been found to have many different histological 
characteristics and as a result of this the American Health Association (AHA) 
has devised a classification system (Table 1.2.i.). Although this system is a 
numerical classification it does not represent a severity scale or route of 
progression. Under normal circumstances it is generally true to say that types 
I-III lesions are small and clinically silent (Stary 2000) and can be found in the 
arteries of the young, potentially acting as precursors to more serious lesion 
types. With regards to lesions types IV-VI no correlation has been found 
regarding the size and composition of a lesion and the extent of lumen 
obstruction and associated clinical manifestations (Stary 2000). Thus any of 
the lesion types IV-VI have the potential of obstructing the lumen of an artery 
causing a clinical event such as a stroke (Wissler and Strong 1998). 
 
LESION TYPE HISTOLOGICAL CHARACTERISTICS 
I (initial lesion) Isolated macrophage foam cells 
II (fatty streak) Foam cells stratified in adjacent layers, few intimal SMCs 
containing lipid droplets, few T lymphocytes and isolated mast 
cells 
III (intermediate) Changes of type II and pools of extra-cellular lipid 
IV (atheroma) Lipid core, foam cells, fibrous cap rich in SMCs, A proportion of 
T lymphocytes and mast cells 
V (fibroatheroma) Lipid core and fibromuscular tissue layers produced 
VI  
(complicated lesion) 
As type IV with complications including surface disruption, 
haematoma, haemorrhage and thrombosis 
VII (calcific) As V but calcification predominates 
VIII (fibrotic) As V but fibrous tissue predominates 
Table 1.2.i. Classification of atherosclerotic lesions. 
Adapted from that stated by the American Heart Association (AHA, 




Current research has highlighted the fact that inflammation is a relevant 
process in the pathology of atherosclerosis. For example the importance of 
oxidants derived from NO, such as ONOO-, in the pathogenesis of 
atherosclerosis was highlighted by the identification in the early 1990’s of 
nitrated proteins localised within human atherosclerotic lesions and vascular 
muscle (Beckmann, Ye, Anderson et al. 1994). Since this initial discovery 
much research has been undertaken regarding protein nitration and the 
pathology of atherosclerosis. Nitrated LDL has now been isolated from 
atherosclerotic lesions in human arteries (Leeuwenburgh, Hardy, Hazen et al. 
1997). NO is produced by both endothelial cells and macrophages within the 
vasculature and appears to have both protective and atherogenic properties, 
depending on its source. Within the vasculature eNOS is the predominant 
NOS isoform and is thought to be responsible for producing most of the NO 
during normal NO signalling and has atheroprotective properties 
(Förstermann, Closs, Pollock et al. 1994). Evidence now suggests that under 
certain conditions, such as the absence of L-arginine or the cofactor 
tetrahydrobiopterin (BH4), the homodimer eNOS ‘uncouples’ and actually 
becomes an important source of ROS (O2.-) and thus proatherogenic 
(Vasquez-Vivar, Kalyanaraman, Martasek et al. 1998, Bevers, Braam, Post et 
al. 2006). iNOS is also thought to have a proatherogenic role and as the 
process of oxidative stress is associated with the disruption of NO signalling it 
is not surprising that the co-distribution of iNOS and Cox-2 with 3NT has been 
observed in macrophages and smooth muscle cells in both native and 
transplant atherosclerosis (Baker, Hall, Evans et al. 1999). Normal NO 
signalling is also thought to be affected during periods of oxidative stress due 
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to the inhibition of eNOS (Cooke 2003). Thus all of the above can contribute 
to the disruption in NO signalling and supports the hypothesis that NO, via 
RNS such as ONOO-, may have a direct role in promoting atherogenesis. It 
has also been reported that MPO may serve as an important link between 
chronic inflammatory events and the development of atherosclerotic plaques 
(Malle, Waeg, Schreiber et al. 2000). For example nitrating intermediates 
formed by MPO, e.g. nitryl chloride formed from the reaction of nitrite with 
HOCl, have been found to mediate LDL protein nitration and peroxidation 
resulting in the conversion of LDL into an atherogenic form (Hazell, Arnold, 
Flowers et al. 1996, Podrez, Schmitt, Hoff et al. 1999). It has recently been 
highlighted that mitochondrial dysfunction may be of importance in the 
pathology of PAD thus providing further evidence of the significance of 
oxidative stress in PAD (Pipinos, Judge, Zhu et al. 2006). MPO-mediated 
oxidation of HDL (both chlorination and nitration) has recently been identified 
as having a potential role in the pathology of atherosclerosis and diabetes 
type II (Shao, Bergt, Fu et al. 2005, Hermo, Mier, Mazzotta et al. 2005). 
Research regarding risk factors associated with the development of clinically 
significant atherosclerosis stems around the coronary and carotid arteries. 
Several risk factors have been associated with the formation of atherosclerotic 
plaques and can be split into two categories: major risk factors such as; 
hyperlipidaemia (McGill, McMahan, Malcom et al. 1997, Ridker, Stampfer and 
Rifai 2001) hypertension (McGill, Strong, Tracy et al. 1995, Murabito, 
D'agostino, Silbershatz et al. 1997), smoking (Morrow, Frei, Longmire et al. 
1995, Waters, Lesperance, Gladstone et al. 1996, McGill, McMahan, Malcom 
et al. 1997, Murabito, D'agostino, Silbershatz et al. 1997, Petruzzelli, Puntoni, 
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Mimotti et al. 1997) and diabetes (McGill, McMahan, Malcom et al. 1995, 
MacGregor, Price, Hau et al. 1999, Pennathur, Wagner, Leeuwenburgh et al. 
2001, Dolan, Liu, Criqui et al. 2002) and minor risk factors such as; age 
(McGill, McMahan, Tracy et al. 1998), sex (McGill, Strong, Tracy et al. 1995, 
Adams, Williams and Kaplan 1995, Murabito, D'agostino, Silbershatz et al. 
1997, Kiechl and Willeit 1999), and obesity (McGill, McMahan, Malcom et al. 
1995). Evidence has been found to suggest that precursor lesions (types I-III) 
may occur as early as adolescence but the frequency of definite lesions 
present remains low until the age of forty in men and the onset of the 
menopause in females, dependent on the individual (Kiechl and Willeit 1999).  
It is evident from the literature that more emphasis is now being made on 
researching risk factors directly associated with the progression of PAD, which 
can result in the development of clinically significant IC. Incidence of IC has 
been found to be more prevalent in those patients suffering from all or one of 
the following risk factors; high cholesterol levels, stage two or greater 
hypertension, diabetes, coronary heart disease and/or smoking (Murabito, 
D'agostino, Silbershatz et al. 1997). It has been highlighted that for the 
progression of large vessel PAD (LV-PAD) and small vessel PAD (SV-PAD) 
risk factors contribute differentially suggesting different pathology for the 
progression of PAD in large and small vessels. For example, smoking, lipid 
status and inflammation were found to contribute significantly to LV-PAD 
whereas for SV-PAD progression diabetes was the only significant predictor 
observed (Aboyans, Criqui, Denenberg et al. 2006). The duration of type II 
diabetes has also been found to be strongly associated with an increased risk 
of development of PAD in men (Al-Delaimy, Merchant, Rimm et al. 2004).  
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A patient is usually assessed for the presence of IC upon reporting a history of 
cramp like pain upon mild exertion which can be relieved by a period of rest. 
Upon reporting such symptoms IC is predominantly diagnosed using non-
invasive techniques, such as a thorough physical examination and recording 
the patient’s medical history, i.e. history of leg and or heart symptoms, family 
history, to determine if they have any risk factors present. The patient’s ankle-
brachial index (ABI, a comparison of the arm and upper thigh, upper knee, calf 
and then ankle systolic blood pressure measurements) is then assessed (see 
Figure 1.2.i). This is a simple and relatively reliable tool in the diagnosis of 
PAD especially IC, and provides the doctor with a more accurate idea of 
where the atheromatous plaques are within the leg. A normal ABI range is 
classed as 0.96-1.2, however there is no consensus on a cut-off level (Meijer, 
Hoes, Rutgers et al. 1998). In a population study it has been found that 68.9% 
of over 55 year olds with IC had an ABI below 0.9, and also that they were 
more likely to be smokers, have hypertension, and have 
symptomatic/asymptomatic CVD (Meijer, Hoes, Rutgers et al. 1998). Although 
ABI is classed as a reliable test for diagnosis of IC, it may not be accurate in 
all patients and it is also important to note that a normal ABI cannot rule out 




Figure 1.2.i. A schematic representation of the measurements taken in order to 
establish a patient’s ankle brachial index. 
Adapted from Meru et al (2006), ABPI: ankle brachial pressure index 
which is an alternative abbreviation for ankle brachial index (ABI). 
 
Another test for IC is a treadmill exercise test allowing the doctor to assess 
the severity of the symptoms being presented by the patient by comparing the 
ABI measurements before and after exercise. When combined these methods 
of diagnosis in most cases provide the doctor with the data to diagnose or rule 
out IC. A major problem in the diagnosis of IC is that even in advanced cases 
patients may present with atypical symptoms or may assume their symptoms 
are as a result of old age. Also, in the elderly, walking problems are often 
present due to other underlying medical conditions therefore causing potential 
problems in correct diagnosis (Murabito, D'agostino, Silbershatz et al. 1997).  
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If left untreated IC can lead to significant functional impairment and an 
increased risk of cardiovascular morbidity and mortality (2.5 fold increase 
compared to an age matched population (Stewart and Lamont 2001)).  That is 
IC is a symptomatic expression of lower extremity PAD and is therefore a 
marker of potentially more serious cardiovascular problems and generalised 
atherosclerosis. IC can lead to gangrenous lower limbs leading to amputation 
and in serious cases death.  Furthermore, due to pain upon exercise the 
individual suffering from IC has a tendency to reduce their exercise levels that 
can result in further clinical problems. Atherosclerosis rarely produces 
symptoms until the extent of disease is severe and arteries are dangerously 
narrowed or in extreme cases completely occluded, therefore the earlier the 
diagnosis the better the prognosis. It is estimated that in the UK 1 in 5 middle 
aged individuals have PAD upon examination but very few of these (25%) are 
symptomatic e.g. presence of IC (Burns, Gough and Bradbury 2003). This 
clearly highlights that there is a discrepancy between the presence of clinically 
significant PAD and the reporting of symptomatic PAD such as IC.  
Early diagnosis of PAD and IC is crucial with regards to reducing the mortality 
associated with IC and improving a patient’s quality of life. With regards to 
claudication it has also been reported that there is no correlation between a 
patient’s quality of life and standard parameters used to assess IC such as 
ABI (Spronk, White, Bosch et al. 2007). The recently published guidelines for 
the management of patients with PAD state that those over the age of 50 
years who have atherosclerotic risk factors present should be assessed for 
the presence of PAD and IC (Hirsch, Haskal, Hertzer et al. 2006) however in 
reality this is not found to be the case. It is known that there is under diagnosis 
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of PAD within primary care practices and that this may result in the lack of 
provision of effective risk factor management and treatment (Hirsch, Criqui, 
Treat-Jacobson et al. 2001). Thus it would be beneficial for the development 
of additional tests for the diagnosis of PAD and IC in order to improve the long 
term prognosis and quality of life of those afflicted with the disease. Another 
reason for the development of additional tests for the detection of IC (such as 
using 3NT as a biomarker) is that physician awareness of PAD diagnosis is 
low (Hirsch, Criqui, Treat-Jacobson et al. 2001). 
1.3. 
As it has been established that 3NT is present within the lesions of those 
suffering from atherosclerosis and since IC is a clinical manifestation of 
systemic atherosclerosis (PAD) it is hypothesised that those patients suffering 
from IC will have high circulating 3NT levels. Moreover, that there will be a 
correlation between circulating 3NT levels in patients and the degree of 
claudication.  
Aims and objectives 
As such the overall aim of this study was to investigate 3NT as a potential 
marker of oxidative stress in people suffering from IC. In order to establish the 
presence of 3NT within the plasma of claudicants, immunoassays, based on 
enzyme linked immunosorbant assay (ELISA), were developed along with 
techniques to visualise the presence of 3NT in plasma samples such as 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), 
Coomassie staining and Western blotting. Additional chromatography 
methods employing affinity purification were also be developed and used 
along with mass spectrometry to further confirm the presence/absence of 3NT 











Subjects who, following consultation with a vascular consultant, had been 
diagnosed as suffering from IC were enrolled onto this study in order to 
assess the validity of using 3NT as a marker of oxidative stress.  
In general the claudicants enrolled onto this study had been referred to the 
vascular clinic after presenting to their general practitioner with symptoms of 
leg pain upon exertion. Upon referral to the vascular clinic the patient would 
initially meet with the consultant where a full patient history was taken. These 
patients then underwent a lengthy medical examination including the 
completion of a questionnaire by a nurse practitioner and taking a full medical 
history along with the examination for the presence/absence of pulses in the 
arms, neck and legs and if there were any bruits present. Haemodynamic 
variables were also measured and recorded at this point, which included 
brachial and ankle blood pressure measurements, to allow the patient’s ABI to 
be ascertained. Once all of the necessary information had been gathered the 
nurse would then consult with the vascular consultant and a diagnosis would 
be made. If the diagnosis of IC was confirmed it was at this point that a patient 
was approached with regards to potential enrolment onto this study and a 
sample of blood taken. Medical information was recorded from that obtained 
by the nurse and consultant during the diagnostic process. 
Introduction 
Within this chapter the medical information gathered from the claudicants 
enrolled, along with that gathered from the control subjects, was evaluated in 
relation to diagnosing IC. This was done in order to assess the 
appropriateness of the current diagnostic tools used in the diagnosis of IC and 
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to highlight the potential need for additional diagnostic tools such as using 





Materials & methods 
Enrolment of claudicants 
Materials: 9ml EDTA blood tubes obtained from Starstedt. Flexi Dopplex 




: Ethical approval was obtained from the Wolverhampton District 
Local Research Ethics Committee, (see appendix A-C for proposal, 
information sheet, consent form and questionnaire). Patients attending the 
weekly vascular disease clinic at Wolverhampton New Cross Hospital were 
assessed for IC by the consultant vascular surgeon and support team after 
reporting leg pains upon exertion to their GP. This assessment included 
measurement of the patients’ ABI (see 2.2.4. below) and taking a full medical 
history. Following consultation those diagnosed with IC were approached for 
enrolment onto the study. Volunteers signed an informed consent form, after 
reading an information sheet (see appendix B), and a blood sample was taken 
into 9ml EDTA tubes. Patients previously diagnosed with IC at the clinic who 
were making a return visit were excluded from enrolment. Samples were 
stored at 4oC during transit (maximum of 2 hours) until the plasma was 
separated from the whole blood using centrifugation for 5 minutes (700 x g). 
The plasma was then divided into two aliquots, one stored at –20oC and one 
at –80oC. The sample stored at –20oC was used as the working aliquot.   
Ethical approval was obtained from Coventry University School of Science 
and the Environment Research Ethics Committee (see appendix D-F for 
Enrolment of control subjects 
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proposal, information sheet, consent form and questionnaire). Healthy 
individuals, approximately age matched to the claudicants, were enrolled onto 
the study. Volunteers signed an informed consent form, and a blood sample 
was taken as before. Past medical history and the patients’ ABI were also 
recorded. The plasma samples were then processed along with the patient 
plasma samples as described in chapter 4. 
2.2.3. 
The BMI was calculated for all subjects, where height (cm) and weight (Kg) 
data were available, as follows:  




Each patient was then categorised using their BMI into the relevant 
classification system illustrated below in Table 2.2.i. 
 
2.2.4. 
Brachial blood pressure measurements were taken from both arms by use of 
a sphygmomanometer and stethoscope. The mean arterial pressure (MAP) 
was calculated as follows: 
Blood pressure and ankle brachial index (ABI) 
BMI =  
Weight (Kg) 






Pressures were also measured for the posterior tibial and dorsalis pedis 
arteries using a sphygmomanometer and a hand held continuous Doppler 
probe. All pressures were recorded with the subjects in a supine posture. The 




The value obtained was then categorised using the classification system 
illustrated below in Table 2.2.ii. 
 
Table 2.2.ii.  ABI classifications. (Daigle 2002) 
 
ABI =  Highest ankle systolic pressure (mmHg) 
Highest brachial systolic pressure (mmHg) 
 
MAP = Diastolic blood pressure + ⅓ pulse pressure 
 






Patients diagnosed with IC (claudicants) were enrolled onto the study over a 
12 month period between September 2002 and September 2003. In total, 33 
patients (26 male and 7 female) were enrolled along with 6 generally fit and 
healthy control subjects from Coventry University (4 male and 2 female). A 
blood sample was collected from all participants along with a record of their 
medical history. 
Claudicant and Control subjects 
  Claudicants Control 
Age 
(years) 
Male 64 ± 8 54 ± 8 
Female 74 ± 10 53 ± 2 
Total 66 ± 9 54 ± 6 
Table 2.3.i. Summary age data for claudicant and control subjects enrolled. 
The above data was collated for both the claudicants (n=33) and the 
control subjects (n=6). Mean ± standard deviation. 
 
With regards to gender and race the majority of the patients enrolled were 
male (79%) and 81% were Caucasian. For the control subjects 67% were 
male and all were Caucasian. 
2.3.2. 
For those patients where height (metres) and weight (kilograms) were 
available their body mass index (BMI) was calculated and categorised (see 
Table 2.2.i.). The mean BMI for the claudicants was 27 (±5) and was thus 
situated within the overweight category (Table 2.3.ii). More than 50% of the 
male claudicants had BMI values which were situated within the overweight 
Body mass index 
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BMI range whereas the female claudicants had a greater percentage situated 
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Table 2.3.ii. BMI classifications for claudicants and control subjects. 
For the claudicants n=23 (n=19 male & n=4 female). The data in brackets 
is that for the control subjects, (n=6, 4 male and 2 female). 
2.3.3. 
Bilateral brachial blood pressure measurements were obtained for each 
participant. Minimal differences in bilateral systolic and diastolic pressures 
were observed for the control subjects and the claudicants (Table 2.3.iii.). It 
was clear that there were noticeable differences in the values obtained both 
within and between gender (more so for systolic blood pressure). Systolic 
blood pressure (SBP) measurements >140mmHg were recorded in 85% of 
the claudicants, and 42% had measurements >160mmHg. With regards to 
SBP it was also observed that the female claudicants had somewhat higher 
recorded readings compared to their male counterparts (e.g. +19mmHg with 
regards to right hand side SBP measurements). There was a less noticeable 
difference when measuring the diastolic pressures (DBP), again the females 




between subjects with regards to the control subjects enrolled along with an 
observed difference between the genders, although this was not so apparent 
(Table 2.3.iii). The mean arterial pressures (MAP) were calculated for all of 
the participants involved and these values further confirmed that the female 
claudicants and control subjects had higher and more variable blood pressure 
readings compared to their male counterparts, Table 2.3.iii. 
  Claudicants 
















































Table 2.3.iii. Summary brachial blood pressure measurements for claudicant and 
  control subjects. 
The above data was collated for both the claudicants (n=33) and the 
control subjects (n=6). Data in brackets represents control subject data. 
MAP – mean arterial pressure; determines the rate of blood flow 
through the circuit. All claudicant blood pressure data was measured by 
a nurse practitioner, the control blood pressure readings were recorded 
by an experienced physiologist at Coventry University. All 
measurements were recorded using a mercury sphygmomanometer, 
Mean ± standard deviation. 
2.3.4. 
When diagnosing claudication it is important to identify common risk factors 
acknowledged to be connected to the development of such vascular disease. 
Claudication risk factors 
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Of the claudicants enrolled, 85% reported that they were or had been smokers 
(55% current smokers, 30% ex smokers). Hypertension (61%), 
hyperlipidaemia (52%) and family history of cardiovascular events (52%) were 
the other major risk factors identified in the majority of the claudicants enrolled 
(Table 2.3.iv). Within the control population all of the males reported that they 
were current or ex smokers and one male subject presented with pre-
diagnosed hypertension. Furthermore 67% of the control subjects reported a 
family history of cardiovascular events.  
Risk factors 
Claudicants Control 
Male Female Total Male Female Total 
Smoking 
(%) 
Current 50 71 55 50 -- 33 
Past 38 -- 30 50 50 50 




Diabetes 19 71 24 -- -- -- 
Hypertension 62 57 61 25 -- 17 
MI 12 -- 9 -- -- -- 
Angina 27 14 24 -- -- -- 
CVA 12 14 12 -- -- -- 
TIA 12 14 12 -- -- -- 
Hyperlipidaemia 54 43 52 -- -- -- 
Family history 50 57 52 50 100 67 
Table 2.3.iv. Risk factors associated with vascular disease reported to be present in 
claudicant and control subjects.  
Claudicants n=33 (26 male, 7 female). Controls n=6 (4 male, 2 female). 
This data was recorded from patient medical notes (where available) 
and self reported using a questionnaire (which was the same for both 
the claudicants and control subjects, see appendices C and F). Family 
history was determined by asking the individuals if there was a close 
family member (mother, father, siblings and/or grandparents) who had a 
history of any of the disorders listed in the table above. 
MI - myocardial infarction; CVA - cardiovascular accident; TIA - 




For all of the claudicants a list of prescribed medications was obtained. It was 
clear from the medical notes of the claudicants enrolled that the majority were 
on a ‘cocktail’ of vasodilator and diuretic medication. These drugs can be used 
for the treatment of hypertension, arrhythmias and angina, although it was not 
always clear what they had been prescribed for. Other drugs being taken 
included anti-clotting drugs such as aspirin and drugs used for the direct 
treatment of angina, diabetes, gastric ulcers and urinary tract problems. In the 
case of the control subjects one male was on prescribed drugs for 
hypertension (angiotensin converting enzyme (ACE) inhibitor, calcium channel 
blocker and diuretic) and one male was on an anti-arrhythmia drug. No in 
depth analysis of the drugs being taken was carried out. 
2.3.5. 
All of the claudicants enrolled (with the exception of one patient) reported that 
they had been suffering from symptomatic IC for a minimum of 1 year. 
Bilateral calf pain was the most predominant IC symptom reported by both the 
male and female claudicants enrolled (Table 2.3.v). Although the majority of 
the patients enrolled reported that the symptoms present were bilateral within 
the calf area (68%), bilateral IC pain was also experienced within the 
thigh/buttock region (33%) and foot (12%). The reported distance walked by 
the claudicants prior to the onset of IC pain was found to be somewhat 
variable with the female claudicants reporting a reduced distance compared to 
their male counterparts (Table 2.3.v). The period of rest needed for recovery 
from symptoms was again found to differ considerably between claudicants 
and was reported to be between 1-10 minutes with a mean value of 4 minutes 




walked prior to the onset of pain and the recorded ankle brachial index (ABI, 
correlation coefficient 0.08 and 0.28 when compared to left and right hand 
side ABI measurements respectively). Again no correlation could be 
established when comparing the reported recovery time and the ABI 
measurements (left and right independently) nor the distance walked before 
the onset of pain and the recovery period required by an individual.  
  Male Female Total 
Thigh/Buttock pain 
(%) 
Left 39 14 39 
Right 50 29 46 
Calf pain 
(%) 
Left 77 86 79 
Right 85 71 82 
Foot pain 
(%) 
Left 19 14 18 
Right 23 14 21 
Distance before onset of pain 
(m) 
Mean ±SD 117 ±99 83 ±73 110 ±94 
Recovery time (min) Mean ±SD 4 ±3 4 ±3 4 ±3 
Table 2.3.v.  Symptoms of claudication reported by enrolled patients. 
Claudicants n=33 (26 male, 7 female). The symptoms were self reported 
to a nurse practitioner during the initial consultation for the presence of 
IC; all of the subjects enrolled were consequently diagnosed with 
intermittent claudication. None of the control subjects enrolled reported 
any symptoms associated with the presence of claudication. ± SD – 
Standard deviation. 
2.3.6. 
The ABI was ascertained for the claudicant and control subjects using the 
brachial SBP recordings and by measuring the ankle systolic pressure (the 
higher value of the dorsalis pedis or posterior tibial systolic pressure) using 
the calculation shown in section 2.2.4. For all patients the ABI value 
calculated was categorised as per Table 2.2.ii. (section 2.2.4.). In brief, an ABI 
below 0.96 was generally classified as being indicative of IC being present. It 
was found that for both the male and female claudicants the mean ABI 
Ankle brachial index 
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reflected moderate disease being present with an overall ABI for all 
claudicants of 0.77 (Table 2.3.vi. and Figure 2.3.i). No correlation was 
observed with regards to SBP and recorded ABI. Bilateral differences in the 
recorded ABIs were observed in both the male and female claudicants. For 
the male claudicants these values were situated within the same disease 
classification bracket however for the females the bilateral measurements fell 
within two different classification brackets (mild and moderate disease). As 
highlighted in Figure 2.3.i. a small number of the patients (18%) subsequently 
diagnosed with IC had ABI values that fell within the generally normal ABI 
classification as set out in Table 2.2.ii., section 2.2.4., although IC symptoms 
were being experienced. In a small percentage of claudicants the recorded 
ABI values also signified the presence of moderate-severe (3%) and severe 
disease (3%) (Figure 2.3.i). 
All of the control patients enrolled, with the exception of the one male, lay 
within the >0.96 bracket (bilaterally), suggesting no disease was present. The 
male control subject who lay out of the normal range (bilaterally) was placed 
within the mild disease classification and had been pre-diagnosed with 
hypertension. 
   Claudicants Control 





























Table 2.3.vi. Recorded ABI measurements for claudicant and control subjects. 
Claudicants n=33 (26 male, 7 female). ±SD – Standard deviation. 
Controls n=6 (4 male, 2 female). The above data represents the highest 
ABI recording for each leg; for a more detailed breakdown of ABI 




































Figure 2.3.i. Percentage distribution of claudicants in each ABI classification. 
The above data represents the % ABI measurements for each leg and 
their severity classification. Claudicants n=33, 26 male (left leg (), right 
leg ()), 7 female (left leg (), right leg ()).  
All of the control patients enrolled, with the exception of the one male, 
lay within the >0.96 bracket (bilaterally). The male control subject who 
lay out of the normal range (bilaterally) was placed within the mild 







The claudicants enrolled onto this study are not necessarily representative of 
the whole claudicant population. It was originally intended to enrol 
approximately 200 subjects; however after 12 months of weekly clinic 
attendance only 33 claudicants were enrolled. The reasons for this were 
thought to be due more to the type of clinic being run by the consultant 
vascular surgeon involved rather than a reflection of the numbers of 
claudicants within the population as a whole. That is, the clinic from which the 
subjects were enrolled onto the study was a general vascular clinic where 
many of the patients attending had vascular problems other than IC e.g. 
severe leg ulceration. This resulted in only 4-5 new patients being enrolled a 
week, also those patients who were attending follow up consultations having 
been previously diagnosed with IC were excluded from this study due to 
treatment already having begun. Thus it is acknowledged that any 
assumptions and conclusions made from this data set may be limited.  
It has been suggested that referral to a vascular surgeon may only be 
necessary when the primary care team are not confident in making such a 
diagnosis, or lack the resources necessary to monitor and treat the disorder, 
or where there are suspected weak/absent femoral pulses (Burns, Gough and 
Bradbury 2003).  The low number of claudicants attending this clinic may 
therefore have been a reflection of low GP referral.  
Enrolment of claudicant and control subjects 
The time needed to diagnose a patient with claudication was somewhat high, 
approximately 30-45 minutes per patient which could also explain why only 4-
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5 new patients were seen at each clinic. The consultation consisted of a full 
patient history being taken by the consultant followed by a thorough medical 
examination and completion of a claudication questionnaire by a nurse 
practitioner. This included the examination for the presence/absence of pulses 
within the arms, neck and legs and to establish if there were any bruits 
present, especially within the aorta and the carotid arteries. Haemodynamic 
variables were also measured at this point which involved recording the 
brachial and ankle blood pressures, which then allowed the patient’s ABI to be 
ascertained. A diagnosis would then be made following a review of the 
findings of the medical examination by consultant.  
The time and resources needed for such a diagnosis to be made clearly 
highlights the need for complementary and perhaps more objective diagnostic 
tools e.g. a biomarker such as 3NT in order to aid the prompt diagnosis of IC. 
The implementation of such a diagnostic tool would allow for the blood test to 
be taken prior to the date of the consultation and the results used in 
conjunction with the current process which may speed up the diagnostic 
process, allowing more patients to be seen within each vascular clinic.  
It is important to note that, although this study is based upon patients suffering 
from IC (a clinical manifestation of PAD), it is probable that those enrolled also 
had systemic atherosclerosis in which multiple arteries are affected. Although 
the severity of atherosclerosis in one area does not allow for the prediction of 
severity in arteries elsewhere it suggests multiple areas being affected. For 
example, one study suggests that further disease extension is almost 
obligatory once more than three atherosclerotic plaques pre-exist in a subject 




PAD has been found by others to disproportionately affect non-hispanic 
blacks (Newman, Shemanski, Manolio et al. 1999, Selvin and Erlinger 2004) 
but the sample size within this study was not big enough to determine this and 
information regarding ethic origin was not always provided, as such no 
analysis with respect to the local population was made. 
Claudicant and control subject data 
Regarding the pathobiological determinants of atherosclerosis in youth 
(PDAY) studies it has been well documented that early atherosclerotic lesions 
can be found in the arteries from a young age (McGill, McMahan, Herderick et 
al. 2000) and that the progression of these early plaques into clinically 
manifest atherosclerotic disease is significantly increased by the presence of 
many different risk factors including age and gender. Within this patient 
population the majority of those claudicants enrolled were male (79%), which 
concurs with previous reports showing that males are at a higher risk of 
atherosclerotic disease compared to their female counterparts (pre-
menopause) (Adams, Williams and Kaplan 1995, Murabito, D'agostino, 
Silbershatz et al. 1997, Kiechl and Willeit 1999, Ridker, Stampfer and Rifai 
2001). It has also been reported that women with PAD are less likely to report 
symptoms of IC than men (Meijer, Hoes, Rutgers et al. 1998, Meru, Mittra, 
Thyagarajan et al. 2006). This observed difference between genders is 
thought primarily to be due to hormonal differences and that these differences 
disappear within 5 years of the menopause after which the progression rate of 
any disease present is similar to that observed in males (Adams, Williams and 
Kaplan 1995, Kiechl and Willeit 1999). The age range of the claudicants 
enrolled onto this study was broad (49-87 yrs) for females; the mean age was 
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found to be 10 years higher than for their male counterparts (74±10 yrs and 
64±8 yrs respectively). Rosamond et al (2007) report cardiovascular events 
increase dramatically with age in females but 10 years later than their male 
counterparts, although this gap decreases with advancing age. 
The mean age of the control subjects was lower than that observed in the 
claudicants (male 54±8 yrs, females 53±2 yrs) and as such was not entirely 
representative of the age range observed for the claudicant population 
enrolled. Originally the intention was to enrol healthy age matched hernia 
patients who were attending the same vascular clinic as the claudicants, as 
mentioned above. However, upon assessment, it was found that those 
approached, who were of comparable age to the claudicants, were 
symptomatic of PAD being present and as such were not suitable control 
subjects. The difficulties found enrolling appropriately age matched control 
subjects were not entirely surprising as it is well documented that the 
presence of PAD dramatically increases with advancing age in both sexes 
(Selvin and Erlinger 2004) and with respect to males the relative risk factor for 
the development of IC increases 2-3 fold with each individual decade of life 
(Dormandy, Heeck and Vig 1999).  
It is clear that age and being male are unavoidable risk factors associated with 
the development of clinically significant arterial disease, such as IC, 
(Dormandy, Heeck and Vig 1999, Khan, Flather, Mister et al. 2007). It is 
however important that an assessment of the relative risk of the development 
of IC should not be solely made on the basis of age and gender but should be 
made in conjunction with the presence of other major risk factors such as 




It has long been noted that a high BMI is associated an increased risk of 
atherosclerosis and associated vascular problems along with the development 
of other major risk factors such as diabetes type II and hypertension (Medalie, 
Papier, Goldbourt et al. 1975, McGill, McMahan, Malcom et al. 1995, 
Murabito, Evans, D'agostino Sr et al. 2005). Adiposity as measured by BMI or 
panniculus adiposus thickness has been found to be associated with more 
advanced and extensive atherosclerosis of the right coronary artery in the 
young which cannot be explained by either serum lipoprotein cholesterol 
levels or smoking (McGill, McMahan, Malcom et al. 1995). When assessing 
the body mass index (BMI) for those enrolled onto this study it was clear that 
there was little difference in the mean BMI values for the male and female 
claudicants, both being situated within the overweight category (26±4, 28±7 
respectively). These values are similar to those previously reported in a study 
of patients with PAD referred to UK vascular clinics (Khan, Flather, Mister et 
al. 2007), although some studies suggest a BMI >30 as a risk factor for IC 
(Murabito, Evans, D'agostino Sr et al. 2005). It is important to note that there 
are differing arguments with regards to the direct effect of obesity on 
atherosclerosis. Although obesity (as determined by BMI) may be of 
importance, some studies have suggested that there is no evidence that a 
high BMI is directly associated with prevalent PAD when no other risk factors 
are present (Solberg and Strong 1983, Selvin and Erlinger 2004). A review of 
autopsy studies also highlighted the fact that there is no consistent direct 
association with regards to obesity and the degree of atherosclerosis present 
(Solberg and Strong 1983). Despite these contradictory reports, all of those 
Body mass index 
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claudicants whose BMI was outside of the normal range were advised to 
address this issue and start a weight loss program in order to reduce their BMI 
and thus risk of further complications.   
2.4.4. 
The findings of this study were not dissimilar to those previously reported 
regarding risk factors associated with the development of clinically significant 
atherosclerosis (McGill, Strong, Tracy et al. 1995, Morrow, Frei, Longmire et 
al. 1995, Waters, Lesperance, Gladstone et al. 1996, McGill, McMahan, 
Malcom et al. 1997, Murabito, D'agostino, Silbershatz et al. 1997, Petruzzelli, 
Puntoni, Mimotti et al. 1997, Selvin and Erlinger 2004, Leibson, Ransom, 
Olson et al. 2004). 95% of persons with prevalent PAD, presenting as IC for 
example, have at least one of the major risk factors attributed with traditional 
cardiovascular disease; namely current smoking status, diabetes, 
hypertension and hypercholesterolaemia (Selvin and Erlinger 2004, Leibson, 
Ransom, Olson et al. 2004). The findings of this study support this with 
current smoking and hypertension being the most prevalent.  
Claudication risk factors 
It has been well documented that hypertension is a risk factor for the 
development of clinically significant atherosclerosis and is thought to be 
attributable to the development of PAD. During the PDAY studies it was 
highlighted that hypertension was positively associated with accelerated 
atherosclerosis in youth, with particular reference to the development of 
fibrous plaques (McGill, Strong, Tracy et al. 1995). Further reports by this 
group go on to suggest that in both men and women, in the third decade of 
life, hypertension augments atherosclerosis principally by accelerating the 
conversion of fatty streaks to raised lesions and importantly that the effect of 
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hypertension increases with age (McGill, McMahan, Tracy et al. 1998). It is 
the conclusion of the PDAY study that by the beginning of the fourth decade 
of life those subjects who are hypertensive have approximately twice the 
extent of raised lesions (in their coronary arteries) when compared to 
normotensive subjects (McGill, McMahan, Tracy et al. 1998). This clearly 
highlights the importance of monitoring such haemodynamic variables and 
more so the need of non-invasive quick tests for the early diagnosis of the 
presence of atherosclerotic disease such as PAD before the onset of clinically 
significant symptoms such as IC.  
Within the published literature it is clear that there are differing values used 
with regards to the cut-off limits used for the definition of the presence of 
hypertension. In general hypertension is defined as any of the following being 
present; SBP ≥140mmHg and/or DBP ≥90mmHg or where anti -hypertensive 
drugs are prescribed (Meijer, Hoes, Rutgers et al. 1998, Hirsch, Criqui, Treat-
Jacobson et al. 2001, Rosamond, Flegal, Friday et al. 2007). Within this 
definition there are also subcategories for hypertension, for example within the 
Framingham heart study (FHS) blood pressure measurements were classified 
as normal (SBP <130mmHg ± DBP <85mmHg), high normal (130-139mmHg 
± 85-89mmHg), stage 1 hypertension (140-159mmHg ± 90-99mmHg), or 
stage 2 hypertension (≥160mmHg ± ≥100mmHg) (Murabito, D'agostino, 
Silbershatz et al. 1997).  In the current study mean SBP’s recorded for the 
claudicants and control subjects suggested hypertension being present, with 
85% of the claudicants having a SBP >140mmHg. Although most of the 
claudicants enrolled were being prescribed anti-hypertensive drugs, the 
current recommended therapeutic goal to achieve <140mmHg systolic over 
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90mmHg diastolic (non-diabetics) in order to reduce the risk of serious 
cardiovascular events and death (Hirsch, Haskal, Hertzer et al. 2006, Khan, 
Flather, Mister et al. 2007) was clearly not being met. In general the female 
claudicants enrolled had SBP readings that were somewhat higher than their 
male counterparts (+19mmHg). This agrees with previously published reports 
in which it has been found that after 54 years of age a higher percentage of 
women have hypertension (Rosamond, Flegal, Friday et al. 2007) and higher 
SBP measurements in females suffering from PAD have been observed 
(Khan, Flather, Mister et al. 2007). Ness et al (2000) reported that when 
hypertension is present there is a significant increased risk of developing PAD 
for both elderly males and females (2.2 and 2.8 times respectively).  
Of the reported risk factors, current smoking status has been identified as an 
important independent risk factor for the development of PAD (Al-Delaimy, 
Merchant, Rimm et al. 2004) and in particular is the most powerful predictor of 
large vessel PAD progression (Aboyans, Criqui, Denenberg et al. 2006). 
Waters et al (1996) demonstrated that atherosclerosis progressed much more 
rapidly in the coronary arteries of smokers compared to non-smokers. In this 
study 85% of the claudicants reported being current or ex-smokers and all of 
the male control subjects reported being current/ex smokers. Jenson et al 
(2005) and Khan et al (2007) also report a strong positive association 
between the prevalence of IC and current and/or previous smoking habits. 
Within this study no analysis was made of the duration of smoking and level of 
smoking (determined by pack/years) due to the documented unreliability of 
patient-offered smoking history (Hobbs, Wilmink, Adam et al. 2005).  
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The presence of diabetes has long been classed as a risk factor for the 
development of atherosclerosis (McGill, McMahan, Malcom et al. 1995, Dolan, 
Liu, Criqui et al. 2002) and a  significantly increased risk of developing PAD 
has been established in elderly men and women suffering from diabetes, type 
I and II (Ness, Aronow and Ahn 2000, Leibson, Ransom, Olson et al. 2004). It 
increases the incidence of and accelerates the clinical course of 
atherosclerosis within the coronary and extracranial carotid arteries along with 
the vascular beds of the lower extremities (Beckman, Creager and Libby 
2002). For example atherosclerotic plaques have been found in the arteries of 
young adults identified as being in a pre-diabetic or early diabetic state, as 
indicated by elevated post-mortem glycohaemoglobin levels (McGill, 
McMahan, Malcom et al. 1995). 
Type II diabetes represents more than 90% of those patients with diabetes 
and atherosclerosis (Beckman, Creager and Libby 2002). A questionnaire 
based study of males indicated that there is a strong correlation between the 
duration of diabetes (type II) and the risk of developing PAD. The study 
suggested that increased risk was further strengthened in men with 
hypertension and who were current smokers (Al-Delaimy, Merchant, Rimm et 
al. 2004). Diabetes is also thought to play a unique role in the progression of 
PAD in that it is a significant predictor for the presence of small vessel PAD 
progression (Aboyans, Criqui, Denenberg et al. 2006). In the claudicant 
population enrolled on this study 24% had been pre-diagnosed with diabetes 
which agrees with the findings of Khan et al (2007).  
In a study comparing lower extremity function & dysfunction in diabetics and 
non-diabetics with PAD it was found that although there was no observed 
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difference in the recorded ABI values it was apparent that those participants 
suffering from both diabetes and PAD were less likely to report classical 
symptoms of IC. Overall it was identified that those patients in which PAD and 
diabetes were found to coexist tended to be younger in age, had a higher 
BMI, an increased prevalence of hypertension and poorer lower extremity 
function compared to those who had PAD alone (Dolan, Liu, Criqui et al. 
2002). It has been suggested that a potential reason behind the higher 
prevalence of PAD in diabetic subjects compared to non-diabetic subjects 
may be due to increased mean levels of triglycerides and SBP (MacGregor, 
Price, Hau et al. 1999). Thus this clearly highlights that those with diabetes 
are a subset of patients in which the development of a biomarker to screen for 
the presence of PAD/IC may be extremely beneficial. 
The current lipid status of the claudicants enrolled was not available and so no 
interpretation of this risk factor was possible, although 52% of those 
claudicants enrolled had been pre-diagnosed with hyperlipidaemia. A high 
percentage of claudicants and control patients reported a family history of 
cardiovascular events (67% and 52% respectively) and to a lesser extent had 
already suffered a cardiovascular event themselves (e.g. MI, angina, 
CVA/TIA). The findings relating history of prior coronary/cerebral artery 
disease were also similar to those recently reported by Khan et al (2007).  
2.4.5. 
Within the claudicant population enrolled onto this study (with the exception of 
one male patient) all reported suffering symptoms suggesting of IC being 
present for >1 year. The mean estimated claudication walking distance 
reported by the patients was 110±94 m which is similar to that reported by 
Claudication symptoms and ABI 
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Khan et al (2007). There was a reduced reported walking distance in the 
females enrolled compared to their male counterparts (83±73 m and 117±99 
m respectively). The calf area was found to be the main area in which IC 
symptoms were reported to be present upon mild exertion although some 
patients also reported experiencing claudication pain within the thigh/buttock 
region and foot. For all of these regions it was found that there was a slightly 
higher incidence of reported pain in the right leg compared to the left.  
It has been well reported that a reduced ABI is an indicator of the presence of 
LV-PAD being present (Feigelson, Criqui, Fronek et al. 1994, Newman, 
Shemanski, Manolio et al. 1999, Hirsch, Criqui, Treat-Jacobson et al. 2001, 
McDermott, Greenland, Liu et al. 2002, Aboyans, Criqui, Denenberg et al. 
2006). Patients with a reduced ABI are also generally regarded as having an 
unfavourable cardiovascular risk profile (Meijer, Hoes, Rutgers et al. 1998, 
O'hare, Katz, Shlipak et al. 2006) and an ABI<0.9 is an independent risk factor 
for incident and recurrent CVD and mortality (Newman, Shemanski, Manolio 
et al. 1999). In general the majority of patients with IC are expected to have 
ABIs ranging between 0.3-0.9 (Sacks, Bakal, Beatty et al. 2003) within this 
study the recorded ABIs were found to range from 0.18-1.10. The overall 
mean ABI for the claudicants enrolled was found to be 0.77 with only small 
bilateral differences observed for the male claudicants and a slightly higher 
right-hand sided mean ABI value for the female claudicants. Again these 
findings are similar to those that have been previously reported (Hirsch, 
Criqui, Treat-Jacobson et al. 2001, Khan, Flather, Mister et al. 2007). In 
contrast, unlike the findings of Khan et al (2007), no correlation was observed 
regarding the distance walked prior to the onset of claudication pain and the 
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recorded ABI, reported recovery time nor SBP and ABI. This may have been 
due to the small claudicant population recruited onto this study.  
Although it has been clearly highlighted that ABI measurement is an effective 
tool with regards to the diagnosis of PAD there are issues surrounding it that 
need to be highlighted. It is well known that there are instances in which an 
ABI measurement is not necessarily a good indicator of lower limb perfusion, 
for example within this study 18% of those enrolled had a mean ABI ≥0.96. If 
this were used as the only screening tool by a GP practitioner these patients 
could have been falsely regarded as not having PAD/IC. Artificially elevated 
ABI measurements can be obtained in patients who have heavily calcified 
non-compressible arteries, like those found in diabetics (Orchard and 
Strandness 1993, Sacks, Bakal, Beatty et al. 2003, Leibson, Ransom, Olson 
et al. 2004, Cassar 2006). McDermott et al (2002) reported that due to having 
calcified lower extremity arteries, which resulted in artificially increased 
pressure, approximately 5% of persons with PAD have a normal ABI. The 
effects of artificially elevated ABI readings due to such issues could potentially 
result in underestimation of disease severity or even worse patients being 
misdiagnosed as being clear of PAD. As such this is a worrying finding when 
considering the elevated CV risk that is associated with the presence of PAD 
(Sacks, Bakal, Beatty et al. 2003). Another issue surrounding the use of ABI 
as an indicator of the presence of PAD is the fact there that there is no 
consensus regarding the cut-off levels currently being used to diagnose PAD. 
Although it is generally accepted that an ABI <0.9 suggests large vessel 
disease being present this value is an arbitrary value and may result in some 
patients being incorrectly classified as having only mild atherosclerosis 
 45 
 
(Meijer, Hoes, Rutgers et al. 1998, Newman, Shemanski, Manolio et al. 1999). 
This lack of consensus may help to explain the different levels of PAD 
prevalence reported within different studies (Meijer, Hoes, Rutgers et al. 
1998).  
The incidence of IC has been found to have declined within the general 
population since 1950 but it has been observed that the level of mortality has 
stayed the same. Within their study on the trends in the incidence of IC 
between 1950-1999 Murabito et al (2005) found that approximately 40% 
patients die within 10 years following initial diagnosis of IC. Due to this 
increased risk of mortality associated with the presence of symptomatic 
vascular disease such as IC, it is clear that such patients need to be 
diagnosed a lot earlier in their disease progression. Furthermore, although the 
prevalence of PAD has been demonstrated to be high within the elderly in 
primary care settings, very few of these have been found to report 
symptomatic leg pain which has led to a diagnosis of IC (Meijer, Hoes, 
Rutgers et al. 1998, Hirsch, Criqui, Treat-Jacobson et al. 2001, McDermott, 
Greenland, Liu et al. 2002). For example Hirsch et al (2001) report that of 
those found to be suffering from PAD only 8.7% reported classical 
claudication symptoms. This is important if patients are only referred to 
vascular surgeons for diagnosis on the basis of reporting classical 
claudication symptoms as it indicates that a potentially large percentage of 
PAD sufferers (85-90%) are not being diagnosed. This low level of IC 
incidence in those found to be suffering from PAD can in part be explained by 
the fact that the elderly may not be walking far enough to experience 
symptoms of IC due to concurrent medical conditions such as osteoarthritis 
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and as such are not consulting their GP for treatment. It is also a concern that 
although there are current recommendations that the ABI test should be 
administered to all patients being evaluated for PAD (Sacks, Bakal, Beatty et 
al. 2003, Hirsch, Haskal, Hertzer et al. 2006) this is not always the case in a 
primary care setting, Findings suggest that clinicians who utilise a classic 
history of claudication alone to detect PAD or do not use an ABI test as 
routine in patients in which common risk factors are present may be missing a 
large percentage of PAD diagnoses (Hirsch, Criqui, Treat-Jacobson et al. 
2001, Khan, Flather, Mister et al. 2007). 
All of the risk factors identified within patients suffering IC, a major clinical 
manifestation of PAD, are also strongly associated with an increased risk of 
more serious atherosclerotic disease. This in itself should then act as a 
warning sign regarding an increased risk of a serious cardiovascular 
event/death occurring in these patients and therefore highlights the need for 
effective diagnosis and management of IC. Although ABI measurements have 
been shown to be an effective tool in the diagnosis of clinically significant 
PAD, in which blood flow is being obstructed, as highlighted in this study and 
by others (McDermott, Greenland, Liu et al. 2002) there are issues regarding 
cases where IC is present but an ABI ≥0.96 is recorded. The data presented 
here agrees with that previously published and illustrates issues surrounding 
the effectiveness of current protocols in place for the early diagnosis of PAD 
prior to the onset of clinically significant manifestations such as IC. An ABI 
<0.9 is indicative of the presence of already diffuse and advanced 
atherosclerosis; as such ABI is more specific to advanced atherosclerotic 
disease and thus may not a useful screening test for early vascular disease 
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(Newman, Shemanski, Manolio et al. 1999). This clearly highlights the need 
for additional screening methods to be developed in order to aid in the early 
diagnosis and administration of risk factor intervention and treatment of 










Since Ohshima et al (1990) first reported 3-nitrotyrosine (3NT) as an in vivo 
marker of reactive nitrogen species, several methods have been developed in 
order to detect both free and protein-bound 3NT within human biological fluids 
and tissues. The methods developed range from simple spectrophotometric 
techniques through to mass spectrometry. In general, the specificity and 
sensitivity of the different methods available for the detection of 3NT varies 
considerably.  
The concentration of 3NT can be quantified spectrophotometrically (A430) at 
alkaline pH due to the pKa of the phenolic group of 3NT (7.5) being 
considerably lower than that of tyrosine (10). As a result of this difference 3NT 
has a peak at 430nm under basic conditions, in addition to the peak observed 
at 280nm. Unfortunately this method it is suitable only for isolated relatively 
‘pure’ proteins due to the potential for interference from prosthetic groups 
which absorb in the 350-450nm region e.g. haem (Crow and Ischiropoulos 
1996). Therefore more specific assay methods are required to detect 3NT-
residues in tissue homogenates and plasma.  
Introduction 
Within biological samples a number of different methods have been reported 
for the separation, detection and quantification of free and protein-bound 3NT. 
These include methods involving the use of high performance liquid 
chromatography (HPLC) combined with various detection systems. Methods 
using HPLC combined with an ultra violet (UV) detection system for the 
detection of 3NT have been reported (Kaur and Halliwell 1994, Van Der Vliet, 
Eiserich, Kaur et al. 1996, Crow and Ischiropoulos 1996). HPLC-UV detection 
of 3NT has the advantage of being able to simultaneously detect other 
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metabolites of tyrosine such as dityrosine. A disadvantage of this method is its 
relative lack of sensitivity, only allowing for the detection of 3NT in samples of 
relatively high concentration (0.1nM) (Crow and Ischiropoulos 1996). When 
HPLC is combined with an electrochemical (EC) detector 3NT has been 
detected in amino acids, peptides and proteins with limits of detection as low 
as a few picomoles per sample (Shigenaga, Lee, Blount et al. 1997, Skinner, 
Crow, Skinner et al. 1997, Shigenaga 1999, Crow 1999, Richards, Silva and 
Devall 2006). HPLC-EC has the advantage of being 1000 times more 
sensitive than HPLC-UV.  Although chromatographic detection systems such 
as HPLC-UV and HPLC-EC are potentially highly sensitive techniques they 
have the disadvantage of requiring relatively large amounts of protein. The 
sample preparation required for such analysis also presents problems as it 
involves acid hydrolysis of the proteins to amino acids. This hydrolysis can 
give rise to the artifactual production of 3NT which may result in the 
overestimation of 3NT content of a sample (Shigenaga, Lee, Blount et al. 
1997). However, methods for the hydrolysis of proteins and subsequent 
derivatisation of 3NT and tyrosine (under alkaline conditions, thus preventing 
artifactual production of 3NT) have been developed (Frost, Halliwell and 
Moore 2000).  
In recent years several techniques employing mass spectrometry have been 
developed for the quantification and identification of 3NT-residues in biological 
samples. For example Kendall et al (2001) used high-resolution electrospray 
ionisation - Fourier transform ion cyclotron resonance - mass spectrometry 
(ESI-FTICR-MS) to confirm the presence of nitration within electrochemically 
nitrated horse heart myoglobin. Using NT-BSA as a test case, matrix assisted 
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laser desorption ionisation - mass spectrometry (MALDI-MS) has been shown 
to be capable of identifying 3NT modifications in complex peptide mixtures 
(Sarver, Scheffler, Shetlar et al. 2001). Kanski et al (2005) have also reported 
the identification of specific modified proteins in ageing skeletal muscle using 
nanoelectrospray ionisation - tandem mass spectrometry.  
The main issue with regards to methods involving HPLC, with various 
detection systems, and mass spectrometry for the detection of 3NT is that 
these techniques involve the use of specialised equipment and require 
extensive sample preparation. As such the screening of large numbers of 
biological samples such as plasma could be an issue and thus highlights the 
need for a more robust and convenient screening tool.  
Commercial and custom made polyclonal and monoclonal antibodies raised 
against 3NT are now readily available enabling the detection of 3NT using 
immunohistochemistry (Ye, Strong, Huang et al. 1996, Viera, Ye, Estevez et 
al. 1999) and immunoassays including enzyme linked immunosorbant assay 
(ELISA) (Khan, Brennand, Bradley et al. 1998, Ter Steege, Koster-Kamphuis, 
Van Straaten et al. 1998, Inoue, Hisamatsu, Ando et al. 2002). 
Immunohistochemical methods have been developed for the detection of 3NT 
in tissues using both polyclonal and monoclonal anti-3NT Abs. Using such 
methods, 3NT has been identified in atherosclerotic lesions in coronary 
arteries; for example using both mono- and polyclonal antibodies (Beckmann, 
Ye, Anderson et al. 1994, Baker, Hall, Evans et al. 1999). Although 
immunohistochemistry is extremely useful for the identification of the presence 
of 3NT within specific tissues, actual quantification of the 3NT is difficult. 
Immunohistochemical analysis of 3NT as a stand-alone assay is generally 
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regarded as a less appropriate method for the quantitative measurement of 
3NT.  
Within this study the aim was to develop novel semi-quantitative 
immunoassays (indirect and competitive ELISA) in order to detect the 
presence of 3NT-containing proteins in the plasma of claudicants. Although 
several ELISA methods have been developed for the detection of 3NT in 
human plasma for other disease pathologies (Ter Steege, Koster-Kamphuis, 
Van Straaten et al. 1998, Khan, Brennand, Bradley et al. 1998, Inoue, 
Hisamatsu, Ando et al. 2002) none have been used for the detection of 3NT in 
the plasma of claudicants. This chapter reports on the development of both 
the indirect and competitive ELISAs. It highlights important issues these 
developments have identified regarding the appropriateness of using 








All chemicals used were analytical grade and purchased from Fisher 
chemicals unless otherwise stated. Unless otherwise stated water was 
obtained by reverse osmosis (RO) to a resistance of greater than 18MΩ.cm-1 
Materials & Methods 
3.2.1. Production of custom polyclonal anti-3-nitrotyrosine antibody 
Materials: An EG&G model 273 potentiostat/galvanostat was used for 
electrochemical nitration. A platinum basket anode was made and supplied by 
The Birmingham Metal company, Birmingham UK. A saturated Calomel 
reference electrode (SCE) was purchased from ABB Kent Taylor. Keyhole 
limpet haemocyanin (KLH, H8283) was obtained from Sigma (Poole, Dorset, 
U.K.). Polyclonal antibody raised against electrochemically nitrated KLH was 
produced by AbCam (Cambridge UK).  
 
Methods:
In brief KLH (1mg/ml) was dialysed into 50mM sodium tetraborate, 20mM 
sodium nitrite pH 9, and then nitrated electrochemically using the method of 
Kendall et al (2001), to an absorbance of 0.446 at 430nm (see figure 3.2.i. for 
schematic diagram of apparatus). The nitrated KLH was desalted via dialysis 
into RO water and freeze-dried. This freeze dried product was then sent to 
AbCam (Cambridge) for production of a polyclonal anti-3NT antibody. The 
rabbit anti-3NT antibody (anti-3NT Ab) was aliquoted into Eppendorf tubes 
and stored at –80oC. The working aliquot was diluted using an equal volume 
of glycerol and stored at –20oC. 
 Electrochemically nitrated keyhole limpet haemocyanin (KLH) was 





Figure 3.2.i. Electrochemical nitration apparatus 
Electronitration (electrooxidation at an alkaline pH in the presence of 
nitrite) is an easily controlled method developed in house and using 
ESI-FTICR-MS it has been confirmed that the only reaction product is 
the nitration of tyrosine residues (Kendall, Cooper, Heptinstall et al. 
2001). Kendall et al (2001) proposed that electronitration of tyrosine 
residues may occur as a result of the oxidation of both nitrite and 
tyrosinate anions at the anode followed by a radical/radical coupling 
reaction (See Figure 1.1.ii, Chapter 1). Although it was accepted that 
they could not rule out the fact that there may be no requirement for 
tyrosine oxidation by the anode in order for nitration to occur, due to 
the possibility of the oxidation of nitrite to NO2+, nor of the formation of 























The following calculation was used to determine the level of nitration in BSA 
and HSA samples nitrated either electrochemically or with peroxynitrite, as 
described in the following sections. 
 
Using A430 to determine 3NT levels at alkaline pH. 
The extinction coefficient (ε) for 3NT = 4300M-1cm-1 (Beckman, Chen, 
Ischiropoulos et al. 1994) 
   Absorbance 4.3 = 1mM 
          A430 0.0043 = 1µM 3NT 
Relative Molecular Mass of BSA = 66000 
 For example - An absorbance at 430nm of 0.262 for nitrated BSA 
0.262/0.0043 = 60.9µM 3NT 
 
Concentration of BSA sample = 1000µg/ml = 1000mg/L 
   = 1000/66000  
   = 0.015mM  
   = 15µM BSA 
 
Therefore level of nitration = 60.9/15 
= 4.06 mol 3NT / 1mol BSA  
Spectrophotometric determination of 3-nitrotyrosine levels 
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3.2.3. Electrochemical nitration protocol 
Materials: See section 3.2.1., Bovine serum albumin (BSA, A8022) and 





 Electrochemical nitration of bovine serum albumin (BSA), human 
serum albumin (HSA) and lyophilised human plasma was as described by 
Kendall et al (2001) with modifications.  
In brief the protein was dissolved in nitration buffer to a final concentration of 
1mg/ml. The nitration procedure was continued until the required absorbance 
had been achieved at 430nm (as described in section 3.2.2.). The nitrated 
product was not separated from any unreacted protein left in solution and was 
dialysed into phosphate buffered saline (PBS, pH 7.4). The samples were 
stored in small aliquots at –20oC, diluted in an equal volume of glycerol.  
NB: When nitrating plasma the level of nitration was difficult to ascertain due 
to the colour of plasma, moreover the sample is poly-disperse with respect to 
RMM. The required A430 was thus estimated on the assumption that HSA was 
the dominant protein, thus the equation as stated in 3.2.2. was used for 
human plasma also (i.e. assumed RMM of 66000).  
Peroxynitrite was prepared as described by Beckman et al (1994). Using this 
peroxynitrite a BSA sample (1mg/ml) was nitrated as described by Khan et al 
(1998) to a level of 3mol 3NT / 1mol BSA (determined using A430, section 
3.2.2.).  
Nitration with peroxynitrite 
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In brief, three additions of the prepared alkaline stock solution of peroxynitrite 
were added to a BSA solution (1mM final concentration of peroxynitrite, 
concentration determined optically at A302 where ε = 1670 M-1cm-1 (Ye, 
Strong, Huang et al. 1996)). The level of nitration was determined using the 
measured absorbance at A430 (as described in section 3.2.2. above). The 
nitrated BSA solution was dialysed against PBS and then stored as described 
in section 3.2.3. above.  
3.2.5. 
Aminotyrosine was produced in order to assess the polyclonal anti-3NT 
antibody specificity towards 3NT residues. The nitrated tyrosine residues 
within the electrochemically nitrated BSA (4mol 3NT / 1mol BSA) were 
reduced to aminotyrosine using sodium dithionite (Crow and Ischiropoulos 
1996).  
In brief, the A430 of the nitrated BSA sample (1ml, 500µg/ml) was measured 
followed by the addition of approximately 100x molar excess of sodium 
dithionite (50µl of 100mM sodium dithionite, pH 9.5). The mixture was 
incubated for 30 minutes at room temperature. To ensure the nitrated tyrosine 
residues had been reduced to aminotyrosine the A430 was again measured to 
confirm the absorbance was zero at A430. This reduction of nitrotyrosine to 
aminotyrosine was also confirmed via dot blot immunodetection with the 
polyclonal anti-3NT Ab (see section 3.2.14. dot blot immunodection). 




Nitrated protein samples were pre-treated with a variety of denaturants in 
order to assess the effects, if any, these had on availability of the nitrated 
epitopes to the anti-3NT Ab. 
  
Nitrated protein; ELISA pre-treatment protocols 
Materials: Mercaptoethanol (M7522) and trypsin (T1426, Chymotrypsin ≤0.1 
BTEE units/mg protein) obtained from Sigma (Poole, Dorset, U.K.). 
Methods:  
Pre-treatment with urea and mercaptoethanol: To a sample of nitrated BSA, 
urea (final concentration 8M) and mercaptoethanol 0.5% (v/v), were added 
and incubated at 37oC for an optimal time (1 hour). These samples were 
prepared fresh when required. 
 
Pre-treatment by boiling with Tween 20: Nitrated BSA was diluted in PBS + 
Tween 20 (0.2%, v/v) and placed in a water bath at approximately 100oC for 5 
minutes. The sample was then diluted into an equal volume of incubation 
buffer used in the ELISA protocol (minus Tween 20) so that the final Tween 
20 concentration was 0.1%. These samples were made fresh when required. 
 
Pre-treatment by trypsin digestion: Nitrated BSA (0.5mg/ml) was dialysed into 
0.1M ammonium bicarbonate. To this nitrated BSA solution (5.5ml), 10µg of 
trypsin (5µl of 2mg/ml trypsin in 20mM calcium chloride, 1mM HCl, pH 2.7) 
was added. The solution was then incubated at 37oC for 2 hours. Following 
this another 10µg of trypsin was added and the solution was again incubated 
at 37oC for 2 hours. The reaction was stopped by boiling the sample for 
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5minutes to denature the enzyme. The samples were stored in small aliquots 
at –20oC, diluted in an equal volume of glycerol. 
 
All of the above pre-treated samples were then used for indirect and 






















3.2.7. Indirect ELISA 
 
 
The microtitre plate is coated with 
the test antigen or standard nitrated 
BSA ( ) 
 
 
The unoccupied adsorption sites 
are then blocked with SMP. The 
anti-3NT Ab ( ) is incubated with 
the antigen  
 
Following a wash phase, incubation 
with the enzyme-labelled antibody 
( , goat anti-rabbit IgG with 
alkaline phosphatase conjugate). 
 
Following a final wash phase, 
incubation with p-nitrophenol 
phosphate substrate ( ) and 
determination of the product ( ) 
 






Materials: Sero-Wel® 96 well flat bottom microtitre plates supplied by Bibby 
Sterilin, Stone, UK. Nunc MaxisorpTM 96 well flat bottom microtitre plates, 
Nunc, part of Thermo Fisher Scientific, Denmark. Immulon 2HB® 96 well flat 
bottom microtitre plates, Thermo scientific. Carbonate buffer (C3041), L-
tyrosine (T4446), 3-chloro-L-tyrosine (C5897), polyclonal goat anti-rabbit IgG 
(whole molecule alkaline phosphatase conjugate, A3812), p-nitrophenol 
phosphate substrate (N4645) and 30% hydrogen peroxide solution (H1009) 
were purchased from Sigma (Poole, Dorset, U.K.). Skimmed milk powder, 
(SMP, Oxoid). OPD tablets (BUF047B, AbD serotec). Rabbit anti human IgG 
with horse radish peroxidase conjugate (DAKO, Denmark). Anthos 2001 plate 
reader (Anthos labtec instruments). 
 
All reagent concentrations were optimised using checkerboard titration. 
Indirect ELISAs were developed using different brands of commercially 
available microtitre plates (Sero-Wel®, Nunc Maxisorp™ and Immulon 2HB®), 
differing nitration protocols as well as both native and pre-treated NT-BSA. 
 
The general protocol used was as follows: 96 well microtitre plates were 
coated with 100µl of the test samples or nitrated BSA standards (calibration 
curves ranging from 40-0µg/ml) using carbonate buffer pH 9.6. The plates 
were then incubated overnight at 4oC. Wells were blocked with 130µl 5% 
skimmed milk powder (SMP) in phosphate buffered saline (PBS x10, pH 7.4; 
80g sodium chloride, 2g potassium chloride, 28.9g sodium hydrogen 
phosphate (ortho) decahydrate, 2g potassium dihydrogen (ortho) phosphate 
made up to 1L) for 1 hour at 37oC. Following blocking the plates were washed 
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with wash buffer (PBS and 0.05% Tween 20) three times. Polyclonal anti-3NT 
Ab (at optimal dilution as determined by checkerboard analysis) was then 
added and incubated for 2 hours at 37oC. The plates were then washed as 
above. Goat anti-rabbit IgG (whole molecule alkaline phosphatase conjugate), 
1/5000 in incubation buffer, was added and incubated for 2 hours at 37oC. 
Following washing as above, substrate (p-nitrophenol phosphate substrate, 
1mg/ml in 0.1M diethanolamine buffer, pH 10.3) was then added. The plates 
were placed in the dark at room temperature for 15 minutes to allow the colour 
to develop. The reaction was stopped using 100µl of 0.75M sodium hydroxide, 
and the absorbance was then read at 405nm using an Anthos reader 2001. 
All antibody dilutions were made in incubation buffer (PBS pH 7.4 with 0.05% 
Tween 20, 1% BSA (unless otherwise stated) and 5% SMP).  
 
All analysis of data was carried out using Microsoft Excel® Office 2003 and 
SPSS v15. Prior to any analysis of the data all of the absorbance values at 
405nm collected from each indirect ELISA were corrected by subtracting the 
mean blank value.  
3.2.8. Testing secondary antibody for non-specific binding to BSA and 
NT-BSA 
The goat anti-rabbit IgG (whole molecule alkaline phosphatase conjugate) 
was assessed for non-specific binding to BSA and NT-BSA as follows: 
A 96 well microtitre plate was coated with BSA and NT-BSA over a range of 
concentrations (80-0µg/ml) overnight at 4oC, using carbonate buffer pH 9.6. 
After this incubation period the wells were emptied and blocked with 130µl 5% 
SMP in PBS pH 7.4 for 1 hour at 37oC and washed with wash buffer three 
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times. The plate was then incubated with the goat anti-rabbit IgG (1/5000 in 
incubation buffer) for 2 hours at 37oC. Following a wash cycle as described 
above, substrate (p-nitrophenol phosphate substrate, 1mg/ml in 0.1M 
diethanolamine buffer, pH 10.3) was then added. The plates were placed in 
the dark at room temperature for 15 minutes to allow the colour to develop. 
The reaction was stopped using 100µl of 0.75M sodium hydroxide, and the 
absorbance was then read at 405nm using an Anthos reader 2001. All 
antibody dilutions were made in incubation buffer. 
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3.2.9. Competitive ELISA 
The microtitre plate is coated with 




The unoccupied adsorption sites 
are then blocked. The anti-3NT Ab 
( ) is then incubated with the 
competitive antigen ( ) and/or the 
standard ( ) 
 
Following a wash phase, incubation 
with the enzyme labelled antibody 
( , goat anti-rabbit IgG with 
alkaline phosphatase conjugate). 
 
Following a final wash phase, 
incubation with p-nitrophenol 
phosphate substrate ( ) and 




Figure 3.2.iii. A schematic diagram of the competitive ELISA method. 
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Materials: See section 3.2.7. for materials 
All reagent concentrations and incubation times were investigated along with 
a variety of reagent formats. Three different commercially available microtitre 
plates were compared as before (Sero-Wel®, Nunc Maxisorp™ and Immulon 
2HB®). All volumes were 100µl unless otherwise stated.  
 
The general protocol used was as follows: Optimally diluted nitrated protein in 
carbonate buffer, pH 9.6, was added to all wells of a microtitre plate and 
incubated at 4oC overnight. Plates were blocked with 5% SMP in PBS (130µl) 
for 1 hour at 37oC and then washed with wash buffer three times. The test 
sample or BSA standard (for the calibration curve), 50µl, were pipetted into 
the appropriate wells along with 50µl of the polyclonal anti-3NT Ab (at optimal 
dilution as determined by checkerboard analysis). The plates were incubated 
for 2 hours at 37oC and then washed with wash buffer as above. Goat anti-
rabbit IgG (whole molecule alkaline phosphatase conjugate), 1/5000 in 
incubation buffer, was added and incubated for 2 hours at 37oC. Following 
washing, the substrate (p-nitrophenol phosphate substrate, 1mg/ml in 0.1M 
diethanolamine buffer, pH 10.3) was added to the plates which were then 
placed in the dark at room temperature for 15minutes to allow the colour to 
develop. The reaction was then stopped using 100µl of 0.75M sodium 
hydroxide, and the absorbance was then read at 405nm. All antibody dilutions 
were made in incubation buffer. 
 
All analysis of data was carried out using Microsoft Excel® Office 2003. Prior 
to any in depth analysis of the data all of the absorbance values at 405nm 
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collected from the competitive ELISA were standardised by subtracting the 
observed absorbance value from mean blank value. This resulted in a positive 
relationship between corrected absorbance and concentration of 3NT. 
3.2.10. Competitive ELISA testing inhibition of anti-3NT antibody 
A microtitre plate was coated and run as described in the general protocol 
above (section 3.2.9.). During the competition phase of the assay a range of 
different substances were tested in order to assess the specificity of the 
polyclonal anti-3NT Ab.  The substances tested in competition with the anti-
3NT Ab over a range of concentrations were as follows: Tryp_NT-BSA, NT-
BSA, BSA, protein-bound aminotyrosine (see section 3.2.5.), free 3-nitro-L-
tyrosine, free L-tyrosine and free 3-chloro-L-tyrosine.  
3.2.11. Sodium dodecyl sulphate – polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Materials: 12% polyacrylamide gel pH 8 with a 4% stacking gel (SciePlas, 
Southam, Warwickshire). 4-20% gradient polyacrylamide Tris-HCl gel, 15 well, 
(BIORAD). Anachem size markers (Anamed Elektrophorese GmbH, 
Germany). 
Methods: Protein samples were separated using 12% polyacrylamide running 
gel, pH 8, with a 4% stacking gel, or gradient polyacrylamide gels. The 
samples to be separated were diluted in an equal volume of sample buffer 
(12.5ml 1.5M Tris-HCl pH 8, 0.5g SDS, 5g sucrose, 0.25ml mercaptoethanol, 
5mg bromophenol blue and made up to 50ml) and then loaded onto the gel. 
Once the samples were loaded, including Anachem size markers, the gels 
were run at 150V for 1 hour in Tris-glycine running buffer (6g Tris, 28.8g 
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glycine (pH 8.48), 1g SDS (pH 8.42) made up to 1L RO water with no pH 
adjustment) or until the dye front had reached the bottom of the gel. The gels 
were then stained either with Coomassie blue R250 or processed by Western 
blotting. 
3.2.12. Coomassie blue staining 
Materials: Coomassie brilliant blue R250 (B7920) Sigma (Poole, Dorset, U.K.). 
UVItec image acquisition system including transilluminator and UVIdoc image 
acquisition software 
 
Methods: Gels from SDS-PAGE, were fixed for 1hour using Coomassie 
fixer/de-stain solution (10% methanol, 10% acetic acid made up to volume 
with RO water). The gels were then placed in Coomassie brilliant blue R250 
stain (0.15g Coomassie brilliant blue, 60ml methanol, 15ml glacial acetic acid, 
75ml RO water and filter) and left over night. The gels were then left to de-
stain (in fixer/de-stain solution) overnight, replacing with fresh de-stain 
periodically. Photographic representations of the gels were taken using an 
UVItec image acquisition system including transilluminator and UVI doc image 
acquisition software. 
3.2.13. Western Blot 
Materials: Hybond C nitrocellulose membrane (Amersham Pharmacia). 




Methods: Separated proteins were transferred from SDS-PAGE gels onto 
Hybond C nitrocellulose membrane using a BioRad Mini Trans-Blot® 
Electrophoretic Transfer Cell as per manufacturer’s instructions.  
In brief the nitrocellulose membrane was equilibrated in Towbin buffer (3.03g 
Tris, 14.4g glycine, 200ml methanol and made up to 1L with RO water) and 
the cell was run at 100V for 1 hour. The membrane was blocked with 3% SMP 
in PBS overnight at 4oC. Once blocked the membrane was incubated for 1 
hour at room temperature in a solution of polyclonal rabbit anti-3NT Ab, at 
optimised dilution, in PBS with 2% BSA. Following a thorough wash in PBS, 
the membrane was then placed in a solution of goat anti rabbit IgG alkaline 
phosphatase conjugated antibody (1:5000 in PBS with 0.5% BSA) and 
incubated for 45 minutes at room temperature. The membrane was again 
washed in PBS followed by rinsing with RO water to remove any residual 
phosphate. The presence of 3NT-containing proteins was detected 
colourimetrically by the addition of fast 5-bromo-4-chloro-3-indolyl phosphate / 
nitro blue tetrazolium (BCIP/NBT) substrate, as per manufacturer’s 
instructions, and incubation of the membrane in the dark. The reaction was 
stopped by rinsing the membrane with RO water. 
3.2.14. Dot blot 
Materials: As for 3.2.13. 
Methods: The patient plasma and electrochemically nitrated BSA tested were 
pipetted (4µl) onto Hybond C nitrocellulose membrane (which had been 
equilibrated in Towbin buffer). The samples were allowed to air dry and then 
treated as described above for western blotting (3.2.13.) starting with blocking 





3.3.1. The effect of protein integrity on 3NT detection 
Prior to developing a competitive ELISA for the detection and quantification of 
3NT-containing proteins in human plasma samples, several parameters 
needed to be investigated; in particular the efficacy of the electrochemically 
nitrated protein (BSA) being used as the standard. These investigations were 
carried out during the development of an indirect ELISA. 
Initial development of the indirect ELISA was performed using a stock 
electrochemically nitrated sample which had been stored at -20oC since 1999. 
Whilst using this sample the indirect ELISA being developed appeared to be 
relatively sensitive and accurate for the detection of 3NT containing proteins 
(based on the optical densities of the dilution curves recorded). However upon 
using a fresh electrochemically nitrated BSA sample it was apparent that the 
assay sensitivity and reliability was dramatically reduced.  
Due to the observations above the effects of storage on the protein integrity 
were investigated using two electrochemically nitrated samples. The first 
sample (NT-BSA/99), prepared in 1999, had been stored at -20oC and had 
gone through the freeze thaw cycle an unknown number of times. The second 
sample was a freshly nitrated sample stored at -20oC in glycerol (50:50) to 
prevent freezing (NT-BSA/02). Although the samples tested were of 
comparable nitration levels (as determined by A430) analysis using indirect 
ELISA revealed that there were differences in the detection of 3NT by our 
polyclonal anti-3NT Ab. Significantly higher optical densities were obtained 
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when assaying the native NT-BSA/99 samples compared to native NT-
BSA/02 at comparable nitrated-protein concentrations (P<0.0001 determined 
using single factor ANOVA).  
Due to this obvious difference both samples were chemically denatured in 
order to allow maximal availability of the 3NT residues to the antibody. 
Several treatments were investigated as denaturants including; acetonitrile, 
urea, and iodoacetamide / mercaptoethanol. These investigations highlighted 
the fact that using 8M urea and mercaptoethanol (0.5%) in combination was 
the best treatment to use for denaturing NT-BSA samples. Time course 
experiments were carried out to establish the optimal incubation parameters 
with the urea and mercaptoethanol. In the case of NT-BSA an incubation time 
of 1 hour at 37oC was found to be sufficient to maximise the optical density 
obtained (results not shown). There was a significant improvement in 
sensitivity when using urea and mercaptoethanol (U+M) to denature the 
protein compared to their native counterparts (Figure 3.3.i., P<0.0001, 
ANOVA single factor). Tukey post hoc analysis highlighted that there was a 
significant difference between the native and denatured NT-BSA/99 and NT-
BSA/02 samples (P<0.05) regardless of the fact that they were of comparable 































Figure 3.3.i.  NT-BSA/99 and NT-BSA/02 with and without pre-treatment with urea 
and mercaptoethanol (U+M). 
Four nitrated BSA samples were assayed to investigate the effects of 
storage and sample pre-treatment with U+M. NT-BSA/99 with no pre-
treatment (), NT-BSA/99 pre-treated with U+M (), NT-BSA/02 () and 
NT-BSA/02 U+M (). Mean ± SEM, 16 replicates for each protein sample.  
 
The two nitrated samples (NT-BSA/99 and NT-BSA/02) were further analysed 
via separation on SDS-PAGE and visualised using Coomassie staining and 
Western blot immunodetection. From this separation it was established that 
there were differences in the integrity of the protein structure between the two 
 72 
 
nitrated samples (Figure 3.3.ii).  The Coomassie stain highlighted that NT-
BSA/99 gave no distinct bands, rather a smear from the bottom of the 
stacking gel to an overloaded band between 66-55kDa within the resolving 
gel. For NT-BSA/02 several bands were observed with a similar large distinct 
band at approximately 66-55kDa, (Figure 3.3.ii.B). Western blot analysis of 
the SDS-PAGE gel clearly showed the presence of 3NT (dark purple staining) 
in the whole of the smear for NT-BSA/99 whereas in the case of the NT-
BSA/02 there were more distinctly stained bands. As with NT-BSA/99 the 
presence of 3NT was detected in more than one band (Figure 3.3.ii.C), mainly 
within the 66-55kDa band and additional smearing from the top of the 










Figure 3.3. ii. NT-BSA/99 and NT-BSA/02 visualised using Coomassie staining and 
Western blot following separation using SDS-PAGE. 
M – Anamed ProteMix size marker; 02 – NT-BSA/02; 99 – NT-BSA/99. All 
samples were loaded onto the gel at approximately 1µg/µl. A – Size 
marker (Coomassie stain); B – Coomassie stain; C – Western blot. 
 
Due to the results above (see discussion) NT-BSA/02 was used in all further 
experimentation and will be referred to as NT-BSA from this point onwards. 
 M   02  99   02  99 








3.3.2. A comparison of different nitration protocols 
Comparisons were made between electrochemically-nitrated BSA and 
peroxynitrite (ONOO-) -nitrated BSA using indirect ELISA. NT-BSA samples 
were nitrated either electrochemically or chemically to approximately the same 
level of nitration (4mol 3NT/mol BSA, as determined by A430) and were 
compared using Sero-Wel® microtitre plates by indirect ELISA and dot blot 
analysis (Figures 3.3.iii. and 3.3.v.). Upon initial testing, a higher response for 
3NT was achieved with ONOO--nitrated BSA compared to electrochemically-
nitrated BSA at comparable concentrations and level of nitration (Figure 
3.3.iii.). It was evident that for both electrochemically nitrated and ONOO--
nitrated BSA there was low assay sensitivity (approximately 10nM), although 
there was a significant difference between the two nitration protocols 
(P<0.0001, two way ANOVA with replication).  
The nitrated proteins were then denatured using U+M in order to determine 
whether the differences observed were due to the availability of the 3NT 
residues to the anti-3NT Ab. After treatment with U+M it was clear that, as 
seen earlier, there was a significant increase in sensitivity of the assay for 
both of the nitrated samples (P<0.0001, for both). It was also evident that the 
initial differences in detection of 3NT-containing residues in ONOO-- and 
electrochemically-nitrated BSA were no longer observed. Indeed upon 
treatment with U+M the assay appeared to be marginally more sensitive to 

























Figure 3.3.iii. Nitrated BSA using different nitration protocols 3NT detection using 
indirect ELISA 
Peroxynitrite-nitrated BSA (), electrochemically-nitrated BSA ().  
























Figure 3.3.iv. Indirect ELISA using electrochemically and peroxynitrite nitrated BSA 
treated or untreated with urea and mercaptoethanol.  
Peroxynitrite nitrated BSA (), peroxynitrite nitrated BSA treated with 
U+M (). Electrochemically nitrated BSA (), electrochemically nitrated 
BSA treated with U+M (x). Mean ± SEM, samples ran in triplicate. 
 
When binding electrochemically- and ONOO--nitrated BSA on a nitrocellulose 
membrane it was observed, via dot blot immunodetection, that there was no 
need for sample pre-treatment with U+M. No obvious visual differences in the 
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detection of 3NT between either nitration protocol both before and after 
treatment with U+M were observed (Figure 3.3.v).  
 
 
Figure 3.3.v. Comparison of different nitration protocols treated and untreated with 
  urea and mercaptoethanol using dot blot. 
A – Treated native BSA; A’ – Untreated native BSA; B – Treated 
electrochemically nitrated BSA; B’ – Untreated electrochemically 
nitrated BSA; C – Treated BSA nitrated using peroxynitrite; C’ – 
Untreated BSA nitrated using peroxynitrite. All samples blotted 4µl of 
1.25µg/ml. 
 
When nitrating BSA using the peroxynitrite protocol it was found that the 
reaction was extremely fast and the nitration level was therefore relatively 
difficult to control. Electrochemical nitration of BSA was a more lengthy 
process but it was easier to control the degree of nitration as the reaction 
could be paused periodically by removal of the applied potential in order to 
measure the absorbance of the sample at 430nm and calculate the degree of 









was used in all further experiments and will be referred to as NT-BSA. The 
level of nitration of the NT-BSA used was calculated to be 4mol 3NT / 1mol 
BSA. 
3.3.3. Comparison of different denaturing protocols and microtitre 
plates 
Preliminary experiments produced differing results when using the indirect 
ELISA protocol with microtitre plates from different commercial sources. Three 
different brands of microtitre plates of varying cost were compared (Sero-
Wel®, Immulon 2HB® and Nunc Maxisorp™). For initial comparisons between 
the different brands checkerboard indirect ELISAs were run using NT-BSA 
(with no prior denaturation) and anti-3NT Ab at varying concentrations. These 
preliminary comparisons suggested that the highest levels of assay sensitivity 
for the presence of 3NT were achieved when using the Immulon 2HB® plates 
(Figure 3.3.vi.). For the calibration curves run on the Immulon 2HB® plates 
optical densities obtained were over a broad range and were linear from 152-
2.4nM with an anti-3NT Ab dilution of 1/1000. In the case of both the Sero-
Wel® and Nunc Maxisorp™ plates there was a narrower range of detection for 
3NT residues (linear between approximately 152-9nM NT-BSA, anti-3NT Ab 
1/1000). There was a significant difference in the levels of detection of 3NT-



























Figure 3.3.vi. Summary of checkerboard indirect ELISA comparing different brand 
microtitre plates. 
Nunc Maxisorp™ (), Immulon 2HB® () and Sero-Wel® (). The above 
data comes from checkerboard analysis using each brand microtitre 
plate. Single point data representing the values obtained when using 
the anti-3NT Ab at 1/1000 dilution, which had been determined as the 
optimal dilution. See appendices H for full checkerboard analysis. 
 
To examine the role of denaturation in the detection of 3NT residues in NT-
BSA, U+M-treated NT-BSA was directly compared to NT-BSA on each of the 
plates. The results of this comparison are shown in Figure 3.3.vii. As before 
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there was an increase in assay sensitivity for denatured NT-BSA, but there 
were also obvious differences between the different plates seen across the 
concentration range. With regards to the Sero-Wel® microtitre plates it was 
clear that the detection limits and assay sensitivity for both native and 
denatured NT-BSA was extremely low, as a result of which these plates were 
not used in further indirect ELISA development. When comparing the Immulon 
2HB® and Nunc Maxisorp™ microtitre plates smaller differences in sensitivity 
were observed. However, for both native and denatured NT-BSA higher 
optical densities were obtained when using the Immulon 2HB® plates (Figure 
3.3.vii). As a result of these findings all further indirect ELISA analysis was 


























Figure 3.3.vii. The effects of protein pre-treatment and different brand microtitre plates 
using indirect ELISA for the detection of NT-BSA. 
The plates tested were Immulon 2HB® (NT-BSA () and U+M treated NT-
BSA()); Nunc Maxisorp™ (NT-BSA () and U+M treated NT-BSA()); and 
Sero-Wel® (NT-BSA () and U+M treated NT-BSA()). Mean ± SEM, 
samples ran in duplicate. 
 
The effects of protein denaturation were further investigated using alternative 
denaturants for use with NT-BSA. Proteins were denatured by boiling in the 
presence of a detergent (Tween 20) or treatment with trypsin to digest the 
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protein. These were then investigated as potential procedures for a more 
sensitive ELISA method. A large number of trials of these different procedures 
were conducted and a summary is presented below. All denaturing treatments 
and native untreated NT-BSA were compared firstly in an indirect ELISA 
(Figure 3.3.viii.). None of these alternative denaturing treatments gave the 
same increase in assay sensitivity as seen when using U+M to denature the 
NT-BSA. It was evident that denaturing NT-BSA by boiling it in the presence 
of Tween 20 actually had a detrimental effect on the sensitivity of the assay. 
With regards to the trypsin digested NT-BSA there was no significant 
difference between it and the native NT-BSA; although, when using untreated 
NT-BSA it was a common finding that wells gave false negative results. This 
anomaly was found to be greatly reduced when using tryptically digested NT-
BSA as the standard antigen. As a result of this tryptically digested NT-BSA 





























Figure 3.3.viii. Comparison of different protocols to denature NT-BSA for use in 
indirect ELISA 
The plates used to carry out these tests were Immulon 2HB® and the anti-
3NT Ab was 1/1000. NT-BSA untreated () and U+M treated NT-BSA (); 
NT-BSA boiled in the presence of Tween 20 () and trypsin digested NT-
BSA (), samples ran in duplicate. The above data is representative of 
multiple trials conducted when assessing the importance of different 








3.3.4. Competitive ELISA development 
All competitive ELISA development was carried out using electrochemically 
nitrated BSA (NT-BSA, 4mol 3NT/mol BSA) and Immulon 2HB® microtitre 
plates. The analysis of different brands of microtitre plates was repeated for 
the development of the competitive ELISA and the findings agreed with those 
reported in section 3.3.3., (results not shown). 
Initially it was apparent that no competition could be achieved between the 
anti-3NT Ab and the NT-BSA in solution when it was freshly nitrated, (results 
not shown). However after the NT-BSA had been through a period of storage 
at -20oC and through the freeze thaw process a number of times, competitive 
checkerboard analysis suggested that the assay gave a linear response over 
a broad range of NT-BSA (606-9nM) when using 1/1000 anti-3NT Ab dilution 
(Figure 3.3.ix.). However there were problems regarding assay sensitivity, 
reproducibility and reliability when using untreated NT-BSA as both the 
coating antigen and as the standard in competition (results not shown). 
Therefore the effects of different forms of sample pre-treatment were 
investigated in order to increase the exposure of the 3NT residues to the anti-
3NT Ab. Either untreated NT-BSA or tryptically digested NT-BSA (tryp-NT-
BSA) were coated onto the microtitre plates and used as the test antigen in 
competition. (Note: - Only tryp-NT-BSA was used as denatured sample since 
residual reagents from the other methods (e.g. U+M) could have potentially 





























Figure 3.3.ix. Checkerboard competitive ELISA on Immulon 2HB® microtitre plates  
The above figure represents single point data taken from a 
checkerboard competitive ELISA over a range of NT-BSA () 
concentrations in the competitive stage (anti-3NT Ab 1/1000). The 
microtitre plate was coated at 2µg/ml of NT-BSA.  See appendices I for 
full checkerboard analysis data. 
 
It was evident that when the plate was coated with native NT-BSA the levels 
of competition achieved for native and tryp-NT-BSA were low (see Figure 
3.3.x.). When native NT-BSA was used as the coating antigen no there was 
 85 
 
no statistical difference between the level of detection of 3NT residues in 
native NT-BSA compared to trypsin digested NT-BSA during competition with 
the anti-3NT Ab (P>0.05, two way ANOVA with replication).  In contrast when 
the plate was coated with tryp-NT-BSA higher levels of competition were 
achieved (Figure 3.3.xi.). It was also evident that when tryp-NT-BSA was used 
as the coating antigen there was a reduced level of assay variation, as shown 
by the SEM. A significant increase in the level of detection of 3NT residues by 
the anti-3NT Ab was observed for tryp-NT-BSA compared to the native NT-
BSA (P<0.0001, two way ANOVA with replication, Figure 3.3.xi.).  
These findings were found to be consistently reproducible in subsequent 
assays. All further competitive ELISAs therefore used tryp-NT-BSA as the 



























Figure 3.3.x. A competitive ELISA using NT-BSA as the coating antigen and 
competition with NT-BSA or trypsin digested NT-BSA 
The competing antigen was either NT-BSA () or trypsin digested NT-
BSA (). Standard curves for both antigens were run from 606-0.3nM. 






























Figure 3.3.xi. A competitive ELISA using trypsin digested NT-BSA as the coating 
antigen and competition with either NT-BSA or trypsin digested NT-
BSA. 
The competing antigen was either NT-BSA () or trypsin digested NT-
BSA (). Standard curves for both antigens were run from 606-0.3nM. 
(mean ± SEM, samples ran in duplicate). 
 
To further improve the assay sensitivity, reliability and reproducibility several 
assay parameters were investigated. When the concentration of the coating 
antigen was increased from 2µg/ml to 4µg/ml of tryp-NT-BSA there was an 
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obvious improvement in assay sensitivity (Figure 3.3.xii.). Furthermore the 
standard curve produced was linear over a larger concentration range (606-
2nM), demonstrating improved assay sensitivity. Increased assay variation 
was observed, for both coating concentrations, as the competing tryp-NT-BSA 
concentration reduced. The continuing issue regarding assay sensitivity and 
reproducibility is further evident when comparing the observed corrected 
optical densities achieved when the coating antigen was 2µg/ml in Figure 
3.3.xii. and those observed in Figure 3.3.xi..  These experiments were 
repeated on several occasions with more replicates in order to further assess 
the observed assay variation (results were as shown in Figure 3.3.xii). 
Although increasing the concentration of the coating antigen improved assay 
sensitivity, further investigations regarding the assay parameters were needed 

























Figure 3.3.xii. Competitive ELISAs with different concentrations of trypsin digested 
NT-BSA to coat the plate. 
Tryp-NT-BSA coated at 4µg/ml () and coated at 2µg/ml (). In 
competition the tryp-NT-BSA standard curve ran from 606-0.6nM. The 
above data is mean data ± SEM, samples ran in duplicate, anti-3NT Ab 
1/1000 dilution. 
 
The constituents of the incubation buffer used within the competitive assay 
were altered in order to assess the effects these had on sensitivity and 
reliability. Concentrations of BSA, ovalbumin and Tween 20 were varied. A 
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significant increase in the levels of competition was achieved when using 
incubation buffer containing 1% ovalbumin and 0.1% Tween 20 compared to 
incubation buffer containing 1% BSA  and 0.1% Tween 20 (P<0.0001 two way 
ANOVA with replication). However a higher level of variation between 
replicates was observed with 1% ovalbumin and 0.1% Tween 20 (Figure 
3.3.xiii.). There was no longer a statistical difference between the levels of 
competition achieved for tryp-NT-BSA diluted in incubation buffer containing 
1% ovalbumin or BSA when there was a reduction of Tween 20 from 0.1% to 
0.05% (Figure 3.3.xiv., P>0.05 two way ANOVA with replication).  
Therefore it was decided that for all further competitive ELISA assays the 
concentration of the coating antigen would be 4µg/ml and the incubation 
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Figure 3.3.xiii. The effects of changing the incubation buffer parameters on intra-plate 
variation (part 1). 
A comparison of 1% BSA () and ovalbumin () using 0.1% Tween 20 as 
incubation buffer components. The plates were coated with tryp-NT-
BSA (4µg/ml) and the antigen in competition was tryp-NT-BSA run from 
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Figure 3.3.xiv. The effects of changing the incubation buffer parameters on  
  intra plate variation (part 2). 
A comparison of 1% BSA () and ovalbumin () using 0.05% Tween 20 
as incubation buffer components. The plates were coated with tryp-NT-
BSA (4µg/ml) and the antigen in competition was tryp-NT-BSA run from 




3.3.5. Competitive ELISA reliability studies 
In order to investigate inter- and intra-plate variation in the competitive ELISA 
a number of repeat assays were performed. Standard curves were generated 
using tryp-NT-BSA as both the coating antigen and competitor. Control 
samples of known concentration of tryp-NT-BSA and of nitrated plasma (NT-
PL, estimated concentration) were included in each plate. Regression analysis 
was used to calculate concentrations from the calibration curves.  
Intra-assay variation was assessed with 8 replicates of each standard dilution 
on a plate and is presented in Figure 3.3.xv. and Table 3.3.i. The standard 
curve was linear over a range of 9.47-303nM (R2 = 0.993).  However, with 
decreasing concentration of the standards the variation can be seen to 
increase (Figure 3.3.xv.) also seen as increasing coefficients of variation in 
Table 3.3.i. Percentage coefficients of variation values ≤10%, the accepted 
range, were only obtained for concentrations ranging between 75.8-303nM 
tryp-NT-BSA which further suggested that the assay lost precision at low 
levels of nitration. 
Tryp-NT-BSA (nM) 303.0 151.5 75.8 37.9 18.9 9.5 
Log Tryp-NT-BSA (nM) 2.5 2.2 1.9 1.6 1.3 1.0 
%CV 2.3 3.8 6.8 10.5 30.6 32.3 
Table. 3.3.i. Percentage coefficient of variation within an assay for tryp-NT-BSA. 
The above data represents calculated percentage coefficient of 
variation (%CV) for serial dilutions of tryp-NT-BSA (n=8 replicates for 


























Figure 3.3.xv. Regression analysis for competitive ELISA using tryp-NT-BSA as 
coating and test antigen. 
Above figure represents corrected optical densities measured in serial 
dilutions of the standard competing antigen (tryp-NT-BSA, ) and the 
resulting regression coefficient. 8 replicates per dilution. 
 
A similar approach was taken to assess inter-plate performance. Fourteen 
competitive ELISAs were run using tryp-NT-BSA as the competitor to produce 
the standard curves along with the controls (all samples were run in triplicate).  
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Standard curves produced on each plate were generally found to be linear 
from 303-2.4nM tryp-NT-BSA. However, the linear range did vary slightly from 
plate to plate. R2 values were generally greater than 0.930 (range 0.805-
0.976). Again variation increased as the concentration of tryp-NT-BSA 
decreased, which can be seen by the %CV values in table 3.3.ii. 
Tryp-NT-BSA (nM) 303.0 151.5 37.9 9.5 4.7 2.4 
Log Tryp-NT-BSA (nM) 2.5 2.2 1.9 1.6 1.3 1.0 
%CV 4 8 22 52 80 170 
Table. 3.3.ii.  Percentage coefficient of variations for inter-assay study using tryp-NT-
BSA. 
The above data represents calculated percentage coefficient of 
variation (%CV) for serial dilutions of tryp-NT-BSA (n=3 replicates for 
each dilution, 14 plates).  
 
For some assays the intra-assay %CV between replicates was well within 
10% but for other plates %CVs of >20% were obtained. For inter-assay 
variation the %CV was found to be less than 10% for high concentrations of 
tryp-NT-BSA (303.0-151.5nM) but then increased significantly.  
The lack of consistency observed within and between assays limits the 
reliability of concentration estimations of the controls. Triplicates of tryp-NT-
BSA (76, 38 and 9nM of tryp-NT-BSA nitrated to a level of 4 mol 3NT / 1 mol 
BSA) and NT-PL (76nM estimated level of nitration equivalent to 4 mol 3NT / 
1 mol BSA) were included on each plate. When using standard curves to 
estimate the levels of nitration in the test tryp-NT-BSA samples, only one of 
the fourteen competitive ELISAs provided acceptable estimated values (level 
of accuracy ±10% of the known value) for the 76 and 9nM standards and two 
assays for the 38nM standard. The %CV for the samples within each plate 
varied between 0-44%, although the majority of assays had %CV values 
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<20%. Estimates between each assay plate were less reliable with %CVs 
significantly above the accepted 10%.  
Results were more reliable for the electrochemically nitrated plasma samples 
(NT-PL). Of the fourteen plates run, nine gave concentrations of comparable 
levels of nitration (exact levels cannot be quoted due to this being nitrated 
plasma). The average estimated concentration for the NT-PL test sample in 
these nine plates was 92±24nM nitro-BSA equivalents. With the exception of 
one plate the intra-assay %CV for NT-PL was found to be ≤20% but the inter -
assay %CV for NT-PL was higher. Although the assay appeared to be more 
precise and reliable regarding the NT-PL samples the intra- and inter-assay 
%CVs were still higher than the accepted ≤10%. These resul ts suggest that 
the use of nitrated plasma in a competitive ELISA needed further 
investigation. 
These assay plates were also those used to calculate the levels of nitration 
found within the claudicant and control plasma samples (affinity purified, see 
chapter 4, section 4.3.3. for these results).  
3.3.6. Nitrated plasma as a potential coating and competitive antigen 
As a result of the findings above electrochemically nitrated plasma (estimated 
level of nitration equivalent to 4 mol 3NT / 1 mol BSA) was investigated as a 
potential alternative coating and competitive antigen for the developed 
competitive ELISA. During these investigations competitive ELISAs were 
coated with either NT-PL or tryp-NT-BSA at comparable concentrations and 
then serial dilutions of NT-PL or tryp-NT-BSA were used as competing 
antigens. A variety of assay parameters, e.g. incubation times, were also 
varied. It was evident that when NT-PL was used as the coating antigen the 
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assay sensitivity was reduced for both NT-PL and tryp-NT-BSA in competition 
(Figure 3.3.xvi.). NT-PL and tryp-NT-BSA were found to compete at 
comparative levels when the plates were coated with tryp-NT-BSA (Figure 
3.3.xvi.). No improvements in intra- or inter-assay were observed when using 
NT-PL as the coating or the competing antigen, as determined by %CVs, 
compared to tryp-NT-BSA. 
3.3.7. Specificity of the anti-3NT Ab within the competitive ELISA 
Percentage inhibition studies were carried out to assess the specificity of the 
anti-3NT Ab within the competitive ELISA assay. Several compounds of 
similar structure to tyrosine and 3NT were investigated and the percentage 
inhibition was noted. The anti-3NT Ab appeared to have the highest affinity for 
tryp-NT-BSA followed by NT-BSA, protein bound aminotyrosine and finally 
free 3-nitro-L-tyrosine. With regards to native BSA, chloro-L-tyrosine (free 
amino acid) and L-tyrosine (free amino acid) no inhibition of the antibody was 
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Figure 3.3.xvi. Competitive ELISA using nitrated plasma and tryp-NT-BSA as coating 
and test antigens. 
Plates were coated with either nitrated plasma (NT-PL) or tryp-NT-BSA 
(4µg/ml at comparable levels of nitration). Serial dilutions of tryp-NT-
BSA were run on the plates coated with tryp-NT-BSA () and NT-PL () 
and serial dilutions of NT-PL were also run on the plates coated with 
tryp-NT-BSA () and NT-PL (▲). N=3 plates per coating antigen with 4 































Figure 3.3.xvii. Percentage inhibition study of anti-3NT antibody binding in the  
  presence of different antigens in the competitive ELISA 
The plates were coated with tryp-NT-BSA (4µg/ml). The competing free 
antigens were: tryp-NT-BSA (, n=3 experiments with 2 replicates on 
each plate); for the following antigens n=3 replicates on one plate NT-
BSA (); BSA (); protein bound aminotyrosine (); free 3-nitro-L-




3.4.1. Indirect ELISA development 
A major objective of this thesis was to develop an immunoassay for the 
detection of 3NT in clinical samples, specifically the plasma of claudicants. 
The successful use of immunoassays for 3NT detection has been reported by 
a number of authors (Ye, Strong, Huang et al. 1996, Khan, Brennand, Bradley 
et al. 1998, Ter Steege, Koster-Kamphuis, Van Straaten et al. 1998, Inoue, 
Hisamatsu, Ando et al. 2002, Franze, Weller, Niessner et al. 2004). These 
studies used a variety of nitration protocols with either polyclonal or 
monoclonal antibodies. The results presented in this chapter have highlighted 
a range of issues concerning the development of a sensitive, reproducible and 
interpretable immunoassay for the detection of 3NT in biological samples and 
suggest that further work is required.  
First of all there is the issue of availability of 3NT within the protein and its 
accessibility to an anti-3NT antibody. The results clearly demonstrated that an 
identical antigen stored at -20oC and freeze-thawed a number of times (NT-
BSA/99) had a greater number of exposed 3NT-residues than a more recently 
produced antigen (NT-BSA/02) electrochemically nitrated to the same level.  
Freeze thawing is known to denature proteins. Substantial protein 
denaturation can occur in proteins stored in sodium phosphate buffered 
solutions going through freeze-thaw cycles potentially due to the selective 
precipitation, and thus concentration, of the disodium phosphate as ice 
crystals form. This observed precipitation, when using sodium phosphate 
buffer solutions, causes a significant shift in pH which could potentially affect 
 101 
 
the stability of the dissolved proteins, although this has not been found to be 
the case within potassium phosphate buffered solutions (Pikal-Cleland, 
Rodriguez-Hornedo, Amidon et al. 2000). Strambini and Gabellieri (1996) 
have put forward an alternative hypothesis regarding the effects of storage on 
protein conformation involving protein-ice interactions. They demonstrated for 
the first time that the native fold of a protein is altered in frozen solutions due 
to the strain on the protein fold which can be attributed to the adsorption of the 
protein molecule onto the ice surface.  
Further investigation of this was conducted by exploring different denaturation 
protocols, mainly using urea and mercaptoethanol (U+M). The use of urea as 
a denaturant allows the unfolding of protein molecules making cysteine 
residues available for reduction using mercaptoethanol (Zadow and Hardham 
1980). Enhanced reliability and specificity of an ELISA via the use of 
mercaptoethanol to cleave/unfold an antigen in order to expose specific 
epitopes to the relevant antibody has been reported by Abass et al (2006). By 
chemically denaturing the nitrated samples (NT-BSA/99 and NT-BSA/02) both 
should be in similar degraded states and should, therefore, have allowed for 
maximal availability of the 3NT-epitopes to the anti-3NT Ab. However, 
although both showed an increase in OD after treatment a higher OD was 
obtained for the NT-BSA/02. This may have been due to protein aggregation 
in the older sample, something which is supported by the Coomassie and 
Western blot analysis. These clearly showed protein aggregates from the 
bottom of the stacking gel and within the resolving gel to approximately 55kDa 
whereas the new protein had distinct bands. During subsequent assay 
development all stock solutions were stored in small aliquots containing 50% 
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glycerol to prevent ice crystals forming and used a maximum of five times 
before disposal. 
To investigate availability of 3NT residues produced with different nitration 
protocols a comparison was made of electrochemically- and peroxynitrite 
(ONOO-) - nitrated BSA, at comparable levels of nitration. Several different 
protocols have been reported for the nitration of proteins in vitro that have 
subsequently been used as standards in ELISAs (indirect, competitive and 
sandwich). These methods include the use of proteins nitrated using 
tetranitromethane (Franze, Weller, Niessner et al. 2004), ONOO- (Ye, Strong, 
Huang et al. 1996, Khan, Brennand, Bradley et al. 1998), and incubation in 
the presence of sodium nitrite (Ter Steege, Koster-Kamphuis, Van Straaten et 
al. 1998), Inoue et al (2002) used peroxidase conjugated free nitrotyrosine. 
These methods also report the use of different anti-3NT Abs including 
polyclonal (Ye, Strong, Huang et al. 1996, Khan, Brennand, Bradley et al. 
1998, Inoue, Hisamatsu, Ando et al. 2002, Franze, Weller, Niessner et al. 
2004) and monoclonal (Ye, Strong, Huang et al. 1996, Ter Steege, Koster-
Kamphuis, Van Straaten et al. 1998, Franze, Weller, Niessner et al. 2004) 
antibodies all of which could also account for the differences observed in 
assay sensitivity.  
The results demonstrated that the anti-3NT Ab initially gave a slightly higher 
response to the ONOO--nitrated BSA but that after U+M treatment a 
significant increase in assay sensitivity occurred for both protocols. This 
suggests that it is not electrochemical nitration that affects 3NT detection. 
Peroxynitrite activity results in products other than tyrosine residues which 
include nitrosylated (R-NO) derivatives as well as more traditional oxidation 
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products (such as hydroxylated aromatics) (Beckman, Chen, Ischiropoulos et 
al. 1994). This should be considered when using ONOO--nitrated BSA as a 
standard and anti-3NT antibodies that have been raised against ONOO--
nitrated KLH. This is because any antibody raised against a protein standard 
that has been nitrated using ONOO- could potentially also have antigenic 
specificity towards these products, thus resulting in an assay that is sensitive 
to products of ONOO- and not nitration exclusively. However, in the method 
developed by Khan et al (1998) they report that their assay was specific to the 
detection of 3NT-residues in proteins and peptides. Their assay showed no 
cross-reactivity with other ONOO- associated amino acid modifications such 
as oxidation of cysteine and methionine and oxidised/nitrated tryptophan. It 
has also been demonstrated by Kendal et al (2001) that, unlike the ONOO--
nitration protocol, 3NT is the only product of the electrochemical nitration 
protocol used within this study. 
When testing proteins from both nitration protocols using dot-blot 
immunodetection on nitrocellulose membrane it was observed that the use of 
U+M denaturation made little difference to 3NT detection; therefore 
highlighting that the manner in which a nitrated protein binds to a solid phase 
directly affects the availability of 3NT-residues to the anti-3NT Ab. Following 
this, differences were also found in the binding capacities of different 
manufacturers’ microtitre plates even after the NT-BSA had been denatured 
using U+M, with Immulon 2HB® producing the best results.  
The reason behind such differences in the binding capacities of different 
manufacturer’s microtitre plates is unclear although intra- and inter-assay 
variation in levels of protein adsorbing to mictotitre plates is well known 
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(Kricka, Carter, Burt et al. 1980). It was thought that such variation may be 
due to differences in the ability of the NT-BSA to adsorb onto the plate. The 
Immulon 2HB® and Sero-Wel® microtitre plates were sent away for analysis 
by infrared spectroscopy - mass spectrometry to establish if there was a 
chemical difference between the two plates. From this analysis it was found 
that both plates were made of polystyrene but that the Immulon 2HB® plates 
did appear to have some form of biological lipid layer present (results not 
shown). This lipid would aid in the binding of hydrophobic regions of proteins 
as well as act to denature the protein. Other factors that may vary between 
plates include desorption of the adsorbed NT-BSA from the solid phase due to 
poor protein-plate interactions (Kemeny and Challacombe 1988: 32-35). It has 
also been reported that the adsorption of BSA onto, and potential desorption 
from, polystyrene can cause irreversible changes in its secondary structure 
(Norde and Giacomelli 2000). They found that irreversible surface-induced 
conformation changes for BSA may have been as a direct result of 
aggregation of BSA molecules brought about by exposure to a hydrophobic 
surface. This could in some part explain the differences between the different 
brands of plate tested. Similar findings have also been reported with reference 
to conformational changes in C-reactive protein once adsorbed onto 
polystyrene microtitre plates resulting in altered antigen binding sites (Shields, 
Siegel, Clark et al. 1991).  
Chemical denaturation with U+M was found to be an extremely effective 
mechanism of increasing 3NT-residue availability to the anti-3NT Ab in the 
indirect ELISA. However, it would not be suitable for a competitive assay due 
to the detrimental effect it would have on the anti-3NT Ab during the 
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competitive stage. Other denaturation methods were investigated but none 
gave a similar increase in sensitivity. Denaturing the NT-BSA/02 via boiling in 
the presence of Tween 20 (0.1%) and digesting the protein using trypsin did 
not result in the same increase in assay sensitivity as U+M. However, 
tryptically digested NT-BSA did produce fewer false negative results. 
Denaturing NT-BSA by boiling it in the presence of Tween 20 was found to 
have a detrimental effect on the sensitivity of the assay possibly through a 
reduction in the ability of the protein to adsorb onto the microtitre well.  
The indirect ELISA was a useful format to investigate assay reagents and 
parameters and revealed a number of issues. However, this format would 
always be limited for detecting 3NT in complex protein mixtures such as 
claudicant plasma. In order to quantify nitrated proteins where different 
proteins may contain different amounts of 3NT-residues a competitive assay 
was required. Franze et al (2004) also reported that indirect ELISAs have 
limited applicability, and sensitivity, with regards to the quantification of 3NT-
containing proteins within complex samples such as those observed in 
plasma.  
3.4.2. Competitive ELISA development 
In the lengthy development of a competitive ELISA there were similar findings 
to the indirect ELISA. Immulon 2HB® microtitre plates were found to be the 
most suitable of those tested. Trypsin digested NT-BSA, as a potential coating 
and competing antigen, was found to increase assay sensitivity and reliability 
compared to native NT-BSA. This was probably due to the 3NT-residues in 
the resultant peptide fragments being more available to the anti-3NT Ab. 
Denaturation, or modification, protocols have not been reported in any of the 
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other studies where similar immunoassays were developed (Khan, Brennand, 
Bradley et al. 1998, Ter Steege, Koster-Kamphuis, Van Straaten et al. 1998, 
Inoue, Hisamatsu, Ando et al. 2002) although some have reported differences 
in the limits of detection dependent upon the source of anti-3NT Ab being 
used (Ye, Strong, Huang et al. 1996, Franze, Weller, Niessner et al. 2004) 
and that their anti-3NT Abs have differing binding affinities for different nitrated 
proteins/peptides (Ye, Strong, Huang et al. 1996, Khan, Brennand, Bradley et 
al. 1998, Ter Steege, Koster-Kamphuis, Van Straaten et al. 1998). The 
sensitivity of the assay may not be solely due to the limited availability of the 
3NT-residues to the Ab but may also be due to the effects of the local 
environment surrounding the 3NT-residue e.g. influences of amino acids 
adjacent to the 3NT residue (Khan, Brennand, Bradley et al. 1998). This 
brings into question the validity of the ELISA as a quantitative method for the 
estimation of 3NT-containing proteins and that the assay should be classed as 
a semi-quantitative screening tool (Khan, Brennand, Bradley et al. 1998). 
Other assay parameters were evaluated to optimise the assay including 
antigen coating concentration and incubation buffer. Coating buffer and 
conditions were not explored as thought not to be significant, in fact binding 
proteins to plastic is thought to be independent of pH and ionic strength of the 
coating buffer (Kemeny and Challacombe 1988: 39). With respect to 
concentration of coating antigen, 4µg/ml of tryptically digested NT-BSA 
resulted in increased assay sensitivity, but was higher than that generally 
accepted for most proteins to form a monolayer of 1µg/ml (Cantarero, Butler 
and Osborne 1980).  
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In order to prevent the non-specific binding of proteins to the microtitre plate, 
plates were initially blocked using skimmed milk powder (5%) with Tween 20. 
This differed to that used in other published assays in which most reported 
using BSA with Tween 20 as the blocking agent (Ter Steege, Koster-
Kamphuis, Van Straaten et al. 1998, Inoue, Hisamatsu, Ando et al. 2002), 
although use of ovalbumin and goat serum have also been reported (Ye, 
Strong, Huang et al. 1996, Khan, Brennand, Bradley et al. 1998). Using 
blocking agents such as BSA and ovalbumin have the potential for non-
specific binding occurring due to the presence of antibodies against these 
proteins in the plasma of humans (Siltanen, Kajosaari, Savilahti et al. 2002, 
Mogues, Li, Coburn et al. 2005). The incubation buffer used in all further 
dilutions for the assay was optimised and it was found that incubation buffer 
with BSA (1%) in the presence of Tween 20 (0.05%) was sufficient to reduce 
background interference brought about by non-specific binding of human anti-
BSA antibodies and thus not impede assay sensitivity. However, the possible 
interaction between BSA and anti-BSA antibodies needs further investigation 
(as reported in Chapter 4). 
With respect to other non-specific reactions involving protein bound 
aminotyrosine, a novel approach in this study was to reduce NT-BSA to 
amino-BSA for use in the competitive ELISA. Although other studies have 
screened amino-BSA on membranes, in an ELISA format it appears that only 
free aminotyrosine has been used and no cross-reaction reported (Khan, 
Brennand, Bradley et al. 1998). In our ELISA the antibody did bind to amino-
BSA at similar levels to native NT-BSA.  This could be explained by the 
epitope environment of protein bound aminotyrosine being similar to that for 
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NT-BSA and it is that environment which is important for antibody binding. It 
may be that binding affinities to free aminotyrosine are similar to free 3NT 
which was seen in this and other studies (Khan, Brennand, Bradley et al. 
1998, Ter Steege, Koster-Kamphuis, Van Straaten et al. 1998) to be 
significantly less compared to protein bound 3NT. As reported by ter Steege 
et al (1998) the increased sensitivity towards protein bound 3NT will provide 
an assay which gives a more accurate determination of the extent of nitration 
within a sample due to the relatively short half life of free 3NT. However, the 
detection of aminotyrosine in proteins should be noted. The reduction of the 
NT-BSA to amino-BSA was confirmed spectrophotometrically and using dot 
blot immunodetection. However it is possible that that the amino-BSA 
autooxidised back to NT-BSA prior to the assay being carried out. Ye et al 
(1996) have reported that protein solutions that have been reduced to 
aminotyrosine, using dithionite, will slowly autooxidise back to nitrotyrosine.  
Despite extensive evaluation and parameter modification the inter- and intra-
plate variation was outside conventional limits of a %CV of ≤10%. Variation 
was reasonable at higher concentrations of standard but poor below 76nM 
tryp-NT-BSA. Regression coefficients were consistently less than 0.99 and 
lower than those of Khan et al (1998) using ONOO--nitrated BSA which were 
>0.99 but higher than those of ter Steege et al (1998). ter Steege et al’s 
(1998) assay differed in that it was a sandwich ELISA in which two 
monoclonal anti-3NT Abs were used. Monoclonals were not investigated in 
the study presented here but may be important for greater sensitivity and also 
reproducibility. Variation within and between plates of control samples (tryp-
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NT-BSA and nitrated plasma) were also greater than those reported for 
controls by Khan et al (1998) and ter Steege et al (1998).  
To continue to improve assay performance other nitrated proteins, as potential 
coating and competing antigens, were investigated. The most notable of these 
being electrochemically-nitrated human plasma (NT-PL), nitrated to an 
estimated level of nitration similar to that of the NT-BSA standard. A benefit of 
using NT-PL was that it would provide a standard more comparable and 
representative of the claudicant plasma samples, i.e. with complex mixtures of 
protein species. That is the anti-3NT Ab would display similar binding kinetics 
to the NT-PL as it would to claudicant plasma.  
Upon investigation it was clear that there was reduced assay sensitivity when 
using NT-PL compared to tryp-NT-BSA but intra- and inter-assay variation 
was comparable. Anti-3NT antibodies have differing binding affinities for 3NT-
residues within different proteins (Khan, Brennand, Bradley et al. 1998, Ter 
Steege, Koster-Kamphuis, Van Straaten et al. 1998). This is another issue for 
these assays as the nitration profile may differ depending on the nature of the 
pathology of the disease involved.  
 
In summary the results presented here have demonstrated that detection of 
3NT in proteins is very sensitive to assay conditions, in particular to the 
accessibility of the residues to the antibody. The structural integrity of a 
protein is, therefore, important and for any sample that may contain nitrated 
proteins the level of 3NT detection would only be proportional to the 
accessible residues. This would further indicate that the conformation of a 
protein (thus availability of epitope) and binding parameters of the solid phase 
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being used all influence the specificity of anti-3NT Abs. Thus an assay may 
underestimate the total nitrated protein population. These findings are 
important with respect to the validity of the use of ELISAs for detection of 
3NT-containing proteins as described in previously published reports (Khan, 
Brennand, Bradley et al. 1998, Ter Steege, Koster-Kamphuis, Van Straaten et 







Detection of 3NT and 
Analysis of the Nitration 




Atherosclerosis rarely produces symptoms until the extent of disease is 
severe and arteries are dangerously narrowed or in the worse case complete 
occlusion of the artery occurs, therefore the earlier the diagnosis the better the 
prognosis. IC is a symptomatic expression of lower extremity atherosclerotic 
disease (PAD) and as such is a marker of more serious cardiovascular 
problems and generalised atherosclerosis. If left untreated IC can lead to 
significant functional impairment and is indicative of an increased risk of 
cardiovascular morbidity and mortality (2.5 fold increase compared to age 
matched population (Stewart and Lamont 2001)).  Also due to pain upon 
exercise the individuals suffering from IC have a tendency to reduce exercise 
levels which can result in further clinical problems. Therefore it is imperative 
that IC should be treated seriously and highlights the need for accurate tests 
to enable early diagnosis. Current diagnostic techniques used for the 
diagnosis of IC rely on the accurate reporting of symptoms by the patient to 
the GP in order be referred to a consultant vascular surgeon (Chapter 2). As 
such it would be beneficial to diagnose the presence of PAD within an 
individual at an earlier stage in the disease process (e.g. when the patient is 
still asymptomatic) leading to more prompt intensive treatment and thus 
potentially a better prognosis.  
Plasma is one of the most informative biological specimens from a medical 
viewpoint but is also one of the most difficult to analyse due to its complexity 
and enormous dynamic range (Anderson and Anderson 2002, Hortin, Jortani, 
Ritchie et al. 2006). Proteomics involves the identification and functional 
analysis of the protein complement (proteome) of a cell, tissue, or bodily fluid 
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such as plasma at a given time. The analysis of biological fluids such as 
plasma and urine has been investigated using both qualitative and 
quantitative techniques for the identification of markers of disease for many 
years. For example, the first protein marker of disease reported was the 
Bence Jones protein in urine (Rosenfeld 1987). In the past 30 years the 
advent of more advanced analytical techniques has allowed for the 
simultaneous analysis of a large number of proteins within complex biological 
samples such as plasma. Although the terms proteome and proteomics were 
coined in the late 1990’s by Marc Wilkins, techniques such as 2-dimensional 
polyacrylamide electrophoresis (2D-PAGE) were first applied to separate 
proteins in the 1970’s. The high resolution separation of human plasma 
proteins using 2D-PAGE was first reported by Anderson, L. and Anderson 
N.G. (1977). Within proteomic studies proteins are resolved by 2D-PAGE and 
then further analysed and identified using mass spectrometry techniques 
including MALDI-TOF-MS and LC-ESI-MS/MS. Even with such advances 
there are still major challenges in the isolation and identification of proteins 
from complex samples such as plasma and it has been reported that the 
proteins identified are dependent upon the proteomic approach used (Omenn, 
States, Adamski et al. 2005).  
Unlike the human genome which is static there are many different proteomes 
(e.g. plasma proteome) which are dependent upon time, location and 
importantly may be affected by disease pathology; therefore investing the 
plasma proteome may provide useful biomarkers of disease. Protein targets of 
nitration have already been established in vivo within different disease states 
and disease models (Aulak, Miyagi, Yan et al. 2001, Lanone, Manivet, 
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Callebert et al. 2002, Kanski, Hong and Schoneich 2005, Casoni, Basso, 
Massignan et al. 2005). It was the aim of the proteomics study herein to 
identify the presence/absence of a nitration profile within the plasma of 
claudicants. Within this study MALDI-TOF-MS and LC-ESI-MS/MS analysis 
were combined to identify proteins that had stained immunopositive for the 
presence of 3NT in corresponding Western blots, excised from 1D SDS-





4.2. Materials and methods 
All chemicals used were analytical grade and purchased from Fisher 
chemicals unless otherwise stated. 
Unless otherwise stated water was obtained by reverse osmosis to a 
resistance of greater than 18MΩ cm-1 
4.2.1. Determination of total protein concentration 
Materials: Bradford reagent (B6916), purchased from Sigma (Poole, Dorset, 
U.K.). Bicinchoninic acid (BCATM Protein assay kit 23225, Pierce). 
 
Methods: 
The methods used for the determination of the protein concentration were 
dependent upon the sample being tested to due to presence of potential 
interfering chemicals. 
 
Lowry (Folin-Ciocalteau) method (Lowry, Rosebrough, Farr et al. 1951): The 
Lowry method was used to determine the total protein concentration of the 
patient and control whole plasma.  
BSA was used as the standard protein to prepare a calibration curve over a 
range of 0-200µg/ml. To 1ml of sample (diluted as necessary) or BSA (0-
200µg/ml), 5ml alkaline copper reagent was added (2% Na2CO3 in 0.1M 
NaOH: 0.5% CuSO4.5H2O in 1% sodium potassium tartrate 50:1). This 
solution was mixed and allowed to stand for 10 minutes. To this solution 0.5ml 
Folin-Ciocalteau Reagent (diluted 1:1 with water, 1M in acid) was then added 
and mixed rapidly by inversion. Following a 30 minute incubation period to 
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allow the colour to develop, the absorbance was read at 750nm. Total protein 
concentrations were then determined from the calibration curve. 
 
Absorbance A280/A260 method: The total protein concentration for each sample 
being tested was determined at A280 (Warburg and Christian 1942). The A280 
and A260 were measured for each sample at room temperature. The A280:A260 
ratio was then calculated and used to determine the corresponding factor for 
the conversion of A280 to protein concentration. (See appendix G for factors) 
 
Example calculation:    
  For sample 1 A280 = 1.74 
A280:A260 ratio = 1.70 
    Factor for 1.70 = 1.118 (appendices G) 
   Therefore protein concentration (mg/ml) = A280  x 1.118 
         = 1.945mg/ml 
 
NB: Since nucleic acid contamination was very low in all samples, the factor 
used was invariably 1.118 
 
Bradford method using microtitre plates: The total protein concentration for 
each of the three samples obtained from HSA fractionation, using dye-ligand 
affinity chromatography on immobilised Cibacron blue columns, was 
determined using the Bradford method adapted for use with microtitre plates 
following manufacturer’s instructions.  
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In brief, BSA was used as the standard protein and a calibration curve was 
prepared over a range of 0-1.4mg/ml. 5µl of sample (diluted as necessary) 
and BSA samples for the calibration curve (0-1.4mg/ml) were added to a 96 
well microtitre plate. To this, 250µl of Bradford reagent was added, mixed for 
30 seconds, and allowed to stand for 45 minutes at room temperature to allow 
the colour to develop, after which the absorbance at 600nm was read. From 
the calibration curve produced the total protein concentrations were 
calculated. 
 
Bicinchoninic method using microtitre plates: The total protein concentration 
for each of the samples obtained from the affinity purification for 3NT-
containing proteins was determined using the bicinchoninic acid (BCA™) 
method adapted for use with microtitre plates following the instructions 
provided by the manufacturer. 
In brief, the working reagent was prepared by mixing 50 parts of BCATM 
reagent A with 1 part BCATM reagent B followed by mixing thoroughly to yield 
a clear green working reagent. Diluted BSA standards were prepared over a 
working range of 20-2000µg/ml. 25µl of each standard and unknown (in 
duplicate) was pipetted into 96 well microtitre plate to which 200µl of the 
working reagent was added. The plates were the mixed thoroughly on a plate 
shaker for 30 seconds, covered and incubated at 37oC for 30 minutes. The 
plates were then allowed to return to room temperature and the absorbance 
was measured at 620nm on a plate reader. 
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4.2.2. Dye-ligand affinity chromatography on immobilised Cibacron blue 
The claudicant and control plasma samples were fractionated using affinity 
purification in order to assess the plasma nitration profile, which potentially 
may have been masked by proteins present in high concentrations. 
 
Human serum albumin (HSA) was separated from other plasma proteins in 
the patients’ plasma using a method adapted from that described by Gianazza 
and Arnaud (1982).  
 
Materials: Fast flow cross-linked agarose gel with covalently coupled Cibacron 
blue dye (C8321) purchased from Sigma (Poole, Dorset, U.K.). 
 
Column preparation: Mini columns were set up using fast flow cross-linked 
agarose gel with covalently coupled Cibacron blue dye. The gel (0.5ml) was 
packed into a small column and equilibrated with five bed volumes of buffer 1 
(0.03M phosphate buffer, pH 7; 10.74g disodium hydrogen orthophosphate 
dodecahydrate and 4.68g sodium hydrogen orthophosphate, made up to 1L).  
 
Chromatography procedure: Patient plasma (500µl) was centrifuged (12100g) 
for 5 minutes after which the supernatant was loaded onto the column. Once 
loaded onto the column the sample was circulated continuously through the 
column for three equivalent column volumes, eluted and the column was 
washed using 3ml of buffer 1 (fraction F1). The column was then washed with 
2ml of buffer 2 (0.03M phosphate buffer, pH 7 plus 0.5M NaCl), and the eluate 
was again collected following a wash of 3 bed volumes of buffer 1 (fraction 
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F2). Finally the tightly bound HSA and lipoproteins were washed from the 
column using 2ml of 0.5M sodium thiocyanate followed by 3 bed volumes of 
buffer 1 (fraction F3). From this separation the three samples obtained were 
dialysed into 10mM Tris-HCl pH 8, diluted with an equal volume of glycerol 
and stored at -20oC. These samples were then further purified/analysed using 
a variety of techniques mentioned below and by ELISA (indirect and 
competitive).  
4.2.3. Affinity chromatography 
Samples from each of the separated fractions obtained from method 4.2.2. 
were further purified using affinity chromatography on immobilised rabbit anti-
3NT antibody. 
 
Materials: Cyanogen bromide activated agarose (C9210) and 3-nitro-L-
tyrosine (N7389) Sigma (Poole, Dorset, U.K.). 
 
Methods:  
Column preparation: Affinity columns were set up using 0.25g cyanogen 
bromide-activated agarose reconstituted in 3ml 0.25M carbonate buffer, pH 
9.5, to which anti-3NT Ab (100µl) was added. This solution was stirred gently 
overnight at 4oC to allow the antibody to bind. The gel slurry was placed into a 
small glass column and washed until the A280 returned to zero using 0.25M 
carbonate buffer, pH 9.5. The remaining active groups present were then 
blocked using 0.25M carbonate buffer plus 10mM ethanolamine, pH 9.5, run 
through the column for 2 hours at room temperature. The column was washed 
again using 0.25M carbonate buffer, pH 9.5. The column was prepared for 
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storage by washing the column with phosphate buffer containing 0.02% (w/v) 
azide and was stored at 4oC. 
   
Affinity purification procedure: The three fractions obtained from the Cibacron 
blue mini columns (F1, F2, and F3) were further purified using anti-3-NT 
antibody affinity purification. The column was equilibrated in carbonate buffer 
(0.25M, pH 9.5) after storage.  5ml of a fraction obtained from the Cibacron 
columns (e.g. F1) were then circulated through the column for 2 hours at room 
temperature after which the column was washed using carbonate buffer 
(0.25M pH 9.5), and the eluate was collected (unbound fraction U). The 
bound, nitrated plasma proteins were eluted from the column using 10mM 
3NT (10ml), followed by washing the column using 0.25M carbonate buffer, 
pH 9.5 (bound fraction B). The two fractions were dialysed into 10mM 
ammonium acetate, pH 7, and freeze dried. The samples were then 
reconstituted in 1ml 10mM Tris-HCl pH 7, ready for further analysis. Each 
affinity column was used specifically for one plasma sample, after which it was 
discarded. 
4.2.4. Sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
(SDS-PAGE) 
For materials and methods see Chapter 3, section 3.2.11. 
4.2.5. Coomassie blue staining 
For materials and methods see Chapter 3, section 3.2.12. 
4.2.6. Western Blot 
For materials and methods see Chapter 3, section 3.2.13. 
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4.2.7. Silver stain 
Materials: ProteosilverTM Plus silver staining kit (PROT-SIL2) Sigma (Poole, 
Dorset, U.K.). Ultra pure water obtained by filtering RO water through an 
Elgastat spectrum water purifier/polisher (Elga Ltd, High Wycombe, Bucks. 
UK). 
Methods: Following Coomassie staining the gradient gels were then 
additionally stained using Proteosilver™ Plus silver staining kit as described in 
the technical bulletin supplied.  
In brief the gels were fixed overnight in fixing solution (50ml ethanol, 10ml 
acetic acid and 40ml ultra pure water). The gels were then washed in 30% 
ethanol solution followed by washing in ultra pure water. Following this the 
gels were placed in sensitizer solution for 10 minutes, again followed by a 
water wash. Silver equilibration then occurred followed by a brief water wash 
(no longer than 1.5 minutes). During gel development the gels were placed in 
developer solution for 3-7 minutes, after which the reaction was stopped using 
Proteosilver stop solution and left for 5 minutes. The gels were then washed 
and stored in ultra pure water.  
4.2.8. Mass spectrometric analysis of plasma proteins 
Following Coomassie and silver staining the gradient gels were sent to 
Warwick University for matrix assisted laser desorption ionization time-of-flight 
mass spectrometry (MALDI-TOF-MS) and liquid chromatography electrospray 
ionisation tandem mass spectrometry (LC-ESI-MS/MS) analysis on excised 
bands. Protein bands which stained positive for 3NT (via western blot 
analysis) were identified and manually excised into a 96 well microtitre plate. 
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(NB: not all bands were excised for further analysis due to limited time & 
resources, those bands excised are highlighted in the results section 4.3.3.). 
The following methodology was carried out by the Biological Mass 
Spectrometry and Proteomics Department, University of Warwick. 
 
Materials: MALDI-TOF-MS (MALDI micro MX).and MassPREPTM PROtargetTM 
plates purchased from Waters®. Liquid chromatography-electrospray 




General protocol for extracting the proteins from the excised bands was as 
follows: The gel plugs were de-stained, reduced, alkylated, and digested with 
trypsin. The resulting peptides were extracted using the Micromass 
MassPREP™ station running the standard digestion protocol supplied by 
manufacturer. The tryptic peptides were transferred to a cooled 96 well 
microtitre plate ready for spotting onto a MassPREP™ PROtarget plate™.  
 
In brief the protocol for spotting the tryptic digests was as follows: the 
MassPREP™ PROtarget™ plate was conditioned by the addition of 1µl of 
acetonitrile to each active well followed by 1µl of trifluoroacetic acid (TFA) 
after 30 seconds. The plate was then left for 2 minutes, after which the 
conditioning solution was removed ready for sample addition.  10µl of the 
tryptic digest (in 0.1% TFA / 30% acetonitrile) was added to an active well, 
and left until it had completely dried. Once dry a further 10µl aliquot was 
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spotted and allowed to air dry. The plate was then further made ready for 
MALDI-MS analysis by washing with approximately 5µl of aqueous 0.1% TFA, 
repeated x3. Once completely dry 1µl of matrix solution (α-cyano-4-
hydroxycinnamic acid (CHCA) 0.5mg/ml / 90% acetonitrile / 0.1% TFA) was 
added and allowed to dry. The plate was then analysed using MALDI analysis 
using a Micromass M@LDI® mass spectrometer fitted with a nitrogen UV laser 
(337nm) incorporating a time of flight (TOF) mass analyser. This data was 
further confirmed or rejected by means of LC-ESI-MS/MS. The MALDI-MS 
and LC-ESI-MS/MS data was then used to interrogate the IPI human protein 
database V.3.07 (or SwissProt where appropriate) using the Mascot search 
engine. 
4.2.9. Indirect and competitive ELISA protocols 
For materials and methods see Chapter 3, section 3.2.7. and 3.2.9. 
4.2.10. Testing for the presence of human antibodies against 3NT, 
BSA or HSA 
A microtitre plate was coated with BSA, NT-BSA, human serum albumin 
(HSA) or NT-HSA (4µg/ml), using carbonate buffer pH 9.6 and incubated 
overnight. The plate was then blocked with 5% SMP in PBS (130µl) for 1 hour 
at 37oC and washed with wash buffer three times. Each claudicant and control 
plasma sample (1/50, in duplicate) was pipetted into an appropriate well 
coated with BSA, NT-BSA, HSA or NT-HSA. The plate was then incubated 
overnight at 4oC. Following a wash cycle (as described in earlier ELISA 
protocols) the plate was probed using an anti-human IgG horse radish 
peroxidase conjugate (1/1000) and incubated for 1 hour at 37oC. Following 
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another wash cycle OPD substrate was added and incubated for 15 minutes 
to allow the colour to develop. The reaction was stopped using 2M sulphuric 
acid and the absorbance was read at 492nm. All antibody dilutions were made 




4.3.1. Initial Screening of the patient and control plasma for 3NT-
proteins 
 
Figure 4.3.i.  Flow diagram to illustrate how the whole plasma samples from the 
claudicants and control subjects were analysed. 
The total protein concentrations for the claudicant and control plasma samples 
were determined using the Lowry method (Lowry, Rosebrough, Farr et al. 
1951) and were found to range from 90-157mg/ml and 96-121mg/ml 




















Total plasma protein concentration 
(mg/ml) 
Claudicants Control subjects 
102 ±13 104 ±9 
Table 4.3.i. Plasma protein concentrations for claudicant and control subjects. 
Total plasma protein concentrations were determined using the Lowry 
method (Lowry, Rosebrough, Farr et al. 1951). ± SD - standard deviation  
 
The presence of nitrated proteins within these plasma samples was 
investigated using a variety of techniques; this will now be described below. 
 
The claudicants’ whole plasma samples were preliminarily screened for the 
presence of 3NT residues using dot blot immunodetection and 3NT was found 
to be present in all thirty three patient samples (Figure 4.3.ii.). When testing 
the whole plasma from the control subjects a similar colourimetric response 
was obtained, suggesting that there are 3NT-containing proteins present in 
the control plasma also (results not shown). 
 
Figure 4.3.ii. Dot blot immunodetection of claudicant plasma. 
Claudicants plasma (n=33) was loaded directly onto the nitrocellulose 
membrane to screen for the presence of 3NT residues. NT-BSA - 4 mol 











In an attempt to identify the nitration profile within the claudicant whole plasma 
samples a selection (CS001-CS006) were separated using SDS-PAGE, 
visualised using Coomassie blue and probed for the presence of 3NT 
residues using Western blot immunodetection. For both the patient plasma 
samples and the NT-BSA standard a cluster of high RMM Coomassie-stained 
bands were observed at the base of the stacking gel and start of the resolving 
gel. An overloaded band was also observed for the NT-BSA standard and 
patient samples within the resolving gel, migrating faster than the 55kDa size 
marker. Although a Coomassie-stained band was observed within the patient 
samples at the same position to the 66kDa band within the size marker, no 
Coomassie-stained protein band was observed for NT-BSA (Figure 4.3.iii). 
Western blot immunodetection clearly highlighted the presence of 3NT within 
all of the bands present within the control NT-BSA sample but no 3NT-positive 
bands were detected in protein bands from the patient samples (results for 
Western blot not shown).  
These results were contradictory to the initial findings using dot blot 
immunodetection, with regard to the presence of 3NT-proteins in the 
claudicant plasma as shown in Figure 4.3.ii. above. Further analysis was 
carried out on both the claudicant and control plasma samples in order to 
confirm the presence/absence of 3NT residues. Upon further analysis using 
both indirect and competitive ELISA, the presence of 3NT-containing proteins 
could not be established in either the claudicant or control plasma samples 








Figure 4.3.iii. Claudicant whole plasma (CS001-CS006) separated on SDS-PAGE 
visualised using Coomassie blue staining 
Samples run on the gel were loaded at 4µl in sample buffer. 
Electrochemically nitrated BSA (NT-BSA) was used as a positive control 
and an Anamed size marker (M) was run for calculation of protein bands 
within samples. Patient sample CS001-CS006 (1-6) were separated on 
the gel. See Figure 3.2.ii. above for molecular masses of the other 
bands in the size marker.  
 
The claudicant and control plasma samples were also screened for the 
presence of anti-3NT Abs using both native and nitrated BSA and native and 
nitrated HSA. With regards to the BSA a significantly higher mean antibody 
response was observed towards native BSA compared to NT-BSA in the 39 
samples tested (2 tailed paired t-test, n=33 claudicants and n=6 control, 
p<0.001, Figure 4.3.iv.). This significant difference was also evident when 
testing the claudicant and control plasma samples independently, but only 
significant to a level p<0.05 in the case of the control subjects. A significantly 




higher mean antibody response towards native HSA was observed compared 
to NT-HSA in the 39 samples (2 tailed paired t-test, n=33 claudicants and n=6 
control, p<0.001, Figure 4.3.iv.). Again when testing the claudicants and 
control subjects independently the mean Ab response to native HSA was 
found to be significantly higher than it was for NT-HSA (2 tailed paired t-test, 
p<0.001). It was also clear that a higher antibody response was observed 
when using native and nitrated HSA compared to native and nitrated BSA for 
both the claudicant and control plasma samples. A higher antibody response 
against both the native and nitrated HSA/BSA was observed within the 























Figure 4.3. iv. Presence of antibodies against nitrated BSA / HSA and native BSA / 
HSA in claudicant and control plasma. 
The above figure represents the mean absorbance values (± SEM) from 
an indirect ELISA screening for the presence of antibodies against 
nitrated BSA / HSA and native BSA / HSA in claudicant (n=33) and 
control (n=6) plasma samples. All absorbances have been corrected to 
the mean of the blank wells. Claudicant plasma samples (, CS001-
CS0033) and control plasma samples (, CD001-CD006) were incubated 





4.3.2. Fractionation of human plasma using dye-ligand affinity 
chromatography on immobilised Cibacron blue 
 
 
Figure 4.3.v. Illustration of the different analytical techniques applied to the 

























To overcome the masking of other proteins by HSA the claudicant and control 
plasma samples were fractionated using dye-ligand affinity chromatography 
on immobilised Cibacron blue (Gianazza and Arnaud 1982). This fractionation 
method resulted in three protein fractions for each plasma sample (F1-F3, see 
table 4.3.ii. for protein concentrations in each fraction). Fraction 1 (F1) 
contained unbound plasma proteins which were eluted from the column using 
0.03M phosphate buffer, fraction 2 (F2) contained loosely bound plasma 
proteins which were eluted from the column in the presence of salt (0.5M 
NaCl). Finally the third fraction (F3) consisted of tightly bound plasma proteins 
which were removed by ‘stripping’ the column using 0.5M NaSCN. 
 Protein concentration (mg/ml) 
 F1 F2 F3 Total (F1-F3) 
Claudicants 1.6 ±0.4 0.8 ±0.2 0.3 ±0.1 2.7 ±0.4 
Control subjects 1.1 ±0.1 0.7 ±0.1 0.5 ±0.1 2.3 ±0.1 
Table 4.3.ii. Protein concentration for each fraction obtained following separation of 
the plasma samples using dye-ligand affinity chromatography on 
immobilised Cibacron blue.   
Protein concentrations calculated using the Bradford method adapted 
for use on microtitre plates. F1 - unbound protein fraction, F2 - loosely 
bound protein fraction and F3 - represents the tightly bound protein 
fraction. Mean data ± standard deviation. 
 
These fractionated plasma protein samples were then further separated using 
SDS-PAGE and visualised via Coomassie staining. From this it was clear that 
the human serum albumin (HSA) had not been completely separated from the 
rest of the plasma proteins within the fractions (Figure 4.3.vi.). Following SDS-
PAGE, the fractions were probed for the presence of nitrated-proteins using 
Western blot immunodetection. Very faint staining for the presence of nitrated 
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proteins was identified in several bands in all three fractions for all claudicant 
and control subjects (Western blot not shown due to poor resolution). The 
corresponding areas in which positive bands for 3NT-containing proteins were 
identified by Western blot analysis have been circled () on the 
representative Coomassie stain shown in Figure 4.3.vi. Due to the nature of 
the assay being used and the low level response observed quantification of 
levels of 3NT present was not possible.  
 
 
Figure 4.3.vi. Visualisation of Cibacron blue affinity fractionated claudicant plasma, 
using Coomassie stain following SDS-PAGE separation.  
 Samples F1 – F3 represent the Cibacron blue fractions for claudicant 
CS001. M - Anamed size maker; A - native BSA; B - NT-BSA. A duplicate 
gel was probed for the presence of 3NT-containing proteins using 
Western blot immunodetection (positive bands identified above with ).  
The above is representative of all of the fractions tested. 
 
The fractions obtained from the Cibacron affinity fractionation procedure were 
also screened for the presence of 3NT-containing proteins using both indirect 
and competitive ELISA (as described in Chapter 3). It was clear from this 
analysis that the presence of nitrated-proteins could not be detected in any of 
the Cibacron fractions tested (from either the claudicants or the control 
F1 F2  F3  M   A   B 
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subjects) using indirect and competitive ELISA. These results did not concur 
with those findings obtained when using different immunodetection methods 
(Western blot immunodetection following SDS-PAGE). The three Cibacron 
fractions were therefore fractionated by affinity chromatography on an anti-
3NT antibody column. 
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4.3.3. Affinity chromatography – purification of nitrated and non-nitrated 
proteins 
 
Figure 4.3.vii. A flow diagram to illustrate the further fractionation and analysis of the 
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Affinity purification of nitrated and non-nitrated plasma proteins 
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The Cibacron fractions from plasma were further fractionated using anti-3NT 
Ab-affinity purification in order to separate nitrated plasma proteins from non-
nitrated proteins. Each Cibacron fraction resulted in two affinity fractions, a 
non-nitrated unbound protein fraction (U) eluted from the column using 
carbonate buffer (0.25M, pH 9.5) and a bound nitrated protein fraction (B) 
eluted from the column in the presence of 10mM free 3-nitro-L-tyrosine. Table 
4.3.iii. shows the protein concentrations of each fraction obtained. 
 Protein concentration (mg/ml) 
 F1 F2 F3 Total  U B U B U B 





























Table 4.3. iii.  Protein concentration for each fraction obtained following affinity 
purification of 3NT-proteins from the Cibacron fractions from section 
4.3.2.  
Protein concentrations were obtained using the BCA method adapted 
for use on microtitre plates. F1-F3 represents the fractions obtained 
from the dye-ligand affinity chromatography on immobilised Cibacron 
blue in section 4.3.2. above. Each of these fractions were further 
purified, producing an unbound (U, un-nitrated) fraction and bound (B, 
nitrated) protein fraction, using a column onto which the anti-3NT Ab 
had been bound. Mean data ± standard deviation. 
 
The indirect and competitive ELISA methods developed were used to quantify 
the concentration of nitrated proteins within each affinity fraction for both the 
claudicants and the control subjects. When testing the affinity fractions using 
the indirect ELISA the presence of 3NT could not be established. However, 
when using the competitive ELISA developed, the quantification of the 
concentration of nitrated proteins within these affinity fractions was possible. 
From this analysis it was clear that there were varying levels of 3NT-
containing proteins present within the different fractions and in general the 
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bound affinity fractions had significantly higher levels compared to the 
unbound fractions. With the exception of the unbound affinity fraction F2U the 
claudicant fractions were found to contain higher levels of 3NT-proteins 
(expressed as µM tryp-NT-BSA equivalents per mg protein) compared to the 
control subjects. It is however notable that nitrated proteins were found within 
the unbound proteins fractions moreover, high levels were also found in the 
equivalent control fractions (Table 4.3.iv).  
 µM Tryp-NT-BSA equivalents per mg protein 
































Table 4.3.iv.  Estimated level of nitration in the affinity purified protein fractions for 
the claudicant and control subjects. 
The above values are presented as tryp-NT-BSA equivalents (µM) per 
mg protein as determined from standard curves constructed using tryp-
NT-BSA standards on competitive ELISA. F1-F3 represent the fractions 
obtained from the dye-ligand affinity chromatography on immobilised 
Cibacron blue in section 4.3.2. above. Each of these fractions were 
further purified, producing an unbound (U, un-nitrated) fraction and 
bound (B, nitrated) protein fraction, using a column onto which the anti-
3NT Ab had been bound. Mean data ± standard deviation. 
 
The proteins within each of these affinity fractions were again visualised using 
Coomassie stain and probed for the presence of nitrated-proteins via Western 
blot immunodetection following SDS-PAGE (Figure 4.3.viii.).  The Coomassie 
stain highlighted that the majority of the protein was found to be located in the 
unbound non-nitrated fractions and that only very faint proteins staining was 
present within the bound fractions (Figure 4.3.viii. a). Upon probing for the 
presence of 3NT-containing proteins using Western blot immunodetection all 
of the affinity fractions, both unbound and bound, were found to contain 
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proteins which stained positive for the presence of 3NT. Although the 
Coomassie stain highlighted that the majority of the protein was present in the 
three unbound protein fractions a similar degree of staining was observed 
within all of the fractions during Western blot immunodetection. The majority 
of the protein bands that stained positive for the presence of 3NT-residues 
were of a molecular mass >100kDa (as determined from the Coomassie 
stain). Due to poor resolution of the bands, determination of the exact 
molecular mass was not possible, estimated to be in the region of 220-
116kDa. Fainter staining was also observed at lower molecular mass within 
the bound affinity fractions (Figure 4.3.viii. b). No differences were observed 




Figure 4.3.viii. Coomassie stain (a) and Western (b) of CS002 Cibacron 
fractions separated on an anti-3NT Ab affinity column 
F1U & F1B, F2U & F2B, F3U & F3B = fraction 1-3 from Cibacron 
separation further separated by affinity purification where U represents 
the antibody unbound fraction and B represents the bound fraction.  
A – Native BSA; B – NT-BSA and M represents the size marker. Areas 
highlighted () indicate where faint staining was also found, not evident 
on figure above. 
 
                        F1  F2    F3                          F1 F2  F3 
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The bound fractions for each subject (F1B-F3B) were pooled, due to low 
protein concentration, and separated using SDS-PAGE on gradient 
polyacrylamide gels (4-20%) which resulted in a better resolution of the 
proteins present within each sample (Figure 4.3.ix. a and 4.3.ix. b). Several 
bands of varying molecular weight were found to stain positive for the 
presence of 3NT-containing proteins in all claudicant and control samples 
when using Western blot immunodetection (Figure 4.3.ix. b). It was evident 
that those bands which produced a strong signal for the presence of 3NT on 
the Western blot did not stain strongly on the Coomassie stained gel, Figure 
4.3.ix. a and 4.3.ix. b.  
     
 
Figure 4.3.ix. Affinity purified claudicant and control plasma fractions visualised 
using Coomassie stain and Western blot immunodetection using 
gradient SDS-PAGE 
The anti-3NT Ab antibody bound affinity purified fractions F1B-F3B for 
each subject were pooled together and loaded onto the gradient gel. a -  
Coomassie-stained gel; b- probed Western blot. Positive control - NT-
BSA (A), protein size marker (M). Wells 1-11 - pooled affinity purified 
samples for 11 claudicants and wells 12-13 control subjects. Similar 
results were obtained for the other claudicant and control samples. Not 
all positive bands are clear on the figure above, areas highlighted ( --) 
indicate where faint staining was also found. 
66kDa 
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The gradient gels were further stained using the more sensitive silver stain in 
order to get a clearer representation of those bands which had been identified 
as containing nitrated proteins using Western blot immunodetection (Figures 
3.4.x.-3.4.xii.). From the silver stain it was evident that the major stained 
proteins within the pooled samples were found to be situated in the resolving 
gel at RMMs ≥55kDa. Protein bands from these silver stained gels, that 
corresponded to bands identified as containing 3NT-proteins using Western 
blot immunodetection (Figure 4.3.ix.), were further analysed using MALDI-MS 
and LC-ESI-MS/MS (by the Biological Mass Spectrometry and Proteomics 
Department, University of Warwick). Those protein bands which were excised 
for MALDI-MS and LC-ESI-MS/MS analysis are highlighted in Figures 4.3.x.-
4.3.xii; not all bands were excised from the gradient gels. All proteins were 
identified using the Mascot search engine which interrogated databases 
including the IPI human protein database (V.3.07) and SwissProt where 
appropriate. The proteins identified in within the bands excised from the 
gradient gels represented in Figures 4.3.x.-4.3.xii are shown in Tables 4.3.v.-
4.3.vii. Several proteins were identified within each excised band with varying 
degrees of percentage sequence coverage by tryptic peptides for each 
protein. The presence of 3NT-residues (i.e. a mass increase of +45Da 
corresponding to +NO2 -H) could not be confirmed within any of the proteins 
identified by either method. The main nitrated proteins identified in both the 
claudicant and control subjects were HSA, serotransferrin precursor, 





Figure 4.3.x. Silver stain of gradient SDS-PAGE gel for pooled affinity fractions for 
Claudicants CS001-CS011 and control subjects CD01-CD02. 
A – NT-BSA; M – Anamed size marker; CS001-CS011 wells 1-11 and 
control subjects CD01-CD02 wells 12-13. 
Band Protein Database No  
(IPI or SwissProt[P]) 
RMM MS Coverage 
(%) 
A Serum albumin precursor (bovine) P02769 71244 28 
B Serum albumin precursor (bovine) P02769 71244 32 
C Albumin protein 00022434 73881 5 

































H Apolipoprotein A1l precursor# 00021854 11282 29 
I Haemoglobin β chain 00218816 16102 29 
J & L Serotransferrin precursor N/A N/A N/A 
Table 4.3.v. Summary data from figure 4.3.x. MALDI-MS & LC-ESI-MS/MS analysis. 
The above table gives a summary of the proteins identified in the bands 
excised from the gradient gels shown in Figure 4.3.x. All of the proteins 
were identified using both MALDI-TOF-MS and LC-ESI-MS/MS unless 
otherwise stated (# - identified by LC-ESI-MS/MS only). 
 A    M    1          3          5         7         9         11        13 
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Figure 4.3.xi. Silver stain of gradient SDS-PAGE gel for pooled affinity fractions for 
Claudicants CS012-CS022 and control subjects CD03-CD04. 
A – NT-BSA; M – Anamed size marker; CS012-CS022 wells 1’-11’ and 
control subjects CD03-CD04 wells 12’-13’. 
Band Protein Database No  
(IPI or SwissProt[P]) 
RMM MS Coverage 
(%) 
A Albumin protein# 00216773 46442 21 






C, D, G & J No significant hits -- -- -- 
E, F, H & I Albumin protein 00022434 73881 -- 
Table 4.3.vi. Summary data from figure 4.3.xi. MALDI-MS & LC-ESI-MS/MS analysis. 
The above table gives a summary of the proteins identified in the bands 
excised from the gradient gels shown in Figure 4.3.xi. All of the proteins 
were identified using both MALDI-TOF-MS and LC-ESI-MS/MS unless 
otherwise stated (# - identified by LC-ESI-MS/MS only). 













Figure 4.3.xii. Silver stain of gradient SDS-PAGE gel for pooled affinity fractions for 
Claudicants CS023-CS033 and control subjects CD05-CD06. 
A – NT-BSA; M – Anamed size marker; CS023-CS033 wells 1*-11* and 
control subjects CD05-CD06 wells 12*-13*. 
 
Band Protein Database No  
(IPI or SwissProt[P]) 
RMM MS Coverage 
(%) 
A No significant hits -- -- -- 
B Apolipoprotein A1 precursor# 
Albumin protein# 
00021841 -- -- 
C Apolipoprotein A1 precursor 00021841 30759 70 
D Haemoglobin β chain 







E Haemoglobin β chain 
Haemoglobin δ chain# 
α 2 globin variant# 













F & G Albumin protein 00022434 73881 -- 
Table 4.3.vii. Summary data from figure 4.3.xii. MALDI-MS & LC-ESI-MS/MS analysis. 
The above table gives a summary of the proteins identified in the bands 
excised from the gradient gels shown in Figure 4.3.xii. All of the 
proteins were identified using both MALDI-TOF-MS and LC-ESI-MS/MS 
unless otherwise stated (# - identified by LC-ESI-MS/MS only). 
 
  A    M  1*         3*        5*        7*        9*       11*      13* 









4.3.4. Determination of the protein concentration of the whole plasma, 
dye-linked and 3NT-affinity purified fractions. 
Several protein determination methods (e.g. Lowry, Bradford and BCA) had to 
be used to determine the total protein concentration of the different protein 
fractions as highlighted in Figure 4.3.xiii. below (for full data see Appendices 
J). Comparisons were made of the total protein values obtained when using 
different methods for the same samples from which it was clear that there 
were stark differences between the different methods (results not shown).  
 
Figure 4.3.xiii. A schematic diagram to illustrate the protein concentrations determined 
for the different fractions obtained for a claudicant plasma sample. 
The above values represent those calculated for claudicant CS002. The 
total protein concentrations for each set of samples were determined 
using different techniques: Lowry method (Lowry, Rosebrough, Farr et 
al. 1951) for the whole plasma; Bradford method adapted for use on 
microtitre plates was used for fractions F1-F3 (obtained from dye-linked 
affinity chromatography on immobilised Cibacron blue); BCA method 
adapted for use on microtitre plates was used for fractions F1U-F3B 
(obtained from 3NT-affinity purified fractions). 
Whole Plasma  













500µl of plasma was centrifuged and 
the supernatant containing the soluble 




















The presence of 3NT-containing proteins have been identified in many 
different diseases such as Alzheimer’s (Smith, Richey Harris, Sayre et al. 
1997), atherosclerosis (Beckmann, Ye, Anderson et al. 1994), celiac disease 
(Ter Steege, Koster-Kamphuis, Van Straaten et al. 1998), chronically rejected 
human renal allografts (Macmillan-Crow, Crow, Kerby et al. 1996), pituitary 
cancer (Zhan and Desiderio 2006), rheumatoid arthritis (Kaur and Halliwell 
1994), and the inflammatory disorder systemic sclerosis (Khan, Brennand, 
Bradley et al. 1998). Within this study we can report that 3NT-containing 
proteins have been identified within the plasma of claudicants. The 
commentary below will now discuss the techniques employed in order to 
establish the presence of 3NT-residues.  
4.4.1. Initial screening for the presence of 3NT using immunodetection 
Initial screening using immunodetection (dot blot analysis) confirmed the 
presence of 3NT-containing proteins within all of the claudicant plasma 
samples tested. This finding was not unexpected as IC is a peripheral 
manifestation of systemic atherosclerotic disease and 3NT-residues have 
been identified within atherosclerotic lesions in coronary arteries using 
immunohistochemical staining techniques (Beckmann, Ye, Anderson et al. 
1994) and lesions in transplant coronary artery disease (Ravalli, Albala, Ming 
et al. 1998). Interestingly dot blot immunodetection also signified the presence 
of 3NT-containing proteins within the plasma of the healthy control subjects 
enrolled onto this study. Currently there is a degree of controversy 
surrounding the presence of 3NT-containing proteins within the plasma of 
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healthy individuals. While nitrated proteins have been confirmed in healthy 
individuals in some studies (Khan, Brennand, Bradley et al. 1998, Frost, 
Halliwell and Moore 2000, Inoue, Hisamatsu, Ando et al. 2002, Capeillere-
Blandin, Gausson, Descamps-Latscha et al. 2004, Dooley, Gao, Bradley et al. 
2006) the range of concentrations reported is highly divergent. Others have 
reported that nitration could not be identified in plasma from healthy 
individuals (Kaur and Halliwell 1994, Ter Steege, Koster-Kamphuis, Van 
Straaten et al. 1998). Although some of these differences can be explained by 
the analytical technique being used, differences in reported values have been 
observed for example in mass spectrometry-based techniques which are 
generally accepted as being inherently specific and accurate (Tsikas and 
Caidahl 2005). These differences could be explained by reports of ‘denitrase’ 
activity, thought to be an enzyme resulting in the reduction of 3NT immuno-
reactivity in proteins (Gow, Duran, Malcolm et al. 1996, Kamisaki, Wada, Bian 
et al. 1998, Irie, Saeki, Kamisaki et al. 2003)  which provides evidence that the 
presence of 3NT-residues within proteins may be a dynamic process that can 
be regulated by the reversal of nitration by ‘denitrase’. This supports the 
hypothesis that protein nitration, and the associated actions of ‘denitrase’, 
may not only be involved in disease pathology but may also be implicated in 
biological mechanisms such as cellular signal transduction (Gow, Duran, 
Malcolm et al. 1996, Kamisaki, Wada, Bian et al. 1998, Irie, Saeki, Kamisaki 
et al. 2003). 
The level at which 3NT has been reported to be present in the plasma of 
healthy individuals may also be dependent upon the technique being used to 
quantify it and if free or protein-bound 3NT is being detected. For example 
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Khan et al (1998) and Inoue et al (2002) reported similar levels of 3NT-
containing proteins in healthy individuals (0.12µM nitro-BSA equivalents and 
0.14µM respectively) by ELISA. Whereas Frost et al (2000), using a GC-MS 
method developed to avoid artifactual 3NT production, reported substantially 
lower levels of free 3NT in the plasma of healthy individuals (0.064µM).  
As dot blot immunodetection is a purely qualitative technique it was not 
apparent from the results the extent to which the plasma proteins were 
nitrated. Further clarification was also required regarding the nitration profile of 
the plasma proteins. Therefore the plasma samples were analysed using the 
indirect and competitive ELISAs developed along with Western blot 
immunodetection following separation using SDS-PAGE. From this analysis it 
was clear that confirmation of the presence of 3NT-containing residues within 
the claudicant and control plasma samples was not possible. These findings 
are contradictory to those reported within this study when using dot blot 
immunodetection and with published reports in which 3NT-containing proteins 
have been shown to be present in human plasma using immunoassays 
(several ELISA formats) and Western blot immunodetection (Macmillan-Crow, 
Crow, Kerby et al. 1996, Khan, Brennand, Bradley et al. 1998, Ter Steege, 
Koster-Kamphuis, Van Straaten et al. 1998, Inoue, Hisamatsu, Ando et al. 
2002, Capeillere-Blandin, Gausson, Descamps-Latscha et al. 2004, Dooley, 
Gao, Bradley et al. 2006, Khan and Siddiqui 2006).  
It is well documented both within this study (Chapter 3) and by others (Ter 
Steege, Koster-Kamphuis, Van Straaten et al. 1998, Khan, Brennand, Bradley 
et al. 1998, Franze, Weller, Niessner et al. 2004) that there are quantitative 
differences regarding the antigen-antibody reaction for the detection of 3NT-
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epitopes within different proteins. When using immunodetection techniques 
such as Western blot analysis there is also the potential of the 
underestimation of 3NT-containing proteins due to reduction of the 3NT-
residues during sample preparation (Pignatelli, Li, Boffetta et al. 2001). They 
reported that boiling protein fractions in sample buffer prior to separation using 
SDS-PAGE can result in the reduction of 3NT to aminotyrosine. This 
temperature-dependent reduction is thought to be a direct result of 
interference from thiols (e.g. mercaptoethanol) within the sample buffer which 
have been identified as agents that are capable of reducing 3NT to 
aminotyrosine (Balabanli, Kamisaki, Martin et al. 1999, Soderling, Hultman, 
Delbro et al. 2007). This sample preparation-induced reduction of 3NT-
residues is not thought to be relevant to this study as the plasma fractions 
were not boiled in sample buffer prior to separation using SDS-PAGE. It is 
postulated that the observed differences between the ELISA and 
immunodetection techniques are more probably due to sample dilution and 
inaccessibility of the 3NT-residues rather than reduction of the 3NT-residues. 
4.4.2. Human anti-3NT Abs 
Several studies have reported the presence of anti-3NT Abs in different 
diseases including rheumatoid arthritis, osteoarthritis, systemic lupus 
erythromatosus (Khan and Siddiqui 2006) and acute lung injury (Thomson, 
Christie, Vadseth et al. 2007). Although the presence of these antibodies 
could not be identified within this study their production in diseases such as IC 
cannot be ruled out. Khan and Siddiqui (2006) reported that anti-3NT Abs 
levels were higher within the synovial fluid compared to the serum in patients 
suffering from both forms of arthritis. Therefore it is credible that, if anti-3NT 
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Abs are produced by claudicants, they may only be detectable during certain 
stages of the pathology of the disease, e.g. 3NT may only be 
produced/present in plasma during periods of oxidative stress, induced by 
ischaemia-reperfusion. At other times any 3NT-residues present may be  
located predominantly within the atherosclerotic lesions of the peripheral 
blood vessels as observed with atherosclerotic plaques within coronary 
arteries (Beckmann, Ye, Anderson et al. 1994). In studies such as that 
described by Thomson et al (2007), affinity purification steps were employed 
prior to confirmation of the presence of anti-3NT Abs however in this study 
only the  whole plasma was assessed for the presence of anti-3NT Abs.  
It has been acknowledged for some time that the presence of antibodies 
directed towards dietary proteins such as BSA exist especially, for example, in 
the young with insulin dependent diabetes mellitus (Hilger, Grigioni, De 
Beaufort et al. 2001, Mogues, Li, Coburn et al. 2005). Within this study both 
the claudicant and the control plasma samples were found to respond towards 
native BSA to a greater extent than that observed for NT-BSA. This 
diminished response observed when using NT-BSA would suggest that 
nitration of BSA actually serves to reduce the antigenic epitope on the BSA 
protein against which the anti-BSA Abs are selective. A similar pattern was 
observed when assessing HSA (both native and nitrated) although the 
response was somewhat higher in the claudicants’ plasma compared to the 
control subjects. These findings regarding the presence of anti-BSA Abs 
within the plasma samples would give rise to non-specific binding when using 
BSA as an antigen within an assay such as an ELISA (e.g. NT-BSA). 
However, in the assay reported here the incubation buffer contained a 
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sufficiently high concentration of BSA and as such should have prevented 
non-specific binding.  
4.4.3. Fractionation of human plasma using dye-ligand affinity 
chromatography on immobilised Cibacron blue 
Human plasma is a complex sample in which currently 289+ plasma proteins 
have been identified although many more are thought to be present, including 
proteins serving as messengers and those that leak into the blood due to 
tissue damage (as reviewed in Anderson and Anderson 2002). The complex 
nature of plasma can cause major problems when devising diagnostic 
techniques involving the characterisation and identification of modified 
proteins (e.g. nitrated proteins) such as the ELISA assay reported here. This 
is further confounded by the high concentration of large plasma proteins such 
as HSA potentially masking changes to proteins present in lower 
concentrations. Therefore when detecting protein markers within human 
plasma (e.g. nitrated-proteins) issues can arise as a direct result of HSA 
constituting approximately 55%, (35-50mg/ml), of the total protein  (Anderson 
and Anderson 2002). This high concentration of HSA could result in the 
masking of 3NT-containing proteins present at lower concentrations. 
Therefore HSA was separated from the other plasma proteins using dye-
ligand affinity chromatography on immobilised Cibacron blue.  
Leatherbarrow and Dean (1980) and Gianazza et al. (1982) state that use of 
immobilised Cibacron blue is a technique which is specific for removal of HSA 
from plasma as it binds HSA with high specificity and the use of a chaotropic 
agent, such as sodium thiocyanate, is required to desorb it off the column. 
Unlike the reports above, within this study HSA was found to be present in all 
 151 
 
of the resulting protein fractions, albeit most was in the expected fraction. This  
may be due to the presence of high levels of fatty acids, within the plasma 
samples, which have been shown to interfere with the binding of HSA to the 
Cibacron blue dye (Leatherbarrow and Dean 1980). 
Using a similar separation technique, Khan et al. (1998) reported the 
identification of 3NT-containing proteins within the plasma of healthy 
individuals and those suffering from the inflammatory disorder systemic 
sclerosis using  competitive ELISA and Western blot immunodetection.  Within 
the current study the presence of 3NT-proteins could not be confirmed in any 
of the plasma protein fractions obtained from this separation using the 
developed indirect and competitive ELISA methods. However, when using 
Western blot immunodetection, 3NT-containing proteins were observed in the 
protein fractions in all of the claudicant and control plasma samples (albeit a 
low level response). These observed differences in assay sensitivity may to 
be due to alterations in the availability and accessibility of the 3NT-residues to 
the antibody brought about by changes in protein conformation and the 
binding capacities of the solid phase being used (similar to that discussed in 
Chapter 3). 
4.4.4. Affinity chromatography on anti-3NT antibody column – 
purification of nitrated and non-nitrated proteins 
The presence of 3NT-containing proteins was confirmed in both the purified 
nitrated and non-nitrated plasma fractions using competitive ELISA and 
Western blot immunodetection following separation using SDS-PAGE on 
linear and gradient gels. 
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Due to the anti-3NT having differing binding affinities for various nitrated 
proteins, as reported in Chapter 3, the competitive ELISA could only be 
classed as a semi-quantitative technique with regards to detecting the 
presence of 3NT-containing proteins. Similar to that reported by Khan et al 
(1998), the results presented here can only be reported as tryp-NT-BSA 
equivalents (µM) per mg of protein and not actual 3NT concentrations. This is 
because the standard used within the assay was a single electrochemically-
nitrated protein (tryptically digested NT-BSA) and as such its reactivity with 
antibody could not be extrapolated to all potentially nitrated proteins in 
claudicant and control plasma. 
Although nitration was found to be present within all of the affinity fractions 
(both bound and unbound fractions), in general elevated levels of nitration 
were observed within the plasma fractions of the claudicants compared to the 
healthy control subjects. This is similar to that reported by Khan et al (1998) 
who found elevated concentrations of nitrated proteins (again reported as NT-
BSA equivalents) within the plasma of patients suffering from the autoimmune 
inflammatory disease systemic sclerosis compared to healthy individuals 
when using their competitive ELISA. This is the first time such separation and 
affinity purification techniques have been reported as being necessary to 
establish the presence of 3NT-residues. 
Within this study the levels of nitration found to be present within the 
claudicant and control plasma fractions are somewhat higher than those 
reported previously in various disease pathologies using analytical techniques 
including ELISA (Khan, Brennand, Bradley et al. 1998, Ter Steege, Koster-
Kamphuis, Van Straaten et al. 1998, Inoue, Hisamatsu, Ando et al. 2002, 
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Dooley, Gao, Bradley et al. 2006) and HPLC-UV (Kaur and Halliwell 1994). 
For example in this study the level of 3NT within the HSA fractions of the 
control plasma samples was estimated to be 92.2 nmol tryp-NT-BSA 
equivalents per mg protein, and even 0.08 nmol tryp-NT-BSA equivalents per 
mg protein in the fraction which did not bind to the antibody column, compared 
to 0.085nmol nitro-BSA equivalents per mg protein (in Cibacron dye-linked 
affinity purified fractions) reported by Khan et al (1998). This observed 
difference could be as a result of the increased availability of the 3NT-
residues to the anti-3NT Ab brought about by the separation and purification 
techniques used. However it is also possible that assay precision (highlighted 
in Chapter 3) and the potential contamination of the bound fractions with free-
3NT (remaining from the affinity purification techniques) may have led to over 
estimation. The concentration of 3NT in the antibody-bound, Cibacron HSA 
fraction (3) was 92.2 nmol tryp NT-BSA equivalents per mg protein, a very 
high level, but this represented only 6% of the HSA in the total fraction 3 from 
the Cibacron column (Table 4.3.iii). 
The estimated levels of nitration within the 3NT-affinity purified samples are 
not only dependent upon an accurate estimation of tryp-NT-BSA equivalents 
from the calibration curves constructed from the ELISA but also the accurate 
determination of the total protein concentration within each sample. Due to the 
nature of the plasma samples, the presence of incompatible substances (e.g. 
glycerol) and the number of samples needing to be processed following the 
affinity purification procedures, several different protein determination assays 
had to be used (Okutucu, Dincer, Habib et al. 2007).  When comparing 
different protein assays using the same protein samples it was clear that there 
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were differences in the determined protein concentrations obtained. The exact 
reason behind these differences is unclear. The accurate determination of the 
total protein concentration within a sample is reliant upon the accuracy of the 
protein assay being used. There are differences in the reliability of the 
different protein assays available with regards to the nature of the protein 
sample being tested (Nishi, Kestner and Elin 1985, Berges, Fisher and 
Harrison 1993, Okutucu, Dincer, Habib et al. 2007). 
Western blot immunodetection, following separation using SDS-PAGE, 
confirmed the presence of 3NT-proteins within all of the affinity purified 
fractions (both bound and unbound) for all of the claudicant and control 
subjects. No apparent difference in the level and pattern of protein staining for 
the presence of 3NT was observed between the claudicant and control 
samples, similar to that findings reported by Capeillere-Blandin et al (2004) 
with reference to plasma from haemodialysed and control subjects. The major 
stained protein band observed on the Coomassie/silver stained gradient gels, 
which ran at a comparable distance to the NT-BSA sample (approximately 
55kDa), was confirmed as being albumin (HSA) protein via MALDI-TOF-MS 
and LC-ESI-MS/MS analysis. This albumin protein band did stain positive for 
the presence of 3NT proteins when using Western blot immunodetection 
(albeit faintly) which differs to that reported by ter Steege et al (1998) who 
reported that no 3NT staining was identified at 66kDa representing HSA. This 
could be explained by the consistent observation in this study that albumin 
(both BSA and HSA) ran further than the 66kDa size marker on the gel for 
which no definitive reason can be suggested. Western blot immunodetection 
showed that those protein bands which staining strongly for the presence of 
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3NT-residues were located within the resolving gel with molecular weights 
greater than 66kDa as also observed by ter Steege et al (1998) but in our 
case faintly stained bands of lower molecular weight were also observed. ter 
Steege et al (1998) report that their findings suggest only high molecular 
weight proteins in serum are subject to nitration. This does not agree with the 
current findings or with those of Khan et al (1998) where proteins staining 
positive for the presence of 3NT were observed at molecular weights both 
higher and lower than 66kDa. This difference in detection of nitrated proteins 
may in part be due to ter Steege et al (1998) only screening whole plasma 
whereas Khan et al (1998) screened dye-ligand purified plasma fractions and 
within this study samples were further purified into nitrated and non-nitrated 
fractions. 
As determined by the competitive ELISA and Western blot immunodetection, 
nitrated proteins were found in both the nitrated and non-nitrated affinity 
fractions. The presence of 3NT-containing proteins in the unbound fraction 
(non-nitrated) could be due the 3NT-residues not being available to the 
antibody at the column fractionation stage. Also if our antibody has low affinity 
for certain nitrated-plasma proteins the quantitative removal of these proteins 
from the solution would not have been possible.  
In recent years researchers have moved towards proteomic techniques in 
order to establish the protein targets of nitration in vivo within different disease 
states and disease models (Aulak, Miyagi, Yan et al. 2001, Lanone, Manivet, 
Callebert et al. 2002, Kanski, Hong and Schoneich 2005, Casoni, Basso, 
Massignan et al. 2005). For example using MALDI-TOF-MS analysis it has 
been found that inducible nitric oxide synthase (iNOS) in the skeletal muscles 
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of septic patients is selectively nitrated (Lanone, Manivet, Callebert et al. 
2002). iNOS has also been found to be expressed in both macrophages and 
smooth muscle cells in the lesions of transplant coronary artery disease where 
it is associated with extensive nitration of cellular proteins (Ravalli, Albala, 
Ming et al. 1998). Many proteins have now been identified as potential targets 
for nitration; there are however conflicting reports regarding the main sites of 
nitrated proteins with some studies reporting high levels within the cytosol of 
the cell (Kanski, Hong and Schoneich 2005) and others within the 
mitochondria (Aulak, Miyagi, Yan et al. 2001). Regardless of the location of 
the nitrated proteins it is probable that nitration of proteins has important 
implications in both physiological and pathological conditions. 
In order to establish the importance of 3NT in the disease state IC it is 
imperative to establish the presence/absence of a nitration profile. MALDI-
TOF-MS and LC-ESI-MS/MS analysis were combined within this study to 
identify proteins that were within PAGE bands that had stained 
immunopositive for the presence of 3NT-proteins. The main putative nitrated 
proteins identified in both the claudicant and control subjects were HSA, 
serotransferrin precursor, apolipoprotein A1 precursor and apolipoprotein A2 
precursor (physiological relevance unknown) although the presence of 3NT-
residues could not be established by mass spectrometry. As mentioned earlier 
it has been previously reported that HSA is a target for nitration (Khan, 
Brennand, Bradley et al. 1998) which has been further confirmed within this 
study. Apolipoprotein A1, the primary protein constituent of high-density 
lipoprotein (HDL) in plasma, is involved in the process of cholesterol 
esterification in plasma via activation of lecithin-cholesterol  acyltransferase 
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(LCAT). As such identifying that this protein may be a target for nitration within 
claudicants is of importance. Apolipoprotein A1 has also been identified as a 
target for nitration in diabetes type II (Hermo, Mier, Mazzotta et al. 2005). 
Shao et al (2005) identified tyrosine 192 as the predominant site of both 
nitration and chlorination with regards to oxidative damage resulting from both 
MPO and ONOO-. However, they could only establish reduced cholesterol 
efflux activity of apolipoprotein A1 following chlorination and not nitration.  
As HSA appeared to be the predominant protein identified within the excised 
protein bands CLUSTAL W (1.83) multiple sequence alignment was carried 
out (See Figure 4.4.i.). In total three HSA accessions to the IPI database were 
identified, all having a signal sequence (pre-peptide 1-18) and a pro-peptide 
(inactivating sequence 19-24) by comparison to BSA. From the mass 
spectrometry analysis, HSA was identified as being present within bands of 
differing molecular mass (from >70kDa to 29kDa). The RMMs quoted for HSA 
are for the whole proteins, as coded in the DNA, but the proteins appearing in 
the plasma should be predominantly the mature versions without the N 
terminal sequences at 1-24 which are therefore >2kDa smaller. Proteins 
larger than these RMMs could be due to protein modification such as 
glycosylation thus giving variable larger sizes. However, smaller proteins must 
be truncated, presumably by proteolysis. For example, band G, in Figure 
4.3.x. where albumin protein (IPI00022434) is apparently 29kDa, is identified 
in MS by only three peptides, covering 5% of the sequence, so this must be a 
fragment from the N-terminal end. This is due to the fact that the three 
peptides identified are at positions 66-75, 76-88 and 287-298 (numbers 
corresponding to the total protein). 
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CLUSTAL W (1.83) multiple sequence alignment 
IPI22434   MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF 60 
IPI384697  MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEEN------------------ 42 
IPI216773  MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEEN------------------ 42 
           ******************************************                   
 
IPI22434   EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP 120 
IPI384697  ------------------------------------------------------------ 
IPI216773  ------------------------------------------------------------ 
                                                                             
 
IPI22434   ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF 180 
IPI384697  ------------------------------------------------------------ 
IPI216773  ------------------------------------------------------------ 
                                                                             
 
IPI22434   FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV 240 
IPI384697  ------------------------------------------------------FKAWAV 48 
IPI216773  ------------------------------------------------------FKALVL 48 
                                                                    ***  
 
IPI22434   ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRAD--LAKYICENQDS--IS 296 
IPI384697  ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRAD--LAKYICENQDS--IS 104 
IPI216773  IAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY 108 
               *      *    ***  *     *      *               *          
 
IPI22434   SKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLY 356 
IPI384697  SKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLY 164 
IPI216773  GEMADCCAKQEPERNECFLQHKDD--NPNLPRLVRPEVD--VMCTAFHDNEETFLKKYL- 163 
                ** *   *   *     *     ** *    *     *         **   *  
 
IPI22434   EYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNC 416 
IPI384697  EYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNC 224 
IPI216773  --------------------YETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNC 203 
                               **************************************** 
 
IPI22434   ELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDY 476 
IPI384697  ELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDY 284 
IPI216773  ELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDY 263 
           ************************************************************ 
 
IPI22434   LSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHAD 536 
IPI384697  LSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHAD 344 
IPI216773  LSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHAD 323 
           ************************************************************ 
 
IPI22434   ICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEG 596 
IPI384697  ICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEG 404 
IPI216773  ICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEG 383 
           ************************************************************ 
 
IPI22434   QKTCCCKSSCLRLITSHLKASQPTMRIRERK 627 
IPI384697  KKLVAASQAALGL------------------ 417 
IPI216773  KKLVAASQAALGL------------------ 396 
            *        * * 
 
PREPEPTIDE  PROPEPTIDE  
 
IPI00022434  RMM 71704  Mature RMM  68810  
IPI00216773  RMM 45160  Mature RMM  42265 
IPI00384697  RMM 47360  Mature RMM  44466  
BSA (P02769)  RMM   69293  Mature RMM  66432 
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Figure 4.4.i. CLUSTAL W (1.83) multiple sequence alignment of the HSA proteins 
identified using MALDI-MS & LC-ESI-MS/MS analysis by Warwick 
University.  
The three RMMs for the total (unprocessed) protein sequences were 
calculated by software from ExPASy and are different from those given 
by Warwick University (Tables 4.3.v. - 4.3.vii.) in that the ExPASy values 
are smaller. The difference cannot be accounted for by isotope use, 
since the ones quoted from Warwick University are monoisotopic 
whereas those from ExPASy are average, the difference being only 
about 500Da in IPI00022434, moreover the average RMM (ExPASy) is 
larger than that calculated for the monoisotopic (Warwick University). 
 
Within this study the proteomic analysis was carried out from tryptically 
digested protein bands, which in corresponding Western blots had stained 
immunopositive for 3NT, excised from 1D SDS-PAGE gradient gels. Within 
each of these bands there was the possibility that there was more than one 
protein present and as such we cannot confidently report which of the proteins 
present were nitrated. It could be that proteins present in amounts sufficient to 
be detected by mass spectrometry of their tryptic peptides were not nitrated, 
whereas those below the level of MS detection may be nitrated and detected 
by antibody. Other studies which have identified the presence of many 
nitrated proteins (40+) have done so using MALDI-TOF-MS analysis of 
proteins separated on 2D gels (Aulak, Miyagi, Yan et al. 2001). Such analysis, 
separation by both RMM and pI, allows for more reliable assignment of single 
protein species to single spots (Molloy 2000), although the logic applied above 
to 1D gels still holds and there is a potential for there to be multiple occupants 
of a spot in which the nitrated species is not the one detected by MS. 
Confirmation can only be made by the isolation and sequencing of a nitrated 
tryptic peptide (+45Da). 
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In summary it is reported here that the presence of nitration has been 
identified within the purified plasma of both the claudicant and control 
subjects. The need for plasma protein purification was apparent due to 
conflicting results obtained during this study regarding the presence of nitrated 
proteins when using differing analytical techniques. The levels of nitration 
reported within the affinity purified samples using our competitive ELISA are 
somewhat higher than that previously reported in whole plasma: although this 
analysis did show that higher levels were present within the purified affinity 
fractions from the claudicant samples compared to the control samples. 
Proteomic studies of the 3NT-affinity purified plasma fractions for both the 
claudicant and control subjects illustrated that the bands staining 
immunopositive for the presence of 3NT residues contained HSA,  
serotransferrin and apolipoprotein A1 and A2 precursors; although the 








The objective of this study was to develop immunoassays for the detection of 
3NT, as a marker of oxidative stress and thus disease, in claudicants and to 
investigate the nitroproteome associated with this disease. Claudicants (n=33) 
and controls (n=6) were enrolled on to the study, their medical histories 
recorded and plasma collected.  
It was clear that all of the risk factors associated with an increased risk of 
more serious atherosclerotic disease (Newman, Shemanski, Manolio et al. 
1999) were present in this claudicant population. Measuring a patient’s ABI 
has been shown to be an effective tool in the diagnosis of clinically significant 
PAD e.g. IC (Newman, Shemanski, Manolio et al. 1999, Hirsch, Criqui, Treat-
Jacobson et al. 2001, Sacks, Bakal, Beatty et al. 2003). However, as also 
reported by McDermott et al (2002), within this study the problem of the 
efficacy of the current protocols in place for the early diagnosis of IC and PAD 
patients were highlighted by the fact that patients with ABI recordings ≥0.96 
were diagnosed with clinically manifest IC. ABI is also now thought to be more 
indicative of advanced atherosclerotic disease and as such is not a useful 
screening test for early vascular disease (Newman, Shemanski, Manolio et al. 
1999). Therefore analysis of patient data has highlighted the need to develop 
additional screening methods to aid in the early diagnosis, administration of 
risk factor intervention and treatment of PAD. 
In the indirect and competitive ELISA availability and accessibility of the 3NT-
residues to the anti-3NT Ab was clearly an issue, demonstrated by changing 
the conformation or structural integrity of the protein either through 
denaturation or by use of substrates with different binding properties. Although 
the reasons are not given, ELISA methods have been published in which the 
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standard 3NT-containing antigen was produced by nitrotyrosinylation (i.e. 
covalent attachment of 3NT) to a protein. Standards used in this way include 
BSA (Torreilles and Romestand 2001) and horseradish peroxidise (Inoue, 
Hisamatsu, Ando et al. 2002, Thomson, Christie, Vadseth et al. 2007). It is 
probable that nitrotyrosinylation of a protein would increase the availability of 
the 3NT-residue to an antibody (compared to nitration) within an ELISA, 
resulting in improved assay sensitivity and precision. Nevertheless, 
nitrotyrosinylation does not reflect the in vivo nitration process and, as such, 
introduces another variable into the assay since the  conformation of the 3NT 
epitopes will be even less representative of those in the test sample (nitrated 
plasma) than those in nitrated BSA. Thus the reliance placed on absolute 
quantitative data from biological samples derived from an assay using a 
standard curve constructed using a nitrotyrosinylated standard is less secure, 
although comparative data are presumably as reliable as those from nitrated 
standards. The use of nitrotyrosinylation to enhance antibody-antigen 
recognition within an ELISA does suggest that the problems identified within 
this study regarding the availability of the 3NT-residue to the antibody and 
hence of assay reliability have been encountered by others but have not been 
published. 
In a recent review Duncan (2003) states that an immunoassay for the 
detection of 3NT in biological samples will be dependent upon a variety of 
parameters including those highlighted within this current study e.g. the nature 
of the selectivity of the antibody and sample composition. As such the use of 
immunoassays for the detection of 3NT in biological samples such as plasma 
can only ever be classified as being semi-quantitative (Khan, Brennand, 
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Bradley et al. 1998, Duncan 2003). Thus the findings reported in Chapter 3 
have important ramifications regarding the implementation of an 
immunoassay as a diagnostic tool for the detection of 3NT-residues within 
biological specimens such as plasma. It also brings doubt on the accuracy of 
the results regarding previously reported levels of 3NT detection in other 
diseases using immunoassays such as ELISA (Khan, Brennand, Bradley et al. 
1998, Ter Steege, Koster-Kamphuis, Van Straaten et al. 1998, Inoue, 
Hisamatsu, Ando et al. 2002). 
The need for plasma fractionation and affinity purification in order to establish 
the presence of a nitroproteome in the plasma of the claudicants and control 
subjects is reported here for the first time. The difficulties in the detection of 
3NT in human biological samples have not been reported by others using 
ELISAs (Ter Steege, Koster-Kamphuis, Van Straaten et al. 1998, Inoue, 
Hisamatsu, Ando et al. 2002). Khan et al (1998) were able to determine the 
concentration of 3NT in whole plasma as 0.12µM. As presented, this 
represents a concentration of 3NT of 120pmol/ml plasma. The concentration 
of 3NT in HSA is reported as 0.085nmol/mg = 85pmol/mg, and, assuming a 
HSA concentration of 40mg/ml (mean values for HSA and prealbumin in 
plasma are 40 and 0.25 mg/ml respectively (Marshall and Bangert 2004), this 
would give a 3NT concentration in plasma of 3.4nmol/ml from HSA alone, as 
opposed to 0.12nmol/ml measured for the whole plasma. The relatively low 
value from whole plasma, compared to that from purified HSA is further 
evidence of the problems inherent in estimating 3NT concentration in complex 
protein mixtures in solution. 
 165 
 
The levels of nitration found to be present within all of the affinity purified 
fractions of the claudicant and control subjects were somewhat higher than 
those previously reported in the plasma of healthy and diseased individuals 
using similar techniques (Khan, Brennand, Bradley et al. 1998, Ter Steege, 
Koster-Kamphuis, Van Straaten et al. 1998, Inoue, Hisamatsu, Ando et al. 
2002, Dooley, Gao, Bradley et al. 2006). There are many potential reasons 
behind such differences including assay precision discussed in Chapter 3, 
background contamination resulting from the presence of free 3NT from the 
affinity purification procedure. As stated in Chapter 4 it is also important to 
note that the values reported are for the affinity purified samples and not 
whole plasma and as such cannot be directly compared to most values 
reported by others. An exception is Khan et al (1998) who did purify HSA from 
control plasma on Cibacron and measured nitration at 0.085nmol/mg protein. 
In the current project, the concentration of 3NT within the bound and unbound 
3NT affinity-purified HSA fractions was 92.2 and 0.08nmol/mg protein 
respectively. Thus the mean 3NT concentration in the control plasma HSA 
would be (92.2 x 0.06) + (0.08 x 0.94) = 5.6nmol/mg, considerably higher than 
that found by Khan et al (1998). Since both studies used a rabbit polyclonal 
antibody raised against nitrated KLH, the difference is unlikely to be 
substantially due to the antibody used. The results in the current study can 
only meaningfully be used comparatively, within the study. Tsikas and Caidahl 
(2005) recognised the potential limitations of using either free- or protein 
bound 3NT as biomarkers in diseases involving oxidative stress due to 




The affinity purification of nitrated proteins from tissue homogenate isolated 
from human pituitary adenoma has been reported for analysis using tandem 
mass spectrometry (Zhan and Desiderio 2006).  Within this study the bound 
fractions from the anti-3NT Ab affinity purification were analysed using mass 
spectrometry in order to establish the importance of nitration within the 
disease state IC. Using both MALDI-TOF-MS and LC-ESI-MS/MS, it was clear 
that although the proteins present within those bands that stained 3NT-
immunopositive using Western blot immunodetection could be identified, 
confirmation of the presence of 3NT-residues (i.e. a mass increase of +45Da) 
could not. Most published reports regarding the identification of nitrated 
proteins in human samples appear to use mass spectrometry to identify the 
peptides/proteins in the corresponding gel spots or bands which have been 
found to stain 3NT-immunopositive using Western blot immunodetection 
(Aulak, Miyagi, Yan et al. 2001). The failure of such methods to characterise 
the presence of nitrated peptides is thought in part to be due to the low 
abundance of specific nitrated proteins along with the actual recovery of these 
proteins from the gels (Kanski, Hong and Schoneich 2005). Furthermore, the 
various mass spectrometry techniques themselves, particularly the detector, 
each define a different, albeit overlapping, series of proteins/peptides within a 
proteome. Even when a pure, small, mononitrated protein was used 
(lysozyme), and no gels were involved, Matters et al (2006) could not confirm 
the site of nitration using either ESI- or MALDI-FTICR or MALDI-TOF 
techniques. Success in finding the nitrated tryptic peptide was only achieved 
with ESI-TOF after “cleaning” (i.e. concentrating certain peptides) the peptides 
with a reversed-phase ZipTip. Nevertheless, some recent methods do report 
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the identification of a mass shift of +45Da indicating the presence of 3NT 
modification using MALDI-TOF (Casoni, Basso, Massignan et al. 2005) and 
nanoelectrospray ionisation ion trap-MS/MS (Kanski, Hong and Schoneich 
2005). An empirical observation is that the most likely mass spectrometry 
method to detect nitrated peptides is using ESI-ion trap (H. Ischiropoulos, 
personal communication, 2006). 
 
There are numerous polymorphisms in the apoA-1 gene leading, usually, to 
pro-atherogenic variants. Thus mutations yield either impaired synthesis or 
the production of an abnormal apoprotein and result in premature 
atherosclerosis, xanthomatosis, and corneal opacities. In cases where no 
plasma apoA-1 is detected, the mutation is associated with increased 
coronary risk (Assmann, Von Eckardstein and Funke 1992). One proband 
who developed early coronary artery disease, had a deletion of the complete 
apoA-I/C-III/A/-IV gene (Rosseneu and Labeur 1995). A Turkish girl had no 
detectable apoA-I and was affected by HDL deficiency with xanthomas.  
Patients with a nonsense mutation in codon 84 of apoA-I, which lead to apoA-I 
deficiency and low apoC-III levels, suffered from premature coronary heart 
disease and had planar xanthomas. A 5.5Kb inversion in the apoA-I/C-III gene 
leads to coronary artery disease, xanthomas, and corneal opacity. The 
truncation of apoA-I at residue 230 leads to corneal opacity and LCAT 
deficiency. The deletion of residues 145-160 results in HDL deficiency and 
xanthomas. A deletion in intron 2 causes coronary heart disease  (Rosseneu 
and Labeur 1995). There are many other examples of missense mutations 
leading to atherosclerotic outcomes. However, in two other cases no 
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increased risk for myocardial infarction could be demonstrated (Assmann, Von 
Eckardstein and Funke 1992). Even more unusually, there is an anti-
atherogenic variant, apo A1 Milano, with an R173C mutation, found in some 
inhabitants of Limone on Lake Garda, which offers protection from coronary 
heart disease (Weisgraber, Rall, Bersot et al. 1983, Gualandri, Franceschini, 
Sirtori et al. 1985). It is tempting to speculate that some claudicants may have 
a pro-atherogenic polymorphism in the apo A1 gene region. Such a study is 
yet to be done.  
The results in Tables 4.3.x and 4.3.xii show an apparent truncated apo A1 
precursor at about 16kDa. The unprocessed apoA-1 of 267 amino acids has a 
RMM of 30,778 whereas the mature protein consists of  243 amino acids with 
a RMM of  28,079 (Swiss-Prot, P02647), but the truncated protein in the 
plasma is most likely to have arisen from proteolysis, since  the same variants 
are found with HSA. 
Apolipoprotein A-1 has previously been identified as a target for nitration 
within atherosclerotic lesions and the blood of those suffering from 
cardiovascular disease (Shao, Bergt, Fu et al. 2005) and those suffering from 
diabetes type II (Hermo, Mier, Mazzotta et al. 2005). MPO-mediated 
modification of apolipoprotein A-1 (nitration and chlorination) is directly linked 
to a reduction/loss in its ability to bind lipids and its reverse lipid-transport 
functions (Zheng, Settle, Brubaker et al. 2005, Shao, Bergt, Fu et al. 2005). 
Thus if the nitrated apoA-1 were confirmed by MS, the results from  the 
current study would provide further evidence towards the hypothesis that 
impaired HDL function may have a direct role in the pathology of 
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atherosclerosis. This is an area in which further research is required in order 
to identify the targets for nitration within apolipoprotein A-1 in claudicants. 
 
Plasma is perhaps one of the most difficult specimens on which to carry out 
proteomic studies due to the wide dynamic range and complexity of proteins 
contained within it (Anderson and Anderson 2002). It has been suggested that 
there may be more than one plasma proteome present within an individual, 
e.g. the plasma proteome of arterial, venous and capillary plasma may differ 
significantly (Anderson and Anderson 2002). Therefore, a potential limitation 
of nitroproteome analysis may be that the blood samples used for analysis in 
this study were taken from the subjects’ arm. This is due to the fact that there 
may be differences in the plasma proteome of claudicants near the site of the 
blockage (peripheral arteries of the legs), where the formation of nitrated 
proteins may take place, and the blood sampling site. Such sampling relies on 
the ‘immediacy’ of the translation of a protein marker from its site of origin to 
the rest of the systemic circulation (along with the active production of RNS 
and ROS). During this transition there is also the possibility that the 3NT-
residues may be removed by anti-3NT Abs (Khan and Siddiqui 2006, 
Thomson, Christie, Vadseth et al. 2007) and/or modified by ‘denitrase’ 
(Kamisaki, Wada, Bian et al. 1998, Irie, Saeki, Kamisaki et al. 2003). Thus it is 
possible that the status of the disease present and the sampling method used 
may directly influence the ability for detection of 3NT in plasma. Also, different 
stages of a disease may directly affect the levels of circulating 3NT-proteins in 
the plasma. For example there are conflicting reports regarding the presence 
of 3NT-proteins in patients suffering from osteoarthritis (Kaur and Halliwell 
1994, Khan and Siddiqui 2006) and at different stages of celiac disease (Ter 
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Steege, Koster-Kamphuis, Van Straaten et al. 1998). In patients with acute 
disorders such as sepsis the duration of exposure of proteins to nitrating 
species may not be long enough for nitrated protein formation to appear in the 
circulation (Ter Steege, Koster-Kamphuis, Van Straaten et al. 1998). This may 
explain some of the variation in reported concentrations of 3NT-proteins within 
the plasma of different diseases. 
Within the current study only the plasma of the claudicant and control subjects 
was investigated for the presence of 3NT-containing proteins. Although there 
is limited knowledge regarding the presence of nitrated proteins within the 
circulating blood cells in vivo, research has shown that nitration can occur as 
a result of ONOO- activity in vitro e.g. in platelets (Low, Sabetkar, Bruckdorfer 
et al. 2002, Sabetkar, Low, Naseem et al. 2002) and erythrocytes (Denicola, 
Souza and Radi 1998). It may be, therefore, that the production of NO and 
related RNS and ROS in the vasculature results in the nitration of circulating 
blood cells. Therefore it may be informative to investigate the presence of 
nitrated proteins within the whole blood as well as plasma in the future. 
Furthermore, the combined analysis of blood and urine for 3NT (and 
associated metabolites) maybe an effective diagnostic tool for pathological 
conditions where oxidative stress is involved such as IC, although the 
potential for selective diagnosis would appear to be limited. The presence of 
3-nitro-4-hydroxyphenylacetic acid and 3-nitro-4-hydroxyphenyllactic acid  
(metabolites of 3NT) in the urine of humans was first reported by Ohshima et 
al (1990) and the measurement of urinary free-3NT has also been suggested 
as a potential biomarker of oxidative stress in various pathological conditions 
(Schwemmer, Fink, Kockerbauer et al. 2000).  
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Within this study only those diagnosed with clinically manifest PAD (IC 
present) were investigated for the presence of nitrated plasma proteins. It has 
been clearly established that the prevalence of IC has been found to be 
relatively low compared to the presence of PAD (Meijer, Hoes, Rutgers et al. 
1998, Khan, Flather, Mister et al. 2007). Thus it may be of benefit in the future 
to assess the levels of nitration present within the plasma of those who have 
risk factors associated with development of atherosclerosis but are currently 
asymptomatic (no IC present). By doing this a wider cohort of patients would 
be eligible for enrolment onto the study increasing the chances of establishing 
any correlation there may be between the levels of circulating 3NT and the 
development of clinically significant atherosclerotic disease. It may be more 
appropriate to analyse a panel of biomarkers rather than relying on one 
protein marker of atherosclerotic disease. For example it has been reported 
that C-reactive protein, and the total cholesterol-HDL ratio are strong 
independent indicators for the development of PAD (Ridker, Stampfer and 
Rifai 2001). Furthermore it has been demonstrated that there is enhanced 
coagulation and endothelium activation in patients with PAD and that this 
activation increases with the severity of the PAD (Cassar, Bachoo, Ford et al. 
2005). Thus by combining the measurement of 3NT with other markers of 
inflammation associated with atherosclerotic disease a more reliable and 
effective diagnostic tool may be developed.  
In conclusion further research is required in order to establish the clinical 
relevance of nitrated proteins and PAD, specifically IC. The identification of 
the targets of nitration in a disease such as IC using proteomic analysis may 
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be more clinically significant compared to the more traditional quantitative 
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Objective –  
To investigate 3-nitrotyrosine as a potential marker of oxidative stress in 
people suffering from claudication. This will involve the development of novel 
immunoassays, based on enzyme linked immunosorbant assay (ELISA), for 
the detection of nitrated proteins and antibodies against these proteins. Using 
these assays 3-nitrotyrosine will be investigated to establish a possible 
correlation between 3-nitrotyrosine levels and the extent of the disease. 
 
Hypothesis –  
Atherosclerosis is associated with increased 3-nitrotyrosine levels in plasma 
and in low-density lipoproteins (LDL) recovered from atherosclerotic plaques. 
Since atherosclerosis is a concomitant condition of claudication it is 
ii 
hypothesised that patients suffering from claudication will have high circulating 
3-nitrotyrosine levels. Moreover, that there will be a correlation between 
circulating 3-nitrotyrosine levels in patients and the degree of claudication. 
Background –  
Peripheral arterial disease (PAD) –  
PAD is an extremely common clinical manifestation of atherosclerosis in the 
lower limbs. In this disorder artery wall linings slowly become narrow leading 
to severely narrowed or, in extreme cases, blocked arteries. Atherosclerosis 
progresses through time at variable rates in individual patients depending on 
factors such as diabetes, hypertension, hyperlipidaemia, and smoking. For 
most individuals’ symptoms do not appear until the artery has narrowed by at 
least 60%. In the majority of patients suffering from PAD the first physical 
indication that there is something wrong is a cramp like pain experienced in 
the muscles of the leg upon light exercise such as walking, known as 
Intermittent Claudication (IC). Relatively few population-based studies on the 
prevalence of PAD and IC have been performed. 
 
Interference with blood flow leads to ischaemia/reperfusion episodes, as 
suffered by claudicants and yields oxidative stress damage including nitration 
of tyrosine both free and protein-bound. In turn 3-nitrotyrosine (3-NT) has 
been found in many disease conditions[1], and the protein apoB from LDL, has 
been shown to be nitrated in atherosclerotic plaques[2-4]. The plasma 
concentration of 3-NT is a well-known marker of oxidative damage in vivo but 
this has not yet been determined in claudicants.  
 
Protein oxidation and 3-NT formation –  
Many proteins contain the amino acid tyrosine and therefore can potentially be 
oxidised to form 3-NT. 3-NT arrives from nitric oxide, a potent vasodilator with 
a diverse array of physiological functions within the body, but which has 
recently been identified as a key mediator in the pathogenesis of many 
inflammatory and degenerative diseases such as acute lung disease and 
atherosclerosis. It has also been implicated in and thought to contribute to 
tissue injury in inflammatory conditions via reactive nitrogen species derived 
from NO, which are powerful oxidants. LDL is of extreme interest in the study 
of atherosclerotic plaque formation and therefore IC. LDL can be oxidised in 
both its lipid (cholesterol, cholesterol ester, phosphoglycerides) and protein 
(apoB) components by complex reactions involving reactive nitrogen species 
generated during periods of oxidative stress. It has been demonstrated, by 
mass spectrometry, that there is a nearly 100-fold higher level of 3-NT in LDL 
recovered from atherosclerotic plaques compared to LDL isolated from 
plasma of healthy donors[2]. The precise nitrating intermediates formed and 
pathways for their generation in vivo, and the complete biological 
consequences of LDL nitration are still unknown. Nevertheless the 
multicellular components of atherosclerotic plaques are known to produce 
both superoxide (O2-) and NO which react to produce peroxynitrite (ONOO-), 
which is known to promote the nitration of protein tyrosine residues in vitro; 
suggesting a possible pathway for LDL oxidation and for the presence of 3-NT 
in vivo[2 5-8]. Alternatively LDL nitration may involve the enzyme 
myeloperoxidase[3 9-12] (release from activated macrophages). Irrespective of 
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the true nature of the nitrating agent responsible for the oxidation of LDL, it is 
an important marker of oxidative stress.   
 
Intermittent Claudication (IC) -   
IC is a common clinical manifestation of PAD that leads to significant 
functional impairment and an increased risk of cardiovascular morbidity and 
mortality (2.5 fold increase compared to age matched population)[13].  IC refers 
to cramping, fatigue or aching that develops in the legs of a sufferer upon 
exercise, this pain is caused due to a blockage within the arteries supplying 
the leg with oxygenated blood. Therefore, IC should be treated seriously and 
highlights the need for accurate tests to diagnose it. Studies have related 
smoking, diabetes mellitus, old age, elevated blood pressure and high 
cholesterol levels as risk factors in the development of IC[14 15]. Moreover at all 
ages men experience nearly double the rate of claudication of women. The 
risks attached to smoking were related to oxidative damage by free 
radicals[16], particularly oxidative modification of low-density lipoprotein (LDL). 
It has also been found that the plasma of 55% of healthy smokers had 3-NT, a 
marker of oxidative damage, present compared to only 11% of healthy non-
smokers[17].  
The tests for diagnosing IC are usually non-invasive. Firstly a thorough 
physical exam is performed and the patient’s medical history is taken, noting 
exposure to and presence of risk factors. The ankle-brachial index (ABI), i.e. 
the ratio of ankle and arm systolic blood pressures, is a simple and reliable 
tool in the diagnosis of PAD, especially IC. A normal ABI range is classed as 
0.95-1.2, however there is no consensus on a cut-off level[18]. A more 
advanced version of this test is where blood pressure measurements are 
taken from the upper thigh; upper knee, calf and then ankle and can indicate 
where the atherosclerotic lesions are within the leg. However ABI may not be 
accurate in all patients, for example patients with long standing diabetes 
mellitus or kidney disease may have rigid vessels resulting in potentially 
inaccurate ABI readings. A more searching test for IC is the treadmill exercise 
test; in which the patient has to walk slowly on a treadmill until it becomes too 
painful to continue. If there is a drop in the ankle blood pressures and ABI 
values after the treadmill exercise test then the patient is suffering from IC that 
is atherosclerosis is present. A major problem in IC diagnosis is that even 
advanced IC patients may present atypical symptoms, moreover in the elderly 
walking problems are often present due to other underlying medical conditions 
therefore causing potential problems in correct diagnosis[15]. Therefore a 
biochemical tool such as 3-NT detection, along with ABI and other indicators 
of IC, could prove valuable in diagnosis.  
 
3-nitrotyrosine (3-NT) detection –  
There are a number of ways in which 3-NT can be detected and quantified. In 
general chemical methods (protein hydrolysis, high performance liquid 
chromatography (HPLC)) can suffer from artefacts. Enzyme linked 
immunosorbent assay (ELISA) is an enzyme immunoassay that combines the 
specificity of antibodies with the sensitivity of simple spectrophotometric 
assays and is relatively cheap and easy to undertake once established. It can 
be used to establish and quantify the presence/absence of the antigen in 
question (3-NT) within the serum of a patient. ELISA’s to detect 3-NT based 
iv 
on a number of assay formats, e.g. competitive and direct, have been 
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Study Design –  
All patients who attend IC clinic for first time during the course of the study will 
be asked to give written consent to become enrolled. Blood samples are 
already routinely taken from each patient, on first visit and after a 3-month 
exercise regime, and at the same point a small sample of blood will be taken 
for use within this study (2ml). This will cause no additional discomfort to the 
patient due to the fact this sample will be taken at the same time as routine 
blood samples. The number of participants within the duration of this study 
(one year) will be approximately 250, all having two samples taken, as 
described above (based on the fact that around five new patients attend the 
clinic each week). Information, which is already gathered as part of the 
consultation, will be obtained as to the patients age, sex, height, weight and 
other contributing factors such as other diseases e.g. diabetes mellitus and 
their smoking status. At all times the patients confidentiality will be respected. 
Plasma will then be tested and quantified for the presence of 3-nitrotyrosine 
(3-NT) and comparisons will be made between the patients initial 3-NT levels 
and levels after the 3-month exercise regime. This will be carried out using a 
novel ELISA method that will be developed using polyclonal antibodies raised 
against 3-NT (using nitrated keyhole limpet haemocyanin) from rabbits. This 
technique will quantify the levels of 3-NT present in IC patients. Using this 
data and the information collected about the patients, e.g. age, sex, the 
patients will be sub-grouped and comparisons will also be made within these 
sub-groups. These findings will be extended using Western Blotting in which 
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separated plasma proteins are probed with 3-NT antibody to produce a 
fingerprint pattern of nitrated proteins. Differences in the pattern of nitration 
may emerge that correlate with the disease origins and contributing factors.  
 
Randomisation –  
No randomisation is required. All new patients that attend the IC clinic will be 
asked to partake in the study (n=250), two blood samples will be taken, one 
on the first consultation and the second on the 3-month check up, at the same 
time as routine samples are taken. The patients 3-NT levels being determined 
and compared before and after the 3-month training program, they will also be 
allocated into sub-sets depending on other contributing factors such as age, 
sex, weight, disease history, to make further comparisons to assess any 
trends in 3-NT plasma levels present. Control samples from healthy adult 
volunteers will be collected from healthy non-smoking staff at Coventry 
University and from an age matched population (hernia patients who have to 
have routine pre-operative blood samples taken, therefore causing no extra 
pain or discomfort) to assess base-line 3-NT levels.    
 
Anticipated Benefits –  
The anticipated benefits of this study will be the development of a novel 
ELISA method to detect and quantify 3-NT in the plasma of patients with 
claudication and therefore aid in its diagnosis and to determine the extent of 
the disease. Oxidised protein profiling (via Western blotting and HPLC) may 
point to specific damage associated with different routes to the disease e.g. 
diabetes mellitus, hyperlipidaemia. This test may also prove valuable in 
monitoring the effects of the training program if it can be established that 3-NT 
levels decrease after the 3- month exercise regime.  
 
5 STUDY SUBJECT 
 
5a Has the investigation been done previously with Human 




5b Subjects:-  How many will be recruited and how selected? 
 
 N=250 all having two routine samples taken (1 on first consultation 
and 1 after 3-month exercise regime) based on the assumption that 
5 new patients attend the clinic every week for one year.  
 
 (a) By the Local Investigator - ALL 
(b) In all study centres – N/A 
 
5c  Controls:- How many are needed and how selected? 
 
 Control samples will be taken from healthy non-smoking individuals 
based at Coventry University. Samples are routinely taken as part 
of other studies therefore a large panel of control samples will be 
available for use (n=30). Control samples will also be taken from an 
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age-matched population, these will be hernia patients who have to 
have blood taken routinely as part of their pre-operative assessment 
therefore causing no extra pain or discomfort.   
 
6a SUBSTANCES AND OTHER THERAPEUTIC INTERVENTIONS to 
be given to the subjects (physical or physiological 
interventions, special diets, drugs, isotopes, questionnaires 
etc. 
  
 There will be no substances or other therapeutic interventions given 
to the patients.  
 
6b If a randomised study, how will randomisation be performed 






7a What samples will be taken from the subjects, what amount 
and what frequency? 
 
 Routine blood samples are already collected from the patients, once 
at the first consultation and the second after the 3-month exercise 
regime, an additional blood sample will be taken at the same time 
as these routine blood samples. As a result of the samples being 
taken at the same time as routine samples those patients involved 
will experience no extra pain or discomfort.  
 
7b Would the sample(s) be taken especially for this investigation 
rather than part of normal patient care? 
 
 Samples will be taken at the same time as routine samples, 
therefore causing no extra pain or discomfort to the patient.  
 
7c Identify any possible discomfort or inconvenience to be 
suffered by subjects and assess likely incidence. 
 
 The patient should experience no extra discomfort or inconvenience 
due to the fact that the blood samples will be taken at the same time 
as routine samples. 
 
 
8 INFORMATION AND CONSENT 
 
8a How will the subjects be informed, who will provide the 
information and in what form will consent be obtained (Written, 
or in special circumstances witnessed verbal) 
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 Patients will be informed both verbally and by letter with respect to 
the aims and objectives of this study and the potential beneficial 
outcomes of this study with respect to the future. Written witnessed 
consent will be obtained by all subjects.  
 
8b The District Local Research Ethics Committee consider it to be 
mandatory to inform the patients  GPs of their inclusion in the 
study, how do you intend to do this?  Please explain your 
reasons if you do not intend to inform the patients  GPs 
 
 The GP’s of the patients participating in this study will be informed 
via a letter sent by the clinic. A letter is routinely sent to the GP to 
inform them of the clinic’s findings and  this will be amended to 
include the relevant information about this study and the fact that 





9a How will the cost of the drugs, substances and materials be 
met? 
 
 EPSRC research grant 
 
9b  (i) Have the investigations to be performed been discussed with 
the appropriate laboratories or departments, and are they 
agreeable to performing these investigations? 
 
 NO – not applicable 
 
 (ii)  If so, how will the cost of the investigations be met? 
   
  Not applicable 
 
9c  Are any payments to be made for entering patients in this 
study and to whom: 
 
 (i) For the patient - No 
 
 (ii) To the researcher - No 
 
10  ANALYSIS  
 
  How will the study be analysed and from whom is statistical 
advice being taken? 
 
  All samples taken from the patients will have the 3-NT plasma 
levels determined and quantified using the ELISA technique 
developed. The samples will then be analysed further using 
Western blotting. All of the data collected will then be analysed 
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using appropriate statistical packages to highlight any significant 
associations with attributable risk factors. Statistical expertise exists 
at Coventry University for all aspects of data analysis.  
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11  DATA PROTECTION ACT 
 





This information supplied above is to the best of my knowledge and 
belief accurate/  I understand my obligations and the rights of the 
patient, particularly the need to obtain freely given written informed 
consent, and to supply an annual progress and final report. 
 




To be completed by the Consultant in Charge or Head of Department  
(this section should be completed by the researcher’s supervisor if the 
project forms part of a degree course). 
 
I hereby endorse this application with my approval:- 
 
 
Name .....................................................................  Department 
................................................. 
 






APPENDICES B - Information leaflet and consent form for 
claudicants 
STUDY INFORMATION LEAFLET FOR CLAUDICATION PATIENTS 
‘3-NITROTYROSINE AS AN INDICATOR OF THE DISEASE STATE IN 
CLAUDICATION’ 
 
We’d like to explain some of the research we’re doing and then ask you if you 
would like to take part in it. 
PLEASE READ THIS LEAFLET CAREFULLY 
 
This study is being undertaken by PhD student Sadie Mercer, B.Sc, from 
Coventry University working in conjunction with Mr A Garnham consultant 
vascular surgeon at the royal Wolverhampton hospitals NHS trust  
 
1. Condition and treatment 
You have recently been informed that you suffer from claudication, which is a 
result of hardening of the arteries (atherosclerosis). Currently claudication is 
diagnosed by taking your medical history, measuring your ankle and arm 
blood pressure (known as ankle-arm index), and using a treadmill. 
The aim of this study is to develop a simple blood test to improve the 
diagnosis of artery disease such as claudication in the future. 
If you agree to take part in this study two small blood samples will be taken 
and tested for the presence of a modified protein and we will compare the 
levels of it with people without claudication. The particular modified protein, 
called 3-nitrotyrosine, is known to exist in similar diseases to that of 
claudication. 
This study will not effect or improve your treatment for claudication. 
 
2. Your study medication 
If you take part in this study you will receive NO extra or different treatment. 
 
3. What the study involves 
This study will last up to 2 years, however you will only be involved for 
3months. During this time you will be asked to give two blood samples 
(approximately 2 teaspoons of blood each time), which will be taken at the 
same time as your routine samples therefore causing you NO extra pain or 
inconvenience. One blood sample at your first appointment at the claudication 
clinic and one after the 3-month exercise program. You will not be required to 
visit the clinic extra time as a result of your participation in this study. All 
information obtained from you and some of your medical records will be 
treated confidentially and by using a coding system your identity will be 
protected at all times.  
 
Side effects 
Taking part in this study should not cause you any side effects because you 




The study will be explained to you in detail by your doctor and by myself.  
Please feel free to ask as many questions as you want.  When you are 
satisfied with the information you have been given and wish to participate in 
the study, you will be required to sign the attached consent form.  If after 
joining the study you wish to leave you can do so at any time without having to 
explain your decision. If you do not wish to be involved, you do not have to 
give a reason. Any decision you make will not affect your doctor/patient 
relationship. 
Although it is not expected, your doctor may end your participation in this 
study if he/she decides that it is not in the best interest of your health to 
continue. You will be told of any new findings that may affect your decision to 
participate in this study. In the unlikely event you suffer any harm as a result 
of taking part in this study your doctor would be able to give you information 
about compensation and treatment. 
It will be necessary for your medical records to be seen by authorised 
personnel associated with the study. All information collected during the study 
will be treated in confidence, and your personal details will not be revealed. 
Your hospital doctor will inform your family doctor/GP that you are involved in 
the study so he/she knows what is happening. 
 
If you have any further questions regarding your participation in the study, or 
need any information or advice during the study, please do not hesitate to 
contact: 
 
Consultant: Mr Andrew Garnham (For medical enquiries about study) 
Telephone Number (Day time): 01902 642904 
Telephone Number (24 Hours): 01902 642894 
 
Name of Investigator: Sadie Mercer (For information about study) 
Telephone Number: 024 7688 7609 
Email: apy088@coventry.ac.uk 
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PATIENT CONSENT FORM FOR ‘3-NITROTYROSINE AS AN INDICATOR 
OF THE DISEASE STATE IN CLAUDICATION’ 
 
I………………………………………………………………………… (Print name) 
agree to participate in the ‘3-nitrotyrosine as an indicator of the disease 
state in claudication’ study. 
 
I have read and understood the patient information sheet provided and any 
questions I had have been answered satisfactorily.  
 
I understand that I am under no obligation to participate in this study, and 
have been informed that if I choose to participate in this study I can withdraw 
from the study at any time without prior notice and that this will not affect my 
normal treatment or relationship with my doctor. 
 
I understand that participating in this study will not improve my treatment or 
disease state in any way. 
 
I have been assured that any information I give to the investigator, Sadie 
Mercer, will be treated as strictly confidential and that my identity will be 
protected at all times. 
 
I have been given adequate time to make my decision and am giving my 







I declare that I have given a full explanation to the above patient of this study, 
answered all of their questions and that consent has been given freely. 
Printed:………………………………………… 
 
Signed:………………………… Date:……………………….(Sadie Mercer) 
xiv 
APPENDICES C - Claudication questionnaire 
 
STUDY NUMBER – CS_____ 
CLAUDICATION QUESTIONNAIRE 
 
1. Date –  
2. NHS Number -  
3. Initials –  
4. Surname –  
5. DOB –  
6. Ethnic origin –  
7. Height – 
8. Weight –  
9. BMI –  
 





11. History of present illness / duration –  
 
Claudication -    Distance Recovery Rest pain 
 
Thigh / buttocks 
   Calf 
   Foot 
   Coldness of feet 
   Ulcers 
 
12. Past medical history –  
 
Diabetes  CVA  Others Operative procedures 
Hypertension TIA   
MI   Amaurosis Fugax 
Angina 
 
13. Medications –  
 
 
14. Allergies –  
 
15. Family history –  
 
16. Psycho social History –  
17. Risk factors identified –  
Smoking   Diabetes   BMI 






18. BP    Systolic BP with Doppler 
Lt 
 
19. Physical assessment of Pulses -   
 







20. Doppler assessment of pulses with ABI Readings – 
 RT LT 
AT (leg)   
DP (foot)   
PT (ankle)   
Peroneal (side of calf)   
ABI   
  
21. Any additional comments -  
 
xvi 
APPENDICES D - Ethics proposal for School of Science and 
the Environment, Coventry University 
 
SCHOOL OF SCIENCE AND THE ENVIRONMENT 
 
 
FORM FOR THE ATTENTION OF 
DR VALERIE COX 
(SUBMIT VIA JAMES STARLEY BUILDING MAIN 
OFFICE) 
 
COVENTRY UNIVERSITY – SCHOOL OF SCIENCE AND THE ENVIRONMENT 
 
STUDENT SUBMISSION TO SCHOOL RESEARCH ETHICS COMMITTEE 
Students must submit the following forms if needed: 
 Completed ethics form 
 Completed subject informed consent form (or Subject Information leaflet if 
appropriate) 
 Risk assessment form; note for taking blood samples you must use the STANDARD 
procedure(s) and append the standard risk assessment form 
 Copies of any other questionnaires that will be issued to subjects/ questions that will 
be used in interviews 
For more guidance please see School Ethics Handbook 
 
 
 Student’s name: 
SADIE MERCER 
2.   Course: 
PhD Student 
 Title of project: 
3-NITROTYROSINE AS AN INDICATOR OF THE DISEASE 
STATE IN CLAUDICATION 
 Name of supervisor 




Aim of research 
To investigate 3-nitrotyrosine as a potential marker of oxidative stress in 
people suffering from claudication. This will involve the development of 
novel immunoassays, based on enzyme linked immunosorbant assay 
(ELISA), for the detection of nitrated proteins and antibodies against these 
proteins. Using these assays 3-nitrotyrosine will be investigated to establish 




It is hoped that a minimum of six subjects, lecturers within school of science 
and environment, will be enrolled onto this study as control patients. These 
subjects will need to be older than 45 years of age and be healthy 
individuals. Information will be obtained as to the subject’s age, sex, height, 
weight and other contributing factors such as other diseases e.g. diabetes 
mellitus and their smoking status. A blood sample will also be taken, 
approximately 9ml by someone qualified. At all times the subject’s 
confidentiality will be respected and no identifiable data will be taken. The 
blood samples taken will then be tested and quantified for the presence of 3-
nitrotyrosine (3-NT) and comparisons will be made between these control 
sample levels and levels found in the plasma of patients suffering from 
claudication. These samples have already been taken and ethical approval 
was obtained from Wolverhampton district local research ethics committee.  
 
Research site: 




The subjects enrolled will be asked to give a blood sample (approximately 
9ml, taken by a person trained in doing so from physiology department, 
adhering to the standard procedure), answer questions regarding their 
medical history, age, sex, race (see questionnaire attached) and will have 
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their blood pressure taken from their arm and ankle to establish their ABI 
(ankle brachial index). 
 
Foreseeable risks or discomforts and actions taken to reduce these 
The only foreseeable risk or discomfort for the subjects taking place on this 
study is potential bruising from blood sampling. 
 
Data protection and Consent 
No information gathered from this study will be available to people other 
than Sadie Mercer in such a way that the subject may be identified.  
 
 
 Will the project involve patients(clients) and/or patient(client) data?  Yes [ X ] No [   ] 
 Will any invasive procedures be employed in the research?  Yes [ X ] No [   ] 
 Is there a risk of physical discomfort to those taking part?  Yes [ X ] No [   ] 
 Is there a risk of psychological distress to those taking part?  Yes [   ] No [ X ] 
 Will specific individuals or institutions (other than the University) be 
identifiable through data published or otherwise made available? 
 Yes [   ] No [ X ] 
 Is it intended to seek informed consent from each participant (or from 
his or her parent or guardian)? 
 Yes [ X ] No [   ] 
 
Student’s signature:        Date: 
Supervisor’s signature:        Date: 
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APPENDICES E - Information leaflet and informed consent for 
control subjects 
 
‘3-NITROTYROSINE AS AN INDICATOR OF THE DISEASE STATE IN 
CLAUDICATION’ 
STUDY INFORMATION LEAFLET & INFORMED CONSENT FORM FOR 
CONTROL PATIENTS 
 
We’d like to explain some of the research we’re doing and then ask you if you 
would like to take part in it. 
PLEASE READ THIS LEAFLET CAREFULLY 
 
This study is being undertaken by Sadie Mercer, B.Sc, from Coventry 
University working in conjunction with Mr A Garnham consultant vascular 
surgeon at the royal Wolverhampton hospitals NHS trust  
 
Thank you for agreeing to consider being a subject in this research. 
 
Purpose of research 
Claudication is a result of hardening of the arteries (atherosclerosis), and 
results in pain in the leg when exercising due to poor circulation. You have 
been selected because you do not have claudication. Currently claudication is 
diagnosed by a taking a patients medical history, measuring their ankle and 
arm blood pressure (known as ankle-arm index), and using a treadmill.   
The aim of this study is to develop a simple blood test to improve the 
diagnosis of artery disease such as claudication. 
If you agree to take part in this study a small blood sample will be taken to test 
for the presence of a modified protein and compare levels of it with people 
who suffer from claudication. This particular modified protein, called 3-
nitrotyrosine, is known to exist in similar diseases to claudication. 
 
Participation in this research will involve 
You will be asked to give a single blood sample for this study (approximately 2 
teaspoons of blood) to be used as a ‘control’ sample. This may result in slight 
discomfort where the blood sample is taken from. You will also have some 
medical history taken and your ankle arm index measured. This consists of 
your ankle and arm blood pressures being taken and compared, this is a pain 
free and fast procedure. This should take approximately half an hour. 
All information gathered from you and parts of your medical records will be 
treated confidentially and your identity will be protected, as your name will not 
be recorded. 
 
Foreseeable risks or discomforts 
You will NOT receive any treatment other than you ankle-arm index being 
measured. You may experience some discomfort and mild bruising where the 
blood test will be taken from. 
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Benefits to the subject of participation 
You will not receive any benefits from participating in this study. 
 
What will happen to your data? 
Any data/ results from your participation in the study will be used by Sadie 
Mercer as part of their project work. The data will also be available to Dr M 
Cox…It may also be published in scientific works, but your name or identity 
will not be revealed. Confidentiality will be maintained as you will be allocated 
a code known only to yourself and Sadie Mercer and no record of your name 
will be made.  
 
If you have any questions or queries Sadie Mercer will be happy to 
answer them. If they cannot help you you can speak to Dr Martin Cox. 
 
If you have any questions about your rights as a participant or feel you have 
been placed at risk you can contact Dr J Henderson. 
 
 
I confirm that I have read the above information. The nature, demands and 
risks of the project have been explained to me.  
I have been informed that there will be no benefits/ payments to me for 
participation 
 
I knowingly assume the risks involved and understand that I may withdraw my 
consent and discontinue participation at any time without penalty and without 
having to give any reason. 
 
Subject’s signature __________________________ Date _____________ 
 
Investigator’s signature _______________________   Date _____________ 
 
 
The signed copy of this form is retained by the student, and at the end of 




APPENDICES F - Control questionnaire 
 
STUDY NUMBER – CN_____ 
CONTROL QUESTIONNAIRE 
 
Date –  
DOB –  
Ethnic origin –  
Height – 
Weight –  
BMI –  
 
Do you ever have pain upon walking? YES/NO 
 
  If Yes please fill in data below –  
 
     Distance Recovery Rest pain 
 
Thigh / buttocks 
  Calf 
  Foot 
  Coldness of feet 
  Ulcers 
 
Past medical history –  
 
Diabetes - YES / NO  
CVA (STROKE) - YES / NO  
Hypertension - YES / NO 
TIA (transient ischaemic attack, short lasting loss of/impaired vision) –  
YES/NO 
MI  (Heart attack) – YES / NO 
Angina – YES / NO 
 
Do you or have you ever smoked?  
 If yes please give details –  
 
 
Others –  
 
 
Operative procedures (in the last 12months)–  
 
 
Are you on any medications if so please state below–  
 
 
Do you have a family history of Heart attack / Stroke / vascular problems? –  
If yes please give details below -  
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APPENDICES G - Factors for A280/A260 Warburg and Christian 
method 





1.75 0.00 1.118 
1.60 0.30 1.078 
1.50 0.56 1.047 
1.40 0.87 1.011 
1.30 1.26 0.969 
1.25 1.49 0.946 
1.20 1.75 0.921 
1.15 2.05 0.893 
1.10 2.40 0.863 
1.05 2.80 0.831 
1.00 3.30 0.794 
0.96 3.70 0.763 
0.92 4.30 0.728 
0.90 4.60 0.710 
0.88 4.90 0.691 
0.86 5.20 0.671 
0.84 5.60 0.650 
0.82 6.10 0.628 
0.80 6.60 0.605 
0.78 7.10 0.581 
0.76 7.80 0.555 
0.74 8.50 0.528 
0.72 9.30 0.500 
0.70 10.30 0.470 
0.68 11.40 0.438 
0.66 12.80 0.404 
0.64 14.50 0.368 
0.62 16.60 0.330 





APPENDICES H - Checkerboard analysis - indirect ELISA 
Full indirect ELISA checkerboard analysis for the different manufacturers microtitre 
plates using electrochemically nitrated BSA. 
NB the legend represents the polyclonal anti-3NT Ab dilutions 
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APPENDICES I - Checkerboard analysis - competitive ELISA  
Full checkerboard analysis for competitive ELISA with Immulon 2HB 
microtitre plates using freshly nitrated BSA (electrochemically nitrated). 
NB the legend represents the polyclonal anti-3NT antibody dilutions, this 
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APPENDICES J - Protein determination for the claudicant and 





























CS001 111 F1 1.8 12.8 9.2 F1U 5.2 5.1 0.018 
            F1B -0.1    
    F2 1.2 12.1 6.0 F2U 2.5 2.7 0.396 
            F2B 0.2   188.678 
    F3 0.3 2.2 1.3 F3U 0.7 0.9 0.534 
        27.1 16.6 F3B 0.2 8.7 108.773 
CS002 90 F1 1.2 12.3 6.2 F1U 7.2 7.4 0.007 
            F1B 0.3   178.704 
    F2 1.0 8.3 5.2 F2U 2.6 2.8 0.009 
            F2B 0.2   172.080 
    F3 0.2 1.6 0.8 F3U 0.9 1.0 0.354 
        22.2 12.1 F3B 0.1 11.3 66.167 
CS003 100 F1 1.0 10.3 5.1 F1U 5.5 5.8 0.002 
            F1B 0.3   145.984 
    F2 0.6 6.6 3.1 F2U 3.1 3.3 0.043 
            F2B 0.2   235.901 
    F3 0.3 2.8 1.3 F3U 1.5 1.6 0.025 
        19.7 9.5 F3B 0.1 10.7 55.373 
CS004 99 F1 1.2 12.3 6.0 F1U 5.2 5.3 0.190 
            F1B 0.0   38.149 
    F2 0.8 8.1 4.0 F2U 2.4 2.4 0.008 
            F2B 0.1   35.155 
    F3 0.4 4.0 1.8 F3U 1.0 1.1 0.012 
        24.3 11.7 F3B 0.2 8.8 46.377 
CS005 99 F1 1.5 15.5 7.6 F1U 8.7 8.9 0.016 
            F1B 0.2   91.068 
    F2 0.7 7.0 3.5 F2U 2.9 2.9 0.365 
            F2B 0.1   250.699 
    F3 0.2 2.0 0.9 F3U 0.8 0.9 0.185 
        24.5 12.0 F3B 0.1 12.7 104.713 
CS006 93 F1 1.1 12.0 5.6 F1U 7.6 7.9 0.100 
            F1B 0.3   86.684 
    F2 0.8 8.4 4.0 F2U 3.0 3.2 0.192 
            F2B 0.2   15.427 
    F3 0.2 2.4 1.1 F3U 0.9 1.1 0.636 
        22.8 10.7 F3B 0.1 12.2 93.175 
CS007 93 F1 1.3 13.3 6.4 F1U 7.6 7.9 0.118 
            F1B 0.3   64.734 
    F2 0.9 9.0 4.3 F2U 3.4 3.6 0.196 
            F2B 0.2   13.458 
    F3 0.2 2.4 1.1 F3U 0.9 1.0 0.588 
        24.7 11.8 F3B 0.1 12.5 80.046 
CS008 98 F1 1.6 16.0 8.0 F1U 8.6 8.9 0.014 
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            F1B 0.3   17.766 
    F2 0.6 7.5 3.1 F2U 2.9 3.1 0.373 
            F2B 0.2   20.166 
    F3 0.2 3.7 1.2 F3U 0.9 1.0 4.864 
        27.2 12.3 F3B 0.1 13.0 620.904 
CS009 92 F1 1.4 16.6 6.9 F1U 7.8 8.0 0.012 
            F1B 0.2   44.875 
    F2 0.9 11.2 4.7 F2U 2.8 2.9 0.317 
            F2B 0.1   150.778 
    F3 0.3 3.5 1.3 F3U 1.6 1.8 2.240 
        31.3 12.8 F3B 0.1 12.7 512.393 
CS010 93 F1 2.1 12.5 10.4 F1U 13.1 13.4 0.029 
            F1B 0.3   22.627 
    F2 0.7 8.9 3.7 F2U 2.6 2.7 0.370 
            F2B 0.1   455.375 
    F3 0.3 3.4 1.3 F3U 1.0 1.1 0.128 
        24.7 15.4 F3B 0.1 17.2 454.365 
CS011 96 F1 2.1 12.5 10.4 F1U 11.8 12.2 0.017 
            F1B 0.4   32.672 
    F2 0.7 10.1 3.6 F2U 2.5 2.6 0.452 
            F2B 0.1   322.329 
    F3 0.3 4.9 1.7 F3U 1.0 1.0 0.638 
        27.5 15.8 F3B 0.1 15.9 811.005 
CS012 97 F1 1.5 14.7 7.3 F1U 8.4 8.5 0.055 
            F1B 0.1   68.697 
    F2 0.9 9.3 4.6 F2U 3.2 3.3 0.494 
            F2B 0.1   307.078 
    F3 0.3 3.2 1.6 F3U 1.2 1.4 1.424 
        27.2 13.6 F3B 0.2 13.2 268.762 
CS013 101 F1 1.9 21.3 9.7 F1U 10.8 11.2 0.012 
            F1B 0.3   4.112 
    F2 0.7 9.0 3.7 F2U 3.2 3.4 0.200 
            F2B 0.2   57.281 
    F3 0.2 2.4 1.0 F3U 0.5 0.8 2.504 
        32.7 14.4 F3B 0.2 15.3 90.190 
CS014 91 F1 1.5 18.9 7.3 F1U 7.5 7.7 0.010 
            F1B 0.2   13.906 
    F2 0.5 6.8 2.6 F2U 2.5 2.7 0.180 
            F2B 0.2   6.925 
    F3 0.2 2.2 1.0 F3U 1.2 1.4 0.115 
        28.0 10.9 F3B 0.1 11.8 44.149 
CS015 112 F1 1.2 15.4 6.1 F1U 6.7 6.9 0.007 
            F1B 0.2   9.761 
    F2 0.6 7.9 2.8 F2U 2.4 2.6 0.263 
            F2B 0.2   11.204 
    F3 0.2 1.8 0.8 F3U 1.3 1.4 0.084 
        25.0 9.7 F3B 0.1 10.9 32.339 
CS016 97 F1 2.1 20.2 10.5 F1U 9.2 9.4 0.045 
            F1B 0.3   18.523 
    F2 0.9 10.6 4.3 F2U 3.0 3.1 0.105 
            F2B 0.1   16.809 
xxvii 
    F3 0.3 3.0 1.3 F3U 0.7 0.8 0.389 
        33.8 16.0 F3B 0.1 13.4 181.513 
CS017 118 F1 2.5 24.0 12.5 F1U 10.5 10.7 0.034 
            F1B 0.3   19.242 
    F2 0.6 9.0 3.2 F2U 2.5 2.6 0.341 
            F2B 0.1   59.920 
    F3 0.3 3.2 1.3 F3U 0.8 0.9 0.262 
        36.2 17.0 F3B 0.1 14.2 92.768 
CS018 100 F1 2.1 24.0 10.3 F1U 9.5 9.8 0.006 
            F1B 0.3   11.343 
    F2 0.7 8.4 3.4 F2U 2.9 3.0 0.230 
            F2B 0.1   47.354 
    F3 0.2 2.9 1.2 F3U 0.9 1.0 0.610 
        35.3 14.9 F3B 0.1 13.8 69.037 
CS019 97 F1 2.2 25.4 11.1 F1U 8.9 9.4 0.013 
            F1B 0.4   9.367 
    F2 0.6 6.3 2.9 F2U 2.9 3.1 0.197 
            F2B 0.3   19.110 
    F3 0.3 3.2 1.4 F3U 1.2 1.5 0.613 
        34.9 15.4 F3B 0.3 14.0 38.000 
CS020 103 F1 1.8 20.7 8.9 F1U 8.1 8.4 0.013 
            F1B 0.3   19.563 
    F2 0.9 9.6 4.4 F2U 3.5 3.7 0.241 
            F2B 0.2   82.043 
    F3 0.2 2.5 1.1 F3U 1.2 1.4 0.292 
        32.8 14.5 F3B 0.2 13.5 89.561 
CS021 96 F1 2.0 24.4 10.0 F1U 8.7 9.0 0.013 
            F1B 0.3   16.168 
    F2 0.7 9.7 3.7 F2U 2.8 2.8 0.195 
            F2B 0.0     
    F3 0.2 3.0 1.2 F3U 1.0 1.2 0.120 
        37.1 15.0 F3B 0.2 13.0 85.008 
CS022 117 F1 1.8 19.4 8.8 F1U 6.0 6.1 0.019 
            F1B 0.2   12.577 
    F2 0.7 9.8 3.5 F2U 2.6 2.7 0.180 
            F2B 0.1   20.186 
    F3 0.3 3.4 1.3 F3U 1.1 1.3 0.642 
        32.6 13.6 F3B 0.2 10.1 63.073 
CS023 109 F1 2.0 25.8 10.2 F1U 9.3 9.6 0.012 
            F1B 0.2   9.924 
    F2 0.7 9.4 3.7 F2U 2.7 2.8 0.230 
            F2B 0.2   12.544 
    F3 0.2 3.1 1.2 F3U 0.9 1.1 1.338 
        38.4 15.2 F3B 0.2 13.5 81.636 
CS024 100 F1 1.7 21.5 8.3 F1U 8.2 8.5 0.067 
            F1B 0.3   34.514 
    F2 0.7 7.6 3.3 F2U 3.1 3.3 0.451 
            F2B 0.2   41.306 
    F3 0.2 3.1 1.1 F3U 1.1 1.3 1.265 
        32.1 12.7 F3B 0.2 13.0 29.072 
CS025 106 F1 1.4 18.1 7.1 F1U 7.2 7.5 0.043 
xxviii 
            F1B 0.2   28.203 
    F2 1.3 15.9 6.3 F2U 3.5 3.7 0.425 
            F2B 0.1   4.067 
    F3 0.2 2.7 1.1 F3U 1.1 1.2 0.650 
        36.7 14.4 F3B 0.1 12.4 145.241 
CS026 93 F1 1.3 17.1 6.6 F1U 7.6 7.9 0.038 
            F1B 0.2   33.040 
    F2 0.8 9.7 3.8 F2U 3.0 3.2 0.367 
            F2B 0.2   179.654 
    F3 0.2 2.4 1.0 F3U 0.9 1.1 0.292 
        29.2 11.3 F3B 0.1 12.1 288.943 
CS027 91 F1 1.4 16.8 7.0 F1U -0.2 4.2   
            F1B 4.4   0.116 
    F2 0.8 9.1 4.1 F2U 3.4 3.6 0.197 
            F2B 0.3   183.395 
    F3 0.1 2.0 0.7 F3U 1.1 1.2 0.186 
        28.0 11.9 F3B 0.1 9.0 357.999 
CS028 96 F1 1.9 23.9 9.3 F1U 4.1 4.2 0.013 
            F1B 0.1   34.738 
    F2 1.0 11.0 5.1 F2U 3.2 3.2 0.220 
            F2B 0.0     
    F3 0.3 4.7 1.7 F3U 0.8 0.9 0.089 
        39.6 16.1 F3B 0.1 8.3 110.390 
CS029 118 F1 1.8 21.2 9.1 F1U 7.5 7.6 0.012 
            F1B 0.1   37.498 
    F2 0.9 11.1 4.6 F2U 3.3 3.3 0.261 
            F2B 0.0   243.170 
    F3 0.3 4.7 1.7 F3U 0.8 0.9 0.150 
        37.0 15.4 F3B 0.1 11.9 99.947 
CS030 94 F1 1.4 16.7 6.8 F1U 5.4 5.5 0.006 
            F1B 0.1   95.092 
    F2 0.8 9.1 4.0 F2U 2.8 2.8 0.178 
            F2B 0.0   1706.932 
    F3 0.3 4.1 1.6 F3U 1.3 1.5 0.036 
        29.8 12.4 F3B 0.1 9.8 253.858 
CS031 103 F1 1.3 13.8 6.3 F1U 7.7 8.0 0.007 
            F1B 0.3   63.422 
    F2 1.1 12.2 5.3 F2U 4.7 4.9 0.076 
            F2B 0.2   35.223 
    F3 0.2 2.9 1.0 F3U 1.0 1.2 0.103 
        28.9 12.7 F3B 0.2 14.1 154.145 
CS032 157 F1 1.2 13.5 6.1 F1U 7.0 7.2 0.004 
            F1B 0.2   130.740 
    F2 1.1 15.4 5.7 F2U 3.4 3.5 0.127 
            F2B 0.1   140.882 
    F3 0.3 3.6 1.3 F3U 1.0 1.1 0.062 
        32.4 13.2 F3B 0.1 11.9 393.343 
CS033 109 F1 1.9 21.7 9.5 F1U 7.3 7.5 0.007 
            F1B 0.2   167.991 
    F2 1.1 14.5 5.6 F2U 3.2 3.3 0.153 
            F2B 0.1   168.441 
xxix 
    F3 0.2 2.5 0.9 F3U 1.2 1.3 0.318 
        38.7 16.0 F3B 0.2 12.1 426.373 
CD001 121 F1 1.3 12.6 6.7 F1U 7.5 7.7 0.000 
            F1B 0.2   0.377 
    F2 0.7 9.7 3.5 F2U 2.6 2.8 0.004 
            F2B 0.1   54.863 
    F3 0.5 6.9 2.5 F3U 1.6 1.7 0.002 
        29.2 12.6 F3B 0.2 12.2 15.795 
CD002 96 F1 1.2 11.8 5.9 F1U 7.1 9.6 0.042 
            F1B 2.5   0.724 
    F2 0.7 9.9 3.5 F2U 0.3 0.5 3.119 
            F2B 0.2   64.241 
    F3 0.4 5.7 2.0 F3U 1.5 1.7 0.116 
        27.3 11.4 F3B 0.2 11.8 70.102 
CD003 98 F1 1.1 11.4 5.7 F1U 6.7 6.9 0.002 
            F1B 0.2   14.238 
    F2 0.6 9.1 3.2 F2U 2.9 3.1 0.115 
            F2B 0.2   125.328 
    F3 0.6 8.1 3.2 F3U 1.7 2.0 0.071 
        28.6 12.2 F3B 0.3 12.0 190.553 
CD004 108 F1 1.2 10.5 5.8 F1U 7.4 7.4 0.001 
            F1B 0.0   61.295 
    F2 0.8 11.5 4.1 F2U 2.5 2.5 0.121 
            F2B 0.0     
    F3 0.4 5.5 2.0 F3U 1.6 1.5 0.094 
        27.5 11.9 F3B 0.0 11.5   
CD005 105 F1 1.0 10.8 5.0 F1U 5.7 5.6 0.004 
            F1B -0.1     
    F2 0.7 9.6 3.4 F2U 2.4 2.4 0.201 
            F2B 0.0     
    F3 0.5 6.5 2.5 F3U 1.3 1.3 0.127 
        27.0 11.0 F3B 0.0 9.3   
CD006 98 F1 0.9 9.6 4.5 F1U 5.1 5.0 0.004 
            F1B -0.1     
    F2 0.9 11.9 4.6 F2U 2.4 2.3 0.185 
            F2B -0.1     
    F3 0.4 6.2 2.1 F3U 1.3 1.3 0.066 
        27.7 11.3 F3B 0.0 8.5   
  
 
 
 
